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List of abbreviations 
 
• ACN/MeCN  Acetonitrile 
• Aib/U  α,α-dimethylglycine 
• ALM  Alamethicin 
• BLM  Black-lipid Membrane (electrophysiology), also: Planar lipid 
• COMU   (1-Cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylamino-  
  morpholino-carbenium hexafluorophosphate 
• DCC  dicyclohexylcarbodiimide 
• DCM  dichloromethane 
• DD  doubly distilled 
• DIC  diisopropylcarbodiimide 
• DIPEA  diisopropylethylamine 
• DMF  N,N-dimethylformamide 
• DMP  Dess-Martin Periodinane 
• DMSO  Dimethylsulfoxide 
• DNA  Deoxyribonucleic Acid 
• DOPC  1,2-dioleoyl-sn-glycero-3-phosphocholine 
• DOPE  1,2-dioleoyl-sn-glycero-3-phosphoethanolamine 
• DPPE  1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine 
• dULC-ALM Alamethicin with all Aib replaced with leucine, and additionally a 
  C-terminal cysteine 
• equiv.  (molar) equivalent 
• EDC.HCl  N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride 
• HATU  1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5- 
  b]pyridinium 3-oxid hexafluorophosphate 
• HBTU  N,N,N′,N′-Tetramethyl-O-(1H-benzotriazol-1-yl)uronium  
  hexafluorophosphate 
• HMBA  4-Hydroxymethylbenzoic acid 
• HOBt  1-Hydroxybenzotriazole hydrate 
• HPLC  High Performance Liquid Chromatography 
• HRMS  High Resolution Mass Spectrometry 
• IBX  Iodoxybenzoic Acid 
• MALDI  Matrix Assisted Laser Desorption Ionisation  
• MOPS  3-(N-Morpholino)propanesulfonic acid 
• NHS  N-Hydroxysuccinimid 




• PCC  Pyridiniumchlorochromate 
• POPC  1-palmitoyl-2oleoyl-sn-glycero-3-phosphocholine 
• SPPS  Solid Phase Peptide Synthesis 
• TBTA  Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine 
• TCEP  Tris(2-carboxyethyl)phosphine hydrochloride 
• TEA  Triethylamine 
• TFA  Trifluoroacetic acid 
• TFE  Trifluoroethanol 
• TIPS  Triisopropylsilyl 
• TIS  tetraisopropylsilane 
• TLC  Thin Layer Chromatography 
• TMS  Trimethylsilyl 
• TOF  Time of Flight 
• UPLC  Ultra Performance Liquid Chromatography 
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Chapter 1 – Introduction 
1.1. Antimicrobial peptides 
Any living organism aims to grow and thrive. With limited resources available, this results in 
constant competition. This competition, in turn, results in attempts at trying to outgrow or 
otherwise outmanoeuvre other organisms and at defending from the potentially harmful 
exterior pathogens to which all organisms are exposed to.  
 
Scheme 1 Unselective defence using antimicrobial peptides (left) and selective defence using antigens 
(right) against prokaryotic organisms.  
In order to survive, most organisms have developed complex host defence mechanisms.[1,2] 
The constant production and release of antimicrobial peptides into the extracellular medium 
is believed to be a primitive part of this defence system.[3] Most eukaryotic organisms have 
conserved this ability, ranging from fungi to insects to mammals, including humans.[4,5] These 
peptides are selectively active against membranes of prokaryotes, which generally have more 
negatively charged membranes than eukaryotic cells.[6,7] The selection mechanism is by no 
means fool proof, as some bacteria, such as Staphylococcus Aureus, are capable of lowering 
the negative charge on their outer membrane, sharply reducing the likelihood of being 
attacked by these antimicrobial peptides.[8-11] 





Figure 1 Overview of the different characteristics a compound may have in regards to solubility in 
particular kinds of solvents.  
Antimicrobial peptides are typically small (<50 amino acid residues) peptides of various 
compositions.[5,12] These peptides come in in a wide variety of forms of α-helices, β-sheets 
and loops, and they may be neutral, cationic or, less frequently, anionic.[13,14] What the 
peptides generally do have in common is an amphipathic nature (i.e. an equal ‘dislike’ for 
both polar or apolar media), making these compounds favour being in or on a lipid 
membrane.[15] These amphipathic characteristics are either innate to the individual peptide, 
or induced when multiple peptides converge on a target membrane.[16] 




Figure 2 different modes in which a pore forming peptide may disturb a (cellular) membrane. a. carpet 
mode; b. toroidal pores; c. barrel-stave pores. 
Regarding activity, most antimicrobial peptides are known to impair the cell membrane of 
their target, allowing the cellular contents to leak out.[17] For the most part they are classified 
as having one of three modes of action: the carpet (a), the toroidal pore (b) and the barrel-
stave pore (c).[18] It should be noted beforehand that these modes are not mutually exclusive 
and depending on the concentration, the same compound may exhibit one or more of these 
modes of action.[19] 
 
Figure 3 The carpet mode of membrane permeation. The actions of the pore forming peptide breaks 
loose micelles from the membrane until the membrane breaks up. 
 




The carpet mode of action, as the name suggests, involves the cell-membrane being 
enveloped in the peptide, which has a high affinity for the head-groups of the phospholipids. 
As the peptide binds to the membrane, it exposes a hydrophilic flank.[20,21] Also, as the 
concentration of peptide on the membrane increases, it is thought that the peptide starts to 
perturb the bilayer.[22] This perturbation, combined with the now exposed hydrophilic side of 
the antimicrobial peptide promotes micelle formation, which creates holes through the 
membrane, allowing cytosol contents to spill out of the cell. As more micelles are formed and 
depart from the membrane, the leaking increases until finally the entire membrane has 
disintegrated. Notable members of this group are ovispirin and cathelicidin, both found in 
mammals, sheep in particular. [23,24] 
 
 
Figure 4 Toroidal pores are formed when the peptide curves the membrane inwards until a hole is 
formed in the bilayer. The pore is continuously lined with the polar headgroups of the lipids in the 
membrane 
Toroidal pores are formed in a similar fashion as the micelles from the carpet method, and 
most antimicrobial peptides capable of forming toroidal pores will also form micelles out of 
the membrane at high enough concentration.[25] The difference lies at lower concentrations, 
where the perturbing action of the peptides is more pronounced.[26] At low concentrations, 
these peptides lie parallel with the membrane. However, due to the peptide-membrane 
interactions, the membrane is curved inwards (positive curvature), creating a break in the 
hydrophobic region of the membrane. When a threshold concentration is reached, the 
peptides start to self-associate, to minimize the exposure of hydrophilic groups to the apolar 
part of the membrane.[27] While doing so, they switch over to an orientation perpendicular 
to the membrane, upon which an opening in the membrane is formed, resulting in cytosol 
spillage out of the cell.[28,29] The membrane itself remains intact from a certain perspective: 
no material is removed from the membrane in this process and the peptide does not interact 
with the central lumen. Examples of this group are mellitin (also found in bee-venom) and 
maiganin. [28,29] 
 
Figure 5 Barrel stave pores are formed when the pore forming peptide penetrates through the 
membrane during pore formation. The centre of the pore still consists out of the apolar tails of the 
lipids, as opposed to the head-groups in the toroidal pores. 
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Lastly, barrel-stave pores are formed by mainly α-helical peptides forming a bundle straight 
through the membrane.[30,31] After binding to the membrane, these peptides aggregate and 
undergo a conformational change.[32,33] These changes induce local thinning of the 
membrane, after which the bundle inserts itself into the membrane, forming initially an ion-
channel lined by the hydrophilic side groups of the peptide, while the hydrophobic groups 
stick into the central lumen of the membrane allowing leakage of some cytosol content out 
of the cell. [34] Depending on the presence of additional peptides on the membrane, the 
channel may grow larger, allowing for the passage of larger molecules than simple ions (H+, 
Na+, Mg2+ etc.). The best know example of this group is alamethicin, produced by the fungus 
trichoderma viride. [35,36] 
1.2. Research interest 
Over 1000 different antimicrobial peptides have been identified.[37] While classical antibiotics 
are losing efficiency due to increasing resistance, most pathogenic strains still have limited to 
no resistance to antimicrobial peptides.[38] This, combined with the fact that antimicrobial 
peptides have a predisposition to affect prokaryotic cells, has led to significant interest from 
the medical community. In fact, some of these peptides have been found to show significant 
promise as new antibiotic agents, such as mellitin, indolicidin and β-protegrin. [39-41] 
Another potential application of these compounds is found in molecular logic devices. If a 
pore forming peptide or cluster thereof can be treated in such a way that it will reliably give 
the same transmembrane pore (or pore size) to the same stimulus, the current going through 
can be quantified. This would form the basis for a bio-compatible sensor, or signal processing. 
[42,43]  














Scheme 2 Strongly simplified diagram for a temperature controller that may be used in an oven. 
Let’s first imagine a simplified temperature control on an oven: at start-up, the heating 
elements and the ‘oven is warming’ light are on. As the temperature rises, a calibrated 
temperature sensor starts to increase its reporting voltage (e.g. +5mV/°C), until a pre-defined 
voltage in the comparator is reached, after which the heating elements and indicator light 
get switched off.[44] 
To translate the above into a molecular sensor: for analyte X, if the concentration is above a 
certain level, pore formation should start, allowing ions to flow through the membrane, 
giving a small but reproducible and quantifiable current across the membrane as output. Or 
in the ideal world, the pore formation and resulting transmembrane current would be a 
function of the concentration of analyte X. The same way the oven sensor indicates when the 
oven is at the desired temperature, this molecular sensor could indicate the presence of 
absence of a certain analyte or process in a cell. 




Figure 6 By measuring the current flowing through a transmembrane haemolysing pore, a DNA 
sequence may be determined 
Some large proteins are already adapted to function in this sense.[45] A well-known example 
of this is α-haemolysin, it is a large membrane-spanning protein that normally serves, 
amongst others, Staphylococcus Aureus and Escherichia coli by latching on to red blood cells, 
perforating the membrane to release the iron content out of the cell, making it available to 
the bacterium.[46,47] It also allows a single strand of DNA to pass through under the effects of 
a transmembrane potential. In this role, haemolysin is used as a DNA sequencing tool as the 
current going through the pore has discrete levels for each base going through it, i.e. the pore 
gets blocked to a different extent per base, which can be quantified and used to determine 
the sequence of the strand going through. [48,49] However, a true sensor that may be dialled 
to a specific compound and concentration at will (with minimal synthetic effort) still is to be 
developed, and proteins in general lack a modular character that would allow for a 
convenient swap to another analyte or concentration level, while maintaining the same 
reporting moiety. 
Pore forming peptides are synthetically much more accessible compared to most proteins, 
and material from a single synthetic campaign could be modified with a variety of 
functionalities without having to go through the entire procedure of expressing and then 
purifying a new protein.[50] The goal of this work, ultimately, will therefore be to develop a 
pore forming platform capable of being tuned for various conditions, to serve as a bio-
compatible sensor. However, to this end, first the platform itself will have to be developed. 
In order to build even the simplest model as described above, several criteria would need to 
be met. 




- A pore forming peptide should not be detrimental to the structural integrity of the 
membrane. 
- A pore forming peptide should tolerate modifications, without complete loss of 
activity 
- Pores should be uniform in size 
- Pores should be uniform in life time 
- Pore forming activity should be switchable and controllable 
Lastly, a modification to the peptide should be developed that can induce all the above in 
response to the presence of an analyte, however that will be beyond the scope of this work. 
The work presented in this manuscript will focus on developing a pore-forming peptide-based 
construct with control over the pore formation process. 
 
Figure 7 Alamethicin(F30) is a peptaibol. Peptaibols are α-helical peptides with the non-proteinogenic 
amino acid α-aminoisobutyric acid and a C-terminal alcohol group (red highlight). 
In the ‘80s it was already discovered that Alamethicin, of the barrel-stave method pore 
forming peptides, perfectly fits the description for the first criterium. First identified in 1967 
Alamethicin (ALM), now identified as Alamethicin F30 (ALM F30), has been extensively 
studied for its pore forming behaviour and is considered the benchmark model pore forming 
peptides.[51-54] It is a member of the family of peptaibols, a group ~300 of compounds deriving 
their name from being a peptide (Pept-aibols) which contain the non-proteinogenic amino 
acid α-aminoisobutryic acid (pept-Aib-ols) and have a C-terminal alcohol (peptaib-ol).[55] 
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As mentioned before, Alamethicin (ALM) operates by forming barrel stave pores. The pores 
consist out of 3-11 units of ALM, with 4-8 units per pore being preferred.[56-59] Pore formation 
is both concentration and voltage dependent, requiring a concentration of 1µM in solution 
and a transmembrane potential of 60 mV or more before pore formation will commence.[60,61] 
Also, at these concentrations, it displays essentially no tendency to break the membrane 
down into micelles, making ALM a good fit for the first criterium of not disturbing the 
membrane. 
The ALM template can also tolerate modification, both on the N- and C-terminus, as well as, 
at least some, modification of the ALM sequence itself. [62] 
 
Figure 8 Adding His-Gly to the N-terminus of Alamethicin allows for pore stabilization in the presence 
of metal ions, by Futaki et al. 
For example, introducing an additional His-Gly unit on the N-terminus causes, when in the 
presence of metal ions (Co2+, Ni2+ and Zn2+), creates a preference towards 8-, 10- and 12-
membered ALM pores over other pore sizes. It also causes a remarkable increase in pore 
lifetime, from a typical 20-100 ms to >4 seconds per pore. Also, if the His residue is 
protonated, all pore forming activity ceases. [63]  
Another modification of note is the tolerance towards extra amino acids being introduced on 
either terminus, the C-terminus being generally the most tolerant of the two termini.[64,65] Of 
particular note is that Cysteines can be introduced as well, opening up additional 
modification strategies.[66,67]  Lastly, several analogues were developed where all Aib residues 
are replaced with Leu, variations named dUL-ALM. The resulting dUL-ALM’s showed a general 
decrease in pore stability but remained similar enough to the original peptide to still be 
considered as working analogues for ALM, mostly owing to the synthetic convenience of 
obtaining the latter versus the original peptide.[68]  
Obtaining ALM through biosynthesis suffers from a limited ability to vary the sequence, while 
Solid Phase Peptide Synthesis (SPPS) generally suffered from poor yields until Skrydstrup in 
2009 and later Brimble in 2017 reported more efficient methods for the synthesis of 
peptaibols and ALM in particular. [69,70] 




With this in mind, also the second criterium of modification tolerance is met by ALM and its 
analogues.  
The third criterium, that of producing a uniform pore size, has been met in several ways.  
 
Figure 9 Coupling several Alamethicin units to one cyclodextrin stabilizes pores by blocking the normal 
migration of the monomers in and out of the pore. 
A first solution was proposed by Futaki via the introduction of the aforementioned histidine 
residue to the N-terminus of ALM, producing selectively pores of 8, 10 of 12 ALM units.[63]  
A second approach was attempted by Nishino et al. in 1996 and Woolley in 2007 and finally 
successfully implemented by Skrydstrup et al. where 6 and 7 ALM units were coupled on a 
synthetically introduced C-terminal propargylglycine residue through a copper catalysed click 
reaction to the same face of a cyclodextrin molecule.[71-73] The resulting constructs would give 
only a single pore size per product with an extreme increase in pore lifetime. 
 
Figure 10 when combined with a Leucine-zipper, alamethicin will only form pores in the presence of 
Fe3+ ions. Removing the ions using EDTA effectively halts pore formation. 
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Another method by which the number of units per pore was controlled was the introduction 
of a Leucine zipper to the C-terminus of ALM, again by Futaki et al. [74] In the presence of Fe3+ 
ions, the zippers would come together in pairs, greatly promoting pore formation, with only 
even numbers of ALM present per pore. Removing Fe3+ by adding an excess of EDTA would 
result in a significant reduction of the observed pore forming activity.  
Criterion four, involving obtaining a uniform pore lifetime has not garnered significant 
attention in its own right. This may be in part due to the fact that introducing any form of 
switching behaviour will more than likely limit the time a pore remains open, after its 
formation becomes disfavoured. Furthermore, with proper statistical processing, pore 
longevity on its own may not need to have a significant effect on a signal under observation.  
The last criterion, introducing an on/off switch in the pore forming behaviour of ALM has 
received more attention.  
With the previous examples by Futaki, we have already discussed two instances where pore 
formation activity could be encouraged or strongly disfavoured, in the His-analogue and the 
Leucine zipper. Two more examples will be mentioned in the following, one by G.M. 
Whitesides et al., and a last example by Futaki et al. 
 
Figure 11 Sulphonamide on the C-terminus of Alamethicin allows the peptide to form pores as normal, 
however, introduction of Carbonic Anhydrase II effectively ceases pore formation by binding to the 
sulphonamide group. 
In the first example, the group of Whitesides synthetically introduced a sulphonamide ligand 
to the C-terminus of ALM. When used in experiments, the ALM would behave normally, until 
the protein carbonic anhydrase II (CA II) was introduced. CA II would then bind to the 
sulphonamide and sterically hinder either the pore formation itself, or block the pores from 
letting anything through. Once 4-carboxybenzenesuphonamide was introduced into the 
solution, competing with the sulpho-ALM for CA II, pore formation activity would be rapidly 
restored. [75] 





Figure 12 Alamethicin modified to contain a C-terminal Ca2+-binding segment of Calmodulin will not 
form pores unless the binding segments are allowed to dimerize in the presence of Ca2+ 
Similarly, when ALM (Alamethicin F50, a more hydrophobic ALM variant) was coupled on its 
C-terminus to the C-terminal Ca2+ binding segment of Calmodulin by the group of Futaki, the 
construct would be active, but not form any clearly identifiable pores, until Ca2+ ions were 
introduced into the mixture, allowing the binding segments to dimerize, inducing pore 
formation. Introducing Mg2+ on the other hand had no effect on the behaviour of the 
construct, indicating that the specific ion was required to induce activity, therefore the 
Calcium binding segment was still governing the pore formation as intended.[76] 
Summarizing, Alamethicin has shown great potential to serve as the basis for the switchable 
pore forming construct, which will be further explored in this work. However, to date no 
construct has been made that can reliably meet all requirements, or at least three out of the 
four at the same time, showing the magnitude of the challenge.  
1.3. DNA in templated pore formation. 
So far, mainly synthetic scaffolds, ALM analogues, synthetic ALM derivatives or modified 
protein fragments have been employed in attempting to better control the pore-forming 
process. As Futaki, Kredics and others have pointed out on several occasions, a major group 
of biologically active molecules, capable of changing conformation according to their 
chemical environment has not been investigated at all to date: DNA. [53,62,77]   
First discovered in 1871 by F. Miescher,[78] and first fully structurally characterized by Watson 
and Crick in 1953, [79,80] DNA (deoxyribonucleic acid) is known to most of the public as the 
primary information carrier in essentially all living organisms. In the views of the general 
audience, DNA is considered to be similar to the hard drive in a computer: it stores 
information which can be read, copies itself prior to cell division, and if too many faults or 
mistakes are made during copying, the whole system starts acting up and one gets cancer or 
another serious systemic disease. [81,82]  




Scheme 3 The four nucleobases in standard duplex binding. left: A(denosine)-T(hymine); Right: 
C(ytosine)-G(uanine) 
DNA is built up out of four building blocks, the nucleobases Adenosine (A), Cytosine (C), 
Guanine (G) and Thymine (T). [83,84] The A and T, and the G and C pairs are complementary to 
each other, and can dimerise through hydrogen bridging. When two single strands (ss) of 
DNA are fully complementary to each other, these hydrogen bridges provide enough binding 
energy to form the very stable and iconic double stranded (ds) DNA double helix.  
 DNA however can be employed in many more versatile ways. For instance, by varying the 
level of complementarity between two or more strands, DNA can be used to build elaborate 
structures, as demonstrated in DNA-origami.[85,86] The above serves as an illustration that it 
is not a far stretch to use DNA as a structural directing agent or template in chemistry, and in 
fact has been already done on numerous occasions.[87-92]  
 
Figure 13 A G-quadruplex consists out of 4 Guanines coordinated around a single monovalent cation 
(preferably K+) 
The versatility of DNA does not stop there. Another interesting ability of DNA is to form a 
quadruplex of four (anti)parallel GGG structures around an ion, preferably K+.[93,94] In cells, 




these quadruplexes form in repeats at the end of a chromosome, forming telomers, which 
help govern the DNA multiplication process, shortening with each multiplication until at a 
critical length, the copying process cannot occur and a cell stops dividing.[95,96] In research, 
the individual quadruplexes have been studied extensively and have been found to be of 
remarkable stability.[97,98] As such they may serve as a template or scaffold for other 
processes, either stand-alone or as part of a larger sequence. 
 
Figure 14 Example of a DNA aptamer (thrombin binding aptamer) which will change conformation and 
change into a G-quadruplex in the presence of thrombin. 
Another ability of DNA for the purpose of this work is aptamerism. Some sequences of ss-
DNA, capable of partial self-complementarity, are known to adopt different conformations, 
and exposing different regions for binding of another strand, depending on their chemical 
environment.[99-101] Frequently, the above-mentioned DNA GGG-quadruplex plays a role in 
the tertiary structure of the aptamers.[102,103] These DNA-aptamers therefore serve as 
sensors, in a way similar to certain proteins.[104,105] 
Finally, DNA can be labelled, functionalized and modified, without significantly losing its 
innate characteristics of forming stable superstructures.[106] Moreover, custom (short) 
oligomers of DNA are readily available from a large variety of commercial sources and come 
with a variety of linkers and functionalities to allow for derivatization.[107] 




Figure 15 the ultimate goal of this thesis is to develop a pore forming peptide which will change 
activity depending on the presence of a particular analyte 
1.4. Goal of the thesis 
Considering the above, one can at this point start to imagine how a DNA-oligomer combined 
with ALM or analogue may form the basis for a basic sensor. ALM would be, as discussed 
earlier, employed as the reporting unit by forming pores in a membrane, allowing for a small, 
reproducible and quantifiable current to be produced across the membrane. The attached 
ss-DNA, as an aptamer would be responsible for the sensing and, through its conformational 
changes, control pore formation, which meets the overall goal for this thesis, to develop an 
easily modified, switchable pore forming molecule, based on a DNA-peptide hybrid. 
Before that can be exploited, a few challenges first will need to be met.  
First, an effective method for conjugating a DNA oligomer with ALM needs to be established. 
The main challenge herein lies with combining the strong hydrophobicity of ALM with the 
hydrophilicity of the oligomer. Bringing the reactants together will not be the largest 
challenge, but a hybrid of these two extremes will have hybrid properties, particularly during 
workup, purification, characterization and testing making these four steps more complicated 
than usual, requiring adaptation of standard techniques. As significant amount of material 
will be consumed for this endeavour, it would also be convenient to have an in-house method 
to produce ALM or relevant analogue in larger amounts.  
Second, it should be investigated how exactly an oligomer will affect the pore-forming 
behaviour of ALM: does an oligonucleotide have the ability to hinder or promote pore 
formation depending on which form is being used. And if so, are there benefits for pore 
lifetime and a more uniform size distribution?  




We expect that a non-self-complementary oligomer attached to ALM will have reduced 
activity, as the oligomer attached will serve as steric hindrance, repelling other units and 
lowering the effective ALM concentration on the membrane. Furthermore, we expect that, 
when two complementary hybrids are mixed, they will join in a ds-DNA duplex, bringing two 
ALM moieties together, raising the effective local concentration, promoting pore formation. 
Other than this, the pairing should also ensure that only pores made out of an even number 
of units will be formed. Also, the effect of the DNA-quadruplex would be interesting to 
investigate: the oligonucleotide required would be relatively small (5’-GGGTT-3’), but it 
should be able to promote only single size of pore of four units of ALM and have exceptional 
stability, possibly even comparable to the cyclodextrin-templated pore by Skrydstrup et al. 
The third challenge would be forming a functional sensor. Once it is determined which is the 
best method to influence pore formation by ALM, in terms of sequence, length and method 
of binding (duplex, quadruplex, a third rail system, etc.), a suitable, simple aptamer should 
be introduced. Only once the aptamer-based hybrid functions as intended, can the challenge 
of building an ALM and DNA based functionalized sensor be considered completed. 
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Chapter 2 – Synthesis of Alamethicin and its derivatives 
2.1. Introduction 
Trans-membrane pores play a vital role in cell biology as was discussed in detail in the 
previous chapter. They govern the permeability of the membrane: allowing for small 
molecule transport across a membrane, for nourishment, cell-signalling or even offence and 
defence. [1] These pores exist in various forms, ranging from complex transmembrane 
proteins and protein-complexes e.g. haemolysin, to relatively simple and small peptides e.g. 
mellitin and alamethicin.[2-4] 
Alamethicin is an amphipathic peptide i.e. the peptide has both hydrophobic and lipophobic 
characteristics. In this case, this manifests itself via a hydrophobic surface on one side of the 
folded peptide and a hydrophilic surface on the other, giving it its function. Alamethicin has 
been studied extensively as an ion-channel forming peptide and has been modified 
synthetically in order to better understand its properties. [4-10] 
 
Scheme 1 Alamethicin forms transmembrane pores of the barrel-stave model 
As discussed in the introduction, the pores formed by Alamethicin consist of 3-11 individual 
peptide helices which have self-assembled in response to the local peptide concentration 
on the membrane, with the individual pore-sizes being related to the local concentration. 
Pore formation commences when alamethicin goes from its dormant form to its active form 
at local lipid-surface concentrations of 1 mol% alamethicin (mol alamethicin/mol lipids in 
membrane). Pores become stable at >3,0-3,5 mol% alamethicin when >80% of the on-
surface alamethicin is active and inserting into the membrane.[11] These bundled helices 
form a barrel-stave type pore which traverses the membrane, where the ‘hydrophilic’ face 
of the peptide points inward towards the centre of the pore (Scheme 1). The pores, once 
formed, allow for free passage through the membrane, provided its diameter is adequate. 
For small pores (n = 3, 4), this means a rapid loss of protons and a sodium ion gradient 








Scheme 2 Dynamic pore formation by Alamethicin. The constant association and dissociation of the 
individual peptides allows for new pores to be formed continually. The insertion or removal of 
individual peptides allows for an existing pore to grow or contract 
The pores formed are dynamic as the interactions that bundle individual peptides together 
to form the pore are not covalent in nature. The association and dissociation of individual 
monomers takes place continuously (Scheme 2). Therefore, some properties of these pores, 
especially the number of monomers of an individual pore, the distribution of pore sizes and 
their life-times will change constantly. Also, N- and, particularly, C-terminal modifications 
have shown to give little or no disturbance towards the pore-forming behaviour of these 
peptides as their function is determined by their interior composition rather than their 
termini. These two characteristics, dynamic nature and known structure-activity 
relationship, are key starting points for further research aimed towards transforming these 
peptides into useful tools for the in-vivo investigation of biological processes. By stabilizing 
a particular pore size to favour its formation over other sizes, or by exclusively managing to 
form only one pore at a controlled given time, a highly sensitive molecular sensor could in 
theory be built.  
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However, to be able to develop any process based on these pore forming peptides, 
Alamethicin F30, or an analogue that can be conjugated more readily, needs to be obtained 
in workable quantities. Batches of approximatively 100 mg or, ideally, more, need to 
become readily available to ensure a sufficient supply for further experimentation. To this 
end, a viable laboratory synthesis needs to be developed. The method preferably only 
employs straightforward and scalable bench-top procedures, as opposed to costly known 
alternatives such as design and overexpression of an Alamethicin analogue. An additional 
benefit of synthesis is that it is inherently more suitable to labelling and modification of the 
peptide. This was the first challenge we tacked during our study of these peptides. The aim 
was to develop a method which would allow us easy access to sufficient amounts of 
material to develop novel molecular sensors based on Alamethicin F30. 
 
Figure 1 Alamethicin F30 in three representations: 3D-model, full structure and amino-acid sequence 
– U represents α-aminoisobutyric acid (Aib, U). 
Peptaibols in general pose a significant synthetic challenge and alamethicin, being one of 
the largest peptaibols, is no exception to this rule.[12] While the alcohol on the C-terminus is 
a unique feature that poses its own problems, it is mainly the presence of the eight α-
aminoisobutyric acid (Aib, U) residues that ensure that good synthetic yields are not easy to 
obtain (Figure 1).  
This non-proteinogenic α,α-disubstituted amino acid is the main reason for the very loose 
α-helix observed in peptaibols. This translates, from a synthetic point of view, into 
significant steric hindrance around the gem-dimethyl group residue, and, due to the 
Thorpe-Ingold effect, keeps the bond-angle of its α-carbon rigidly at a 109.5°.  
Ac-UPUAUAQUVUGLUPVUUEQ-Pheol 
 




This combination causes severe difficulties when this residue needs to be incorporated into 
the peptide chain: both the carbonyl activating reagent and the following nucleophile are 
hindered in their attack angles due to the steric hindrance caused by the gem-dimethyl 
group and the sigma donation effect of the neighbouring residue lowers the electrophilicity 
of the carbonyl moiety.  
Previous synthetic attempts indeed suffered greatly from this effect.[12] Those using either 
the (asymmetric) anhydride methods or nowadays classical coupling reagents (e.g. DCC, DIC 
and HBTU/HOBt) gave yields as low as 70% per coupling step, which is insufficient for a 
workable and viable synthesis of a 19-residue peptide. Furthermore, the incorporation of 
the following residue also suffered from steric hindrance as the amine is more hindered 
than in a standard α-amino acid exalting the problem. 
 
Scheme 3 Fluorine activated, microwave assisted synthesis of Alamethicin F30 by Skrydstrup et al. 
Several successful syntheses of Alamethicin have been performed. Most notable among 
these are the works of the group of Skrydstrup and more recently, the group of Brimble 
(published after work on this project was completed).[13, 14] Skrydstrup’s group reported an 
automated, microwave assisted, method employing fluorine-activation of Aib to overcome 
the difficult coupling of this amino acid and a double coupling step for the residue following 
an Aib (Scheme 3). Using this method, overall yields of up to 24% were achieved for 
Alamethicin F30. However, the fluorine anions that get released during each of the coupling 
steps retain corrosive properties and over time form precipitates in the equipment lines, 
blocking or damaging them. It is also generally known that fluorine containing salts are 
corrosive to metals and glass, particularly when heated as these methods often require. 
Hence, using this synthetic approach requires the use of dedicated and costly equipment. 




Scheme 4 Synthesis of Alamethicin F30 by Brimble et al. using a double linker strategy: Rink-AM with 
a second HMBA linker for SPPS followed by  a final NaBH4 reduction to cleave the HMBA linker after 
purification of the crude peptide product. 
Brimble et al. employed a double linker strategy in a carefully tuned manual peptide 
synthesis sequence which employs optimized coupling strategies for each step, ranging 
from classical DIC/HOBt couplings to more specialized crosslinking agents such as COMU 
and HATU this combined with acid fluoride activation for the Aib steps. Their optimized 
approach gave the full-length peptide with a minimum of side-product formation (scheme 
4). The power behind this strategy is the double linker employed, which allowed for facile 
clean-up of the crude peptide product. Due to this linker, the purification of the peptide by 
chromatography was simpler as it now displayed better visibility at 256 nm and eluted 
better due to a slimmer peak shape. After purification, the HMBA linker was cleaved using 
NaBH4 to afford the target peptide. With their method, an overall yield of 18% could be 
achieved. 
In this project, the goal was to develop a facile synthesis of Alamethicin, and potentially 
interesting analogues, using mild reaction conditions and that can be performed on a bench 
without the use of dedicated equipment. 
2.2. Results and discussion 
Initial attempts using automated solid-state peptide synthesis (SPPS) resulted in trace 
quantities of the desired peptide only, confirming earlier reports in literature. In order to 
establish a viable synthetic route, a short model peptide (Ac-VUUEQF-NH2) was selected to 
test different synthetic approaches for both the Aib incorporation and the incorporation of 
the first amino acid after Aib. 
  






Entry Activator Aib-source Product Des-Aib Deprotected 
1 DIC Aib-OH 70% 30% - 
2 HOBt/HBTU Aib-OH 80% 20% - 
3 DIC/OxymaPure Aib-OH 75% 25% - 
4 OxymaPure/HBTU Aib-OH 85% 15% - 
5 COMU Aib-OH >95% <5% - 
6 HATU Aib-OH >95% <5% - 
 - Aib-F 90% n.d. 10% 
Table 1 Screening of activation strategies for the incorporation of Aib in the sequence Ac-UUEQF-NH2. 
Scale: 0.10 mmol, 3.5 equiv. Act/3.0 equiv. Aib, reaction time: 30 min at rt. 
Firstly, an optimal method to incorporate the Aib residue onto a pre-made peptide on resin 
(Fmoc-EQF-RinkAM) was investigated. Classical coupling reagents afforded moderate yields 
of up to 80% per step over 3 steps (Table 1, entries 1-3), which is in line with earlier findings 
of 77% per step for the Aib couplings. Alternatives, such as a combination of HBTU/Oxyma 
or COMU gave improved yields of up to 95% per step (entries 4 and 5). Even better results 
were obtained when using THF as a solvent as opposed to DMF.[15] HATU was particularly 
effective (entry 6), giving rise to yields up to 98% per step.  




Scheme 5 Fluorine mediated Fmoc-deprotection analogous to deprotection by TBAF as reported by 
Amemiya et al. 
A test reaction with Aib(U)-fluoride to obtain a 6-residue peptide (derived from the first 6 
residues in Alamethicin: Ac-VUUEQF-NH2) gave initially only 90% yield per step, but 
interestingly, no Aib(U)-deletion products were found. Other than the desired compound 
the major side products were identified to be Ac-VUUUEQF-NH2, Ac-UUUEQF-NH2 and traces 
of Ac-UUEQF-NH2. The lack of any products where simply one (or more) Aib residues were 
missing from the sequence indicated that during the coupling process the Fmoc protecting 
group was cleaved and the resulting amine subsequently was capped. This process was 
previously encountered in literature by Amemiya et al. when using tetrabutylammonium 
fluoride (scheme 5). [16] It stands to reason that the DIPEA-HF salt can cause similar 
problems. To overcome this problem several potential scavengers were tested, based on 
the work of Jones et al.[17] 
  







Entry Scavenger Product Deprot. Other 
1 - 90% 5% 5% 
2 TMS-OH 85% 10% 5% 
3 iPr3Si-H 80% 10% 10% 
4 iPrOTMS >95% n.d. n.d. 
5 tBu-OTMS >95% n.d. n.d. 
6 (iPr)2CHOTMS 90% 5% 5% 
7 nBuOTBS >95% n.d. n.d. 
8 (iPr)2CHOTBS >95% n.d. n.d. 
Table 2 Performance of silyl-ether based scavengers in Aib-Fluoride peptide coupling 
It was decided to add silyl ethers to the solution as scavengers (Table 2). This greatly 
improved the outcome of the reactions, with several attempts (entries 4, 5, 7 and 8) 
furnishing near quantitative yields per step. TMS-ethers (entries 4 and 5) gave slightly lower 
yields than the TBS-ethers (entries 7 and 8), most likely due to their relative lack of stability 
towards hydrolysis in general. More bulky silyl ethers (TIS, TBS, TBDPS) all performed 
similarly well, with the parent alcohol playing an apparently marginal role. Slightly fewer 
side-products were observed when the diisopropylcarbinyl-ether was used as opposed to 
isopropyl and methyl ethers.  
A method for the complete synthesis of Alamethicin F30, composed of two sets of coupling 
conditions, was thereafter designed based on these findings. For all non-Aib couplings, the 
COMU/Oxyma method in DMF (single or double coupling) was employed while for Aib-F 
couplings, the DMF, DIPEA with TISOiPr as scavenger method was used. During the actual 
synthesis of the complete peptide, it became apparent that the previously employed 
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coupling time of 30 minutes (with agitation) was insufficient and that increasing reaction 
time to 2 hours gave rise to too many side reactions. After some optimisation, a coupling 
time of 60 minutes per batch of reagents was established as being optimal. 
With this procedure in hand, Alamethicin F30, and Cys-Alamethicin F30 were successfully 
synthesized in 4% and 3% isolated yield respectively. These yields were acceptable for initial 
attempts; however, more fine-tuning of the protocol would be required in due time. During 
the analysis of the crude peptides, it became apparent that most of the Aib-related issues 
were resolved and that problems now arose after both proline residues were incorporated 
as significant capping occurred during these steps. A similar issue existed after the Leucine 
and the UVU sections were incorporated, significant capping could again be observed after 
these steps reproducibly over several attempts. These issues could have most likely been 
solved by further optimizing the reaction conditions, likely by switching to the HATU 
coupling reagent (which was later supported by the work of Brimble et al.)[14,18] and also by 
potentially switching to agitation with additional heating or to manual operation of an 
automated SPPS machine. However, because the synthesis proved to be laborious and 
time-consuming, a decision was made to discontinue this original approach, and switch to 
an alternative design.  
An alternative to Alameticin F30 was found in dULC-Alamethicin F30, an analogue where all 
Aib residues are replaced by Leu, a standard amino acid. This analogue has been pioneered 
by DeGrado et al. and was found to display similar pore-forming behaviour, albeit that it is 
less active and the pores are less stable in general.[19,20 ] This behaviour was attributed to 
the tighter α-helix and a further increase in hydrophobicity due to the additional leucines. 
As the mode of action of this analogue was reported to be similar to the original peptide, it 
was regarded as an alternative option for Alamethicin. 
The method by which dULC-ALM-F30 can be synthesized was suitable for automated SPPS 
although it should be noted that due to the strong apolar nature of the peptide, amino acid 










Synthetic yields matched values reported by DeGrado and co-workers, around 20% after 
purification. 
2.3. Conclusion 
A manual SPPS method for the synthesis of ALM-F30 and derivatives was successfully 
developed with promising initial yields. This method uses a combination of Fluorine 
activation of the challenging Aib residue during its incorporation step and a tailored 
activating agent mixture for the remaining coupling steps.  
Also, an analogue of ALM-F30, dULC-ALM-F30, where all Aib are replaced by Leu, has been 
successfully synthesized and characterized.  
2.4. Supplementary Information 
General Experimental 
Unless noted otherwise, all reactions were carried out under a nitrogen atmosphere. 
Reactions were monitored by TLC. All solvents and reagents were obtained commercially. 
The solvents were used without any further purification, reagents were purified as required 
following procedures described in “Purification of Laboratory Chemicals (sixth edition).” 
The 1H NMR spectra were recorded at 400 MHz and 13C NMR spectra were recorded at 100 
MHz. The chemical shifts are reported in ppm relative to solvent residual peak.  
Analytical RP-HPLC was performed on a Shimadzu LC-10AD VP machine using XTerra MS 
C18 Column, 125Å, 3.5 µm, 4.6 mm X 100 mm 
Semi-preparative RP-HPLC purification was performed on a XTerra MS C18 Prep Column, 
125Å, 5 µm, 7.8 mm X 100 mm, with a flow rate of 1.5-2.0 mL/min @ 45°C 
The solvent system was: A = 0.1% TFA in MeCN, B = 0.1% TFA in H2O (double distilled - dd) 
Absorbance was monitored at 210 nm and product percentages are given by peak areas at 
210 nm. 
Low resolution mass spectra were recorded on a XEvo LC-Q-TOF (Waters, ESI-Pos. or Neg. 
mode). 
High resolution mass spectra were recorded on an Orbitrap XL (Thermo Fisher Scientific; ESI 
pos. or neg. mode). 
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2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-isobutyric acid (Fmoc-Aib-OH) 
α-aminoisobutyric acid (5.2 g, 50 mmol, 1.0 equiv.) 
and Na2CO3 (26.4 g, 250 mmol, 5 equiv.) were 
dissolved in water (200 ml, 0.25 M) , followed by 
adding 1,4 dioxane ( 200mL, 0.125 M) and addition of 
9-fluorenylmethoxycarbonyl chloride (15.7 g, 55 
mmol, 1.1 equiv.) while stirring vigorously. After the 
starting material was consumed according to TLC, water (200 mL) was added and the 
mixture washed with Et2O (3 x 250 mL). Subsequently, the aqueous phase was acidified 
with concentrated HCl (aq., final pH = 1) and extracted with EtOAc (3x 300 mL). The organic 
layer was subsequently dried over Na2SO4, filtered and concentrated in vacuo. The resulting 
white powder was used without any further purification (14.1 g, 43 mmol, 87%). 1H-NMR 
(400 MHz, CDCl3): δ (ppm) 12.30 (s, 1H), 7.67 (d, J = 7.3 Hz, 2H), 7.56 (d, J = 7.3 Hz, 2H), 7.31 
(t, J = 7.3 Hz, 2H) 7.33 (t, J = 7.3 Hz, 2H), 4.22 (d, J = 6.6 Hz, 2H) 4.14 (d, J = 6.6 Hz, 1H), 1.41 
(s, 6H) 13C-NMR (100 MHz, CDCl3): δ (ppm) 176.0, 155.1, 144.0, 140.8, 127.8, 127.2, 125.4, 
120.2, 65.4, 55.3, 46.8, 25.3; MS (ESI-TOF): calculated for C19H20NO4 [M+H]+: m/z 326.14, 
found 326.14. 
2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-2-methylpropanoic fluoride 
In a flame-dried Schlenk flask under Argon, Fmoc-Aib-
OH (1.63 g, 5 mmol, 1.0 equiv.) was suspended in CH2Cl2 
(25 mL, 0.2 M). Pyridine (0.41 mL, 5 mmol, 1.0 equiv.) 
was added and the mixture was cooled to 0° C. Cyanuric 
Fluoride (0.19 mL, 10 mmol, 2.0 equiv.) was added 
dropwise and the resulting solution was stirred 
overnight, while slowly warming to room temperature. CH2Cl2 (100 mL) was added and the 
mixture was washed with water (3 x 100 mL). The organic phase was dried over Na2SO4, 
filtered and concentrated in vacuo. The resulting solid was recrystallized from CHCl3 and 
pentane, resulting in white needles, which were used without further purification (1.32 g, 
4.0 mmol, 80%). 1H-NMR (400 MHz, DMSO-d6): δ (ppm) 8.17 (s, 1H), 7.89 (d, J = 7.6 Hz, 2H), 
7.70 (d, J = 7.2 Hz, 2H), 7.42 (t, J = 7.2 Hz, 2H), 7.33 (t, J = 7.6 Hz, 2H), 4.38 (d, J = 6.4 Hz, 2H), 
4.23 (t, J = 6.4 Hz, 1H), 1.43 (s, 6H). 13C-NMR (100 MHz, DMSO- d6) δ (ppm) 164.4, 155.4, 
143.6, 140.8, 127.6, 127.0, 125.1, 120.1, 65.7, 55.0, 46.9, 24.2; MS (ESI-TOF): calculated for 
C19H19NO4 [M+H]+: m/z 328.13, found 328.13. 
General procedure manual solid phase peptide synthesis (SPPS). 
All resins and amino acids (excluding the acid fluorides) were purchased from Iris Biotech 
(Germany) and used directly. SPPS was carried out manually on a 0.10 mmol scale. Peptide 
grade DMF and CH2Cl2 were purchased from Fischer Scientific and used as provided. 




Prior to use in synthesis, the resin was loaded in a 20 mL fritted syringe, washed with DMF 
(3x 10 mL), and swelled in CH2Cl2 (10 mL) for 15 minutes. 
A general coupling cycle contained the following steps (detailed below): 
Single coupling: 
Deprotection, wash, coupling, wash, acetylation, wash 
Double coupling: 
Deprotection, wash, couple, couple, wash, acetylation, wash 
Fluoride coupling: 
Deprotection, wash, fluoride coupling, fluorine wash, acetylation, wash 
Double fluoride coupling: 
Deprotection, wash, fluoride coupling, fluorine wash, acetylation, wash 
Deprotection: 
Added 20% piperidine in DMF (10 mL), agitated for 15 minutes, check by UV-Vis for full 
deprotection: 2 quartz cuvettes (1 mL) at 301 nm against a 20% piperidine in DMF as a 
blank; ε = 7800 M-1 cm-1 – if required, repeat the procedure. 
Wash: 
The resin was washed with DMF (3 x 10 mL), quickly agitated after each addition of DMF 
Fluorine Wash: 
The resin was washed with DMF (3 x 10 mL), CH2Cl2 (3x 10 mL) and again DMF (3 x 10 mL) – 
the resin is agitated for ~10 seconds after each solvent addition. 
Coupling: 
0.5 mmol of Fmoc-AA-OH was dissolved in 2 mL of a solution of COMU in DMF (0.25 M, 
freshly prepared), the solution was then transferred to the syringe. Subsequently 4 mL of 
DIPEA in DMF (0.5 M) was added to the syringe containing the resin and the resin was 
agitated for 60 minutes, after which the solution was discarded. 
Fluorine Coupling: 
0.5 mmol of Fmoc-AA-F was dissolved in 2 mL DMF, 4 mL of DIPEA in DMF (0.5 M) was 
added, along with 1 mmol of triisopropylsilylisopropyl ether. The solution was transferred 
to the resin and agitated for 60 minutes. 




3 mL of acetic anhydride in DMF (0.5 M) and 3 mL of DIPEA (0.5 M) were added to the resin, 
which was subsequently agitated for 45 minutes, after which the solution was discarded. 
The previously mentioned coupling cycles were used as follows: 
Standard amino acids, not after Aib    Single coupling 
Standard amino acids, after Aib (and after 15 AAs)  Double coupling 
Aib-fluoride, not after Aib, Ala, Val or Leu    Fluoride coupling 
Aib-fluoride, after Aib, Ala, Val or Leu    Double Fluoride 
coupling 
Kaiser test [21] 
Solution A: 0.5 g ninhydrin dissolved in 10 mL EtOH (96%) 
Solution B: 0.4 mL of 0.001 M KCN (aq) dissolved in 20 mL pyridine. 
Transfer some washed and dried resin beads (~1 mg, ad lib.) from the resin holder to a 
small glass test-tube or cuvette. Add 200 µL of solutions A and B and mix well. Heat for 5 
minutes in a 120 °C oven. Let cool down and inspect, a (dark) blue colour on the beads is 
considered “positive” and indicates an incomplete coupling reaction on the resin. 
Alamethicin fragment (Ac-VUUEQF-NH2) 
Synthesized on a Rink-AM resin using the above synthetic protocol. A Kaiser test was 
performed after each coupling, if it was found to be positive, a second coupling step using 
the same residue would be initiated. After synthesis the final deprotection was carried out 
with 20% piperidine in DMF after which the workup was acetylation and an extensive wash 
cycle. The resin was subsequently cleaved using a mixture of TFA/CH2CL2/TIS/H2O (90/4/4/2 
v/v) for 10 minutes, the resulting solution was concentrated to approximately 1 mL and 
subsequently precipitated with ice-cold Et2O. The resulting solid underwent repeated (3 
cycles) centrifugation, decantation and trituration, until the final solid was dried under 
reduced pressure to yield the crude peptide (143 mg, 31% purity). The crude peptide was 
dissolved in MeCN and purified using semi-preparative HPLC using a linear gradient of 30% 
to 100% B in A, which after lyophilisation gave the pure peptide (53 mg, 73%, 95% purity). 
Low resolution Mass spectrometry: C34H54N7O10 [M+H]+, Calculated: 720.39 found: 720.38 
Alamethicin F30 (Ac-UPUAUAQUVUGLUPVUUEQPheol) 
Synthesized on a 2-chlorotrityl resin loaded first with N-Fmoc-phenylalaninol, then as 
described, with a Kaiser test after every second coupling to monitor coupling efficiency. 




Final deprotection was carried out with 20% piperidine in DMF (2 x 10 mL for 30 minutes 
each), followed by acetylation and an extensive wash cycle. The resin was subsequently 
cleaved using a mixture of TFA/CH2CL2/TIS/H2O (90/4/4/2 v/v) for 10 minutes. The resulting 
solution was concentrated to approximately 1 mL and subsequently precipitated with ice-
cold Et2O. The resulting solid underwent repeated (3 cycles) centrifugation (maximum 
setting permissible for the container, at least 10 minutes), decantation and trituration. The 
product was dried under reduced pressure to yield the crude peptide (92 mg, >25% purity). 
The crude peptide was dissolved in MeCN:H2O (2:1) and purified using semi-preparative 
HPLC using a linear gradient from 40% to 100% of A in B with a flow-rate of 2 ml/min, 
resulting in the pure peptide after lyophilisation (8 mg, 4%, 95% purity). MALDI-TOF, 
calculated (M-H)-: 1962.1, found: 1984.1 (M+Na-2H)- 
Cys-AlmF30 (Ac-UPUAUAQUVUGLUPVUUEQFC-NH2) 
Synthesized on a Rink-AM resin as described, with a Kaiser test after every second coupling 
to monitor coupling efficiency. Final deprotection was carried out with 20% piperidine in 
DMF (2 x 10 mL for 30 minutes each), followed by acetylation and an extensive wash cycle. 
The resin was subsequently cleaved using a mixture of TFA/CH2CL2/TIS/H2O (90/4/4/2 v/v) 
for 10 minutes, the resulting solution was concentrated to approximately 1 mL and 
subsequently precipitated with ice-cold Et2O. The resulting solid underwent repeated (3 
cycles) centrifugation (maximum setting permissible for the container, at least 10 minutes), 
decantation and trituration. The product was dried under reduced pressure to yield the 
crude peptide (137 mg, >20% purity). 
The crude peptide was dissolved in MeCN:H2O (2:1) and purified using semi-preparative 
HPLC using a linear gradient from 40% to 100% of A in B with a flow-rate of 2 mL/min, 
resulting in the pure peptide after lyophilisation (7 mg, 3%, 90% purity). HRMS (ESI-Pos), 
Calculated (M+Na)+ 2102.1079, found: 2102.0995 (M+Na)+ 
General procedure Automatic SPPS 
Synthesis was carried out using a CEM Liberty microwave assisted peptide synthesizer on a 
0.10 mmol scale. Prior to use, the resin was swelled for 15 minutes in a mixture of DMF and 
CH2Cl2 (1:1 v/v). Only pre-installed cycles of the CEM Liberty system were employed during 
synthesis. Amino acids and other reagents are dissolved in DMF, unless noted otherwise. 
Microwave heating is only employed in the Fmoc-deprotection and µW-heating steps. 
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Standard single coupling cycle (0.10 mmol scale) 
Operation    Reagent   Vol   Time  
 End temp 
1) Fmoc deprotection  20% piperidine in DMF  7.0 mL x 2  0.5 + 3 min 
 20 and 70 °C 
2) Drain and wash  DMF     7.0 mL x 4  -  
 20 °C 
3) Add amino acid  0.30 M Fmoc-AA-OH   3.0 mL   -  
 20 °C 
4) Add HBTU   0.50 M HBTU   1.0 mL   -  
 20 °C 
5) Add DIPEA   2.00 M DIPEA in DMF  0.5 mL   -  
 20 °C 
6) μW heating   -    -  5 min  
 80 °C 
7) Drain and wash   DMF    7.0 mL x 3  -  
 20 °C 
Standard double coupling cycle (0.10 mmol scale) 
Operation    Reagent   Vol   Time  
 End temp 
1) Fmoc deprotection  20% piperidine in DMF  7.0 mL x 2  0.5 + 3 min 
 20 and 70 °C 
2) Drain and wash   DMF    7.0 mL x 4 -  
 20 °C 
3) Add amino acid   0.20 M Fmoc-AA-OH  2.5 mL   -  
 20 °C 
4) Add HBTU   0.50 M HBTU   1.0 mL   -  
 20 °C 
5) Add DIPEA   2.00 M DIPEA in DMF  0.5 mL   -  
 20 °C 
6) μW heating   -    -   5 min  
 80 °C 
7) Drain    -    -   - 
 - 
8) Repeat 3) to 7) 
9) Wash    DMF    7.0 mL x 3  -  
 20 °C 





Standard amino acids, not after Aib    Single coupling 
Aib and all amino acids after Aib     Double coupling 
 
Attempted synthesis of Alamethicin F30 (Ac-UPUAUAQUVUGLUPVUUEQPheol) 
Synthesized on a 2-chlorotrityl resin loaded first with N-Fmoc-phenylalaninol, then as 
described. Final deprotection was carried out with 20% piperidine in DMF (2 x 10 mL for 30 
minutes each), followed by acetylation using a mixture of Ac2O (1 mmol) and DIPEA (1 
mmol) in DMF (8 mL, 0.125 M each) and a wash cycle with DMF (3 x 10 mL) and CH2Cl2 (3 x 
10 mL). The resin was subsequently cleaved using a mixture of TFA/CH2CL2/TIS/H2O 
(90/4/4/2 v/v) for 10 minutes, the resulting solution was concentrated to approximately 1 
mL and subsequently precipitated with ice-cold Et2O. The resulting solid underwent 
repeated (3 cycles) centrifugation, decantation and trituration. The product was dried 
under reduced pressure. No (significant) amount of target peptide was identified. 
Synthesis of dULC-Alamethicin F30 (Ac-LPLALAQLVLUGLLPVLLUEQFC-NH2) 
Synthesized on Rink-AM resin as described. Final deprotection was carried out with 20% 
piperidine in DMF (2 x 10 mL for 30 minutes each), followed by acetylation using a mixture 
of Ac2O (1 mmol) and DIPEA (1 mmol) in DMF (8 mL, 0.125 M each) and a wash cycle with 
DMF (3 x 10 mL) and CH2Cl2 (3 x 10 mL). The resin was subsequently cleaved using a mixture 
of TFA/CH2CL2/TIS/H2O (90/4/4/2 v/v) for 10 minutes, the resulting solution was 
concentrated to approximately 1 mL and subsequently precipitated with ice-cold Et2O. The 
resulting solid underwent repeated (3 cycles) centrifugation, decantation and trituration. 
The product was dried under reduced pressure to yield the crude peptide (157 mg, 40% 
purity) 
The crude peptide was dissolved in MeCN:H2O (4:1 v/v), and purified using semi-
preparative HPLC using a linear gradient from 60% to 100% of A in B with a flow-rate of 1.5 
mL/min, resulting in the pure peptide after lyophilisation (42 mg, 18%, 95% purity). HRMS 
(ESI-pos), Calculated (M+2H)2+: 1152.6971, found:  1152.6901. 
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Chapter 3 – Synthesis and Characterization of Alamethicin-DNA 
hybrids. 
3.1. Introduction 
Trans-membrane pore formation by peptides and proteins has been of research interest 
since the early 1950’s to the present date.[1-3] The research goals pertaining to these have 
evolved from trying to understand how the pores function (insertion, stabilization, (ion-
)selectivity, life times, etc.) to attempting to utilize these processes, chiefly though among 
others, as a molecular sensors.[2] In the world of proteins, the most well-known application 
of these pore forming peptides is the use of Haemolysin as a RNA/DNA-sequencing tool.[3] 
When a membrane that contains Haemolysin is exposed to a transmembrane potential, these 
pores will allow a strand of single-stranded DNA (ss-DNA) to pass through the membrane. 
The variations in the transmembrane current caused by the passing of the DNA (which 
temporarily blocks the pore to a varying degree) can be measured. These variations can then 
be used to determine the nucleotide sequence of this strand.[4] Other known applications are 
the detection of ions, small molecules and peptides.[5-10]  
 
 
Figure 1 Schematic overview of a triggered pore formation of a dormant modified pore-forming peptide 
by a target analyte. 
Pore forming peptides, and Alamethicin in particular, provide more of a challenge to work 
with as one cannot benefit from a (large) pre-made pore generated by a single protein 
inserting in the membrane which can be readily accessed. Pore forming peptides typically 




need to gather on a membrane and will only insert upon reaching a certain local 
concentration. Furthermore, in contrast to the single, steady pore offered by a large protein, 
the pores formed by these peptides may vary in size depending on the number of peptides 
participating in the pore, which depends on again the local concentration, transmembrane 
potential and susceptibility of the membrane for the particular peptide. However, as 
discussed in the previous two chapters, these peptides are far more readily available in large 
(mg-g) quantities at a fraction of the cost of a similar quantity of large pore forming protein. 
Lastly, the pore forming peptides can be subjected to significant modification as a function 
of the total mass of the peptide, without fear of disturbing the relatively delicate tertiary or 
quaternary structure of a protein. Particularly the C-termini of these peptides may be heavily 
modified. In all, the flexibility and relatively high accessibility of pore forming peptides 
counterbalances the aforementioned downsides, making them a suitable platform with 
which further applications may be developed. [11-16] 
With regards to insertion and or diffusion of these peptides (acting as monomers prior to 
pore formation) and the resulting pore sizes and lifetimes of these pores, the pore forming 
peptides may be employed in potentially more complex situations. As pore formation is 
highly dynamic there is no need for the peptide to be present on the membrane from the 
start of the experiment, and similarly it may be possible to drive the peptides from the 
membrane prior to terminating a measurement. Potentially, these characteristics could be 
combined to form a functional molecular sensor which could be added to a complex sample 
and which would give reliable and quantifiable transmembrane activity when triggered by a 
target analyte, which is the ultimate goal of this project. 
In order to arrive at this goal, several key issues need to be addressed before a functionalized 
pore-forming peptide, based on Alamethicin, can be obtained, as outlined in the 
introduction. First, the resulting pore stability needs to be improved. Once formed, a pore 
should remain stable for a certain, known, period of time. Initially, therefore, our goal will be 
to increase the life-time of the formed pores which should be as long as possible. Later, with 
specific applications in mind, the lifetime of such a pore should be tailorable to suit a 
particular need and also produce pores that are constant in size. Its targeted lifetime and size 
should also allow for reliable and facile quantification of a transmembrane signal.  
Second, especially when considering that barrel-stave type pores will often consist of a 
variable number of monomers, such as in the case of Alamethicin, the resulting pore size 
needs to be more carefully controlled. Indeed, as various pore-sizes give rise to different 
levels of conductance, a non-controlled pore size formation will result in a high variance of 
readout which is contrary to the needs of a molecular sensor which requires a significant, 
quantifiable and reproducible output. This reliability can best be achieved by ensuring only 
one pore size is assembled in a membrane. This in turn can only be done by ensuring that a 
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fixed number of monomers are incorporated when the pore is formed, or at least that this 
number is strongly favoured over others in a distribution.  
Last, for the development of a molecular sensor based on pore-forming peptides, the pore-
forming behaviour itself should become controllable meaning that formation and 
dissociation should be controllable by an exterior factor.  
Overall, if the first two elements could be combined with the latter ability to activate or 
deactivate pore-formation altogether at will one would have an efficient and tuneable 
molecular probe in hand. This (de-)activation of pore formation would ideally be controlled 
by a target analyte, and would result in a quantifiable and reproducible result, depending on 
the concentration of that target analyte. 
 
Figure 2 Pore stabilization of the Alamethicin pores by means of Cyclodextrin linking (Skrydstrup) and 
Calmodulin binding segments (Futaki). 
Two striking examples have been offered by the groups of Skrydstrup and Futaki (See Chapter 
1 for a more detailed review). Skrydstrup et al. successfully addressed the first two challenges 
by tethering six monomers together, linking the Alamethicin C-termini to a cyclodextrin ring, 
forming a pre-fabricated pore with an unprecedented lifetime and a single pore selection. 
[17,18] Futaki et al. have managed to address all three challenges separately. They managed to 
stabilize the Alamethicin pore by introducing zinc-finger proteins on the C-terminus, also 




introducing the ability to switch pore-formation ‘on,’ provided the initial mixture did not 
contain any zinc ions.[13,19,20] Later, they improved this concept by introducing the Calcium 
binding domain of calmodulin to mediate pore formation, which had an even greater impact 
on pore formation and stability. Switching the pore forming activity ‘off’ from an earlier ‘on’ 
state still remains to be achieved however.  
 
Figure 3 Modes of DNA-hybridization to stabilize a dULC-ALM-F30 pore. Left: duplex; centre: single 
strand (non-hybridized); right: G-Quadruplex. 
DNA, however, has, to the best of our knowledge, not yet been investigated as a C-terminal 
additive to pore forming peptides with the aim of controlling or influencing pore formation. 
Yet it would be a highly interesting modification as, with its unique properties compared to 
small molecules and peptides or proteins, it has been successfully employed in a plethora of 
different applications, giving structure, stability or a design template to hybrid materials.  [21-
24]  As such, it could be the ideal candidate for developing a switchable artificial pore-
forming peptide. DNA can stabilize a pore through duplex or G-quadruplex formation, 
forming either a partially pre-formed pore in solution or in the latter case, an entire 
premade pore.[25-27]  
The advantages of DNA do not end there. Indeed, single-strand DNA (ss-DNA) will in general 
not dimerize with itself. This behaviour arises due to a general lack of self-complementarity 
in most (but not all) sequences. This could be used to greatly reduce the activity of an 
attached Alamethicin unit in view of pore size control. Using the duplex to stabilize a pore 
could result in an increase in pore lifetime as well as a reduction in the amount of 
conductance states (related to the monomers per pore), as it limits the options of pore sizes 
to even numbers of monomers. DNA-quadruplexes are even more interesting in this regard 
as they should limit pore sizes to only one preferred size and greatly increase the lifetime, 
comparably to the work of Skrydstrup et al., but with the benefit that the G-quadruplex can 
be disassembled.  




Scheme 1 schematic representation of a thrombin binding aptamer employing a G-quadruplex 
Another reason why DNA is an attractive candidate for modifying the behaviour of 
Alamethicin is the fact that some DNA sequences can also be used as a sensor.[28-32]  These 
DNA aptamers are sequences that can bind to particular target analytes (e.g. thrombin, see 
scheme 1) and, in doing so, undergo conformational changes. An aptamer undergoing these 
changes can expose previously hidden domains of its chain as a single (accessible) strand 
across its surface, resulting in alteration of how it interacts with its environment and what 
complementary strands may bind to it. Combining the ability  of an aptamer to respond to its 
environment with an inactive ss-DNA-Alamethicin complex (complementary to the activated 
aptamer) would result in the complex being capable of reversibly activating pore formation 
only when a certain trigger is encountered.  
The goal of this chapter is to prepare and characterize ss-DNA-Alamethicin conjugates. The 
overall objective is to generate conjugates which will allow for the evaluation of the intended 
deactivation of the pore-forming activity of Alamethicin by lone ss-DNA, the stabilization of 
pores by ds-DNA and the pre-made pores of a G-quadruplex hybrid. 
3.2. Results and discussion 
Initially it was envisioned to follow a conjugation strategy similar to what was reported by 
Whitesides et al.[15] This route (Scheme 2), which employed commercially available 
Alamethicin F30 (eliminating any need to synthesize additional materials), began with the 
oxidation of the C-terminal alcohol of Alamethicin F30 to the corresponding aldehyde using 
Dess-Martin periodinane.[33] The desired  oxime was then formed by condensing the newly 
formed aldehyde with the appropriate O-hydroxylamine.  
Alternatively, it was shown that the aldehyde could be used in a reductive amination, 
resulting in the amine analogue of the oxime proposed in Scheme 2. After a proof of principle 




had been established for introducing an oligonucleotide via the oxime pathway, the 
alternative of using reductive amination was proposed to be of particular interest for further 
explorations, as most commercial oligonucleotides are offered with an amine functionality, 
whereas hydroxyl amines are not standard on offer (or at a significantly increased price). This 
Alamethicin F30 Aldehyde provides a flexible platform to make several ALM-F30-Oligo 
hybrids, with options to readily vary the sequence, linker length and characteristics.  
This flexibility greatly appealed to us as it would give us the tool we required to approach our 
final goal, which was to obtain a series of hybrids with different stabilisation techniques: two 
pairs of duplex formers (short, 11-mer and long, 24-mer), a quadruplex-former, and several 
reference compounds to help distinguish behaviour introduced by the oligomer from the 
behaviour of the native peptide (table 1). 
 
Scheme 2 Modification of Alamethicin F30 with oligonucleotides based on the procedure by Whitesides 
et al. 
Nr. Oligonucleotide Sequence Role 
1 - Blank 
2 5’-TGA TT-3’ DNA-Blank 
3 5’-GGG TT-3’ Quadruplex stabilization 
4 5’ ACC ATG CTT AA-3’ Duplex stabilization  (with 5) 
5 5’-TTA AGC ATG GT-3’ Duplex stabilization (with 4) 
Table 1 Designated oligonucleotides for modification of Alamethicin, with predicted function. 
 – Chapter 3 – 
 
45 
We began by attempting to reproduce this model reaction on our substrate to later be better 
able to adapt it to our purpose. To this end, a set of three readily synthesized O-
hydroxylamines was proposed for use in a series of test-reactions. The goal of these tests was 
first to determine if this reaction would reliably convert the terminal alcohol of our peptide 
into the aldehyde and subsequently to the oxime, with minimal to no formation of potentially 
hard to remove side products, in a one pot manner.  Second, we wanted to establish if this 
approach would be suitable for use with our oligonucleotides and their associated 
purification procedures. 
Initial attempts resulted in the decomposition of the starting peptide. Although Dess-Martin 
periodinane and IBX are generally very mild oxidants, it is possible that either a trace 
contaminant in these or a by-product of the reaction caused either the loss, or the total signal 
suppression of the starting peptide and/or product(s) as was evidenced by both MALDI-TOF 
and HPLC analysis of the reaction media. 
 
# Oxidation method Time (h) Conv. (%) Prod. (%) 
1 DMP 3 Full Trace. 
2 IBX 18 n.d. n.d. 
3 Parikh-Doehring 1 Full Trace. 
4 Swern 1 60% Trace. 
5 PCC 18 n.d. n.d. 
Table 2 Screened oxidants for oxidation-modification process: 40 equiv. oxidant in CH2Cl2, 23 equiv. 
benzylhydroxylamine. 
Alternative oxidants were explored as well in an attempt to optimise the Whitesides protocol. 
With the majority of oxidants tested (Dess-Martin Periodinane – DMP, Table 2, entry #1; 
Iodoxybenzoic acid – IBX, #2; Pyridinium chlorochromate – PCC, #5), no product was 
observed. Either the starting materials were recovered or only decomposition of the 
(starting) product could be observed. In later attempts, we decided to use wet 
dichloromethane, obtained by shaking dichloromethane with deionized-water, as solvent. 
The Dess-Martin periodinane (DMP) oxidation strategy gave trace amounts of product under 




these conditions indicating that with sufficient optimisation, the protocol could work. The 
more surprising results were obtained from the Swern and related Parikh-Doehring 
oxidations (entries #3 and #4) which gave full conversion of the starting material to the 
intermediate with relatively limited degradation. Trace amounts of the target product could 
also be observed in the reaction media[34,35]. What drew our interest was that most of the 
material appeared to smoothly convert to the aldehyde but the latter did not further react 
with the hydroxylamine. Decomposition of the material over time seemed to only occur when 
the reaction was performed with excess hydroxylamine in an attempt to drive the reaction 
to completion. Therefore, with apparent good and reproducible conversion of the starting 
alcohol to the aldehyde, the Swern oxidation was selected for further testing and 







1 10 Benzyl  1 n.d. 
2 40 Benzyl 1 Trace.* 
3 200 Benzyl 1 <5%** 
4 2000 Benzyl 1 Decomp. 
5 200 Benzyl 0.5 Trace.* 
6 200 Benzyl 5 <5%** 
7 200 3,4-dimethoxybenzyl 1 n.d. 
8 200 n-octyl 1 n.d. 
Table 3 Screening of reaction conditions and various hydroxylamines for the functionalization of ALM-
F30 using an initial Swern oxidation (1 equiv. oxidant equals 1 equiv. COCl2 and 1.2 equiv. DMSO). 
Reaction time relates to the oxidation step only. *target peak observed in LCMS/MALDI, no LC-peak 
area determined. **no isolated yield, yield estimated on LC-peak area. 
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In order to confirm the effectiveness of the oxidation method further, the Swern conditions 
were varied and more electron rich O-hydroxylamines were used in an attempt to drive the 
reaction towards completion. However, despite repeated attempts, no significant amounts 
of product were observed (table 3).  
As sadly no clear single reason could be identified for the lack of conversion to the oxime of 
the aldehyde, which was apparently formed cleanly, we had to reconsider our approach. In 
our new strategy, we hypothesised that an Alamethicin analogue that required no post-
synthetic modification other than the coupling-step with the target oligonucleotide itself 
could be employed.  
 
 
Scheme 3 Modification of dULC-ALM-F30 with an oligonucleotide as described by L. Gjonaj, n=3, 6. 
3.3. Alternative approach 
In her thesis, L. Gjonaj described an alternative method to arrive at the desired peptide-
oligonucleotide complexes based on a Cysteine - maleimide/O-succinimide - amine linking 
strategy.[36] In this approach, rather than using naturally occurring Alamethicin F30, a C-
terminal Cysteine is added to the sequence to provide an anchor point for the linker and 
attached Oligonucleotide. For reasons of convenience the used peptide was switched for 
dULC-Alamethicin F30 (dULC-ALM-F30), the preparation of which was described in Chapter 
2.[37] 
In this approach, the appropriate amine-functionalized oligonucleotide was first reacted with 
a large excess of linker agent in a buffer-DMF system, followed by purification over a size-
exclusion column and lyophilisation, typically giving rise to quantitative yields of conjugate. 
Second, the conjugate is reacted with an excess of peptide, followed by semi-preparative 




HPLC and a second lyophilisation to afford the final product. The main benefit of this 
procedure is that no additional steps are required on the peptide and only one reaction under 
mild conditions has to be performed on the oligonucleotide before it can be reacted to give 
the final product. 
 
Scheme 4 attempted synthesis of maleimide functionalized oligonucleotide TGATT with 6 carbons 
between oligo and the amine and a 3-carbon linker to the maleimide. 
Several oligonucleotides were tested, initially with a short, 3-carbon, linker (scheme 4), then 
with a longer, 6-carbon, linker between the amide and maleimide functionality. The synthesis 
of the shortest non self-complementary oligonucleotide, TGATT-linker-dULC-ALM, was 
approached first to test the strategy. Out of the two evaluated linkers, only the C6-chain 
appeared to give the desired dULC-ALM-F30 – DNA hybrids (Scheme 5 and Table 4), whereas 
the 3-carbon linker failed to form the first intermediate (Scheme 4).  
  





Scheme 5 Synthesis of dULC-ALM-F30 – Oligonucleotide hybrids in two steps. 1) 5-hexylamine 
functionalized oligonucleotide in phosphate buffer(300µl, pH 7) is reacted with 6-maleimidohexanoic 
acid N-hydroxysuccinimide (100 µl, 20 mg/ml). 2) the maleimido modified oligonucleotide was reacted 
with dULC-ALM-F30 in DMF (500 µl, 6 mg/ml).   
 







2 5’-TGA TT-3’ 11% 
3 5’-GGG TT-3’ 17% 
4 5’ ACC ATG CTT AA-3’ 25% 
5 5’-TTA AGC ATG GT-3’ 27% 
6 




5’-TTC GTC TCC GAT TAG CGC ACT 
ATA-3’-ALM 
12% 
Table 4 synthesized conjugates and final yield - established by UV-Vis absorption @270 nm 
 
Using the C6-linker, all intended products were obtained in medium yield, but in more than 
sufficient quantities for all remaining experiments and therefore no further optimisation was 
performed. Although not explored in this thesis, entries #6 and #7 (table 4) with the longer 
oligonucleotides indicate that this particular method may need further optimization if even 
longer oligonucleotides are pursued.  






Figure 4 HPLC and MALDI traces of dULC-ALM-F30-TGATT hybrid using optimized synthetic and 
analytical approaches. 
The conjugates displayed a strong tendency to aggregate, a tendency which became 
particularly apparent in HPLC and MS experiments as well as when (re)-dissolving the 
materials. In general, a solution would not remain stable for more than a few hours at room 
temperature after which a white deposit would form. It was noticed however that adding 1-
3% of DMF to the solution improved the stability of the solution. The best results were 
obtained in this manner by first dissolving the conjugates in DMF, then diluting the solution 
with water to ~3% (v/v) DMF concentration  
However, adding DMF to the HPLC eluents proved to be detrimental for the separation, even 
when it was only present in the sample as the only solvent. Omitting DMF entirely from the 
sample resulted in a loss of the products on the column, most likely as a result of 
precipitation. The optimal result was obtained by injecting into the HPLC the crude mixture 
after filtration, including DMF in moderate amounts (100 µL), and using a relatively long 
gradient at high flowrates. The reason for this peculiar behaviour is most likely due to the 
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chimeric character of these conjugates which present on one side the extremely hydrophobic 
(amphipathic) Alamethicin and on the other side the strongly hydrophilic oligonucleotide.  
Only linear (very) low-resolution MALDI-TOF in negative mode using CHCA/Citrate matrix 
gave a reliable signal, typically within 20 m/z units of the expected product, which was within 
the margin of error for this particular technique and the related equipment used. HRMS of 
the conjugates were obtained using DMF as a solvent at nanomolar concentrations with both 
Atmospheric Pressure Photoionization (APPI) and Electrospray Ionisation (ESI) being equally 
effective ionization methods.  
Surprisingly, indications for the presence of intact quadruplexes with potassium cations was 




In order to arrive at the ALM-DNA hybrids for analysis of their pore-forming behaviour, their 
synthesis had to be explored and optimized. It was initially attempted to prepare ALM-DNA 
hybrids using a combination of oxidising the C-terminal alcohol of ALM and subsequently 
introducing the oligonucleotide via either reductive amination or oxime-formation. This 
strategy met with little success and was discontinued as generating the final products from 
the aldehyde in one step proved to be unreliable and would require more optimization than 
was considered acceptable for this investigation. An acceptable solution was found by using 
an adapted procedure of L. Gjonaj which ultimately resulted in the successful synthesis of a 
small library of dULC-ALM – Oligonucleotide hybrids and relevant control-compounds. Also, 
for the first time, these compounds were fully characterized. 
3.5. Supplementary Information 
General Information 
Unless noted otherwise, all reactions were carried out under nitrogen atmosphere. Reactions 
were monitored by TLC Silica 60 (Merck Millipore), examined under UV (365 nm and 254 nm), 
and stained by KMnO4, ninhydrin, vanillin or H2SO4 in MeOH (1%). Chromatography was 
performed using the flash-protocols by Still et al. on Silica gel 60 (0.040-0.063 mm) from 
Merck Millipore. [38] 
All solvents and reagents were obtained commercially. Oligonucleotides were obtained from 
Biotez GmbH (Berlin, Germany). ALM-F30 (also: commercially from Sigma Aldrich) and dULC-
ALM-F30 were obtained synthetically, as described in chapter 2. The solvents were used 




without any further purification, reagents were purified as required following procedures 
described in “Purification of Laboratory Chemicals (sixth edition).”[39] 
The 1H NMR spectra were recorded at 400 MHz and 13C NMR spectra were recorded at 100 
MHz. The chemical shifts are reported in ppm relative to solvent residual peak.  
Analytical RP-HPLC was performed on a Shimadzu LC-10AD VP machine using XTerra MS C18 
Column, 125Å, 3.5 µm, 4.6 mm X 100 mm 
Semi-preparative RP-HPLC purification was performed on a XTerra MS C18 Prep Column, 
125Å, 5 µm, 7.8 mm X 100 mm, with a flow rate of 1.5-2.0 mL/min @ 45°C 
The solvent system was: A = 0.1% TFA in MeCN, B = 0.1% TFA in H2O (dd) 
Absorbance was monitored at 210 nm and product percentages are given by peak areas at 
210 nm for non-fluorescent compounds (e.g. alamethicin F30), or at 270 nm (for 
oligonucleotide containing compounds). For reasons of convenience, yields were based on 
the molar absorptivity coefficient of the parent oligonucleotide, not compensating for the 
presence of the peptide (assumed to not absorb significantly in that region). 
Low-resolution mass spectra were recorded on an Applied Biosystems MALDI-TOF 4700 in 
linear negative mode, using a CHCA-matrix with monosodium citrate in Ethanol/water (1:1), 
using pre-mixing of the sample. 
High-resolution mass spectra were recorded on an Orbitrap XL (Thermo Fisher Scientific; ESI 
pos. or neg. mode). 
Experimental procedures 
3-maleimido propanoic acid 
β-alanine (4.45 g, 50 mmol, 1 equiv.) was dissolved in glacial acetic acid 
(200 mL, 0.25M). Maleic anhydride (4.9 g, 50 mmol, 1 equiv.) was 
added and the resulting mixture was heated under reflux for 17 h. The 
acetic acid was removed in vacuo. The residue was taken up in 
chloroform (100 mL) and washed with 1M HCl (2 x 100 mL) and brine 
(100 mL). The organic phase was dried over Na2SO4 filtered and concentrated in vacuo to 
yield the crude product as a white powder. Flash Chromatography (Silica, 60% EtOAc in 
Heptane to 80% in two steps) afforded the pure products as a white powder (7.7 g, 45.7 
mmol, 91%). 1H-NMR (400 MHz, CDCl3): δ (ppm) 6.70 (s, 2H), 3.82 (t, J = 7.1 Hz, 2H), 2.70 (t, J 
= 7.1 Hz, 2H); 13C-NMR (100 MHz, CDCl3): δ (ppm) 176.6, 170.4, 134.3, 33.3, 32.6. Mass (LC-
ESI+TOF): calculated for C7H8NO4 [M+H]+: m/z 170.04, found m/z 170.04. mp. 103-106 °C. 
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3-maleimido propanoic acid N-hydroxysuccinimide ester 
3-maleimido propanoic acid (1.7 g, 10 mmol, 1 equiv.) was 
dissolved in HPLC-grade, dry MeCN (100 mL) N-
hydroxysuccinimide (1.2 g, 10.5 mmol, 1.05 equiv.) was added 
and the solution cooled to 0°C. Diisopropylcarbodiimide (1.9 mL, 
12 mmol, 1.2 equiv.) was added dropwise over 10 minutes after 
which the reaction mixture was stirred for 17 hours while letting 
it return to room temperature. The mixture was then filtered 
and concentrated in vacuo. Flash Chromatography (silica, 50% EtOAc in heptane to 70% 
EtOAc in heptane over 3 steps), followed by a recrystallization from hot EtOAc/pentane 
afforded the product as a fine white powder (825 mg, 3.1 mmol, 31%). 1H-NMR (400 MHz, 
CDCl3): δ (ppm) 6.72 (s, 2H), 3.94 (t, J = 7.0 Hz, 2H), 3.02 (t, J = 7.0 Hz, 2H), 2.82 (s, 4H); 13C-
NMR (100 MHz, CDCl3): δ (ppm) 170.0, 168.7, 166.0, 134.4, 32.9, 29.8, 25.5.Mass (LC-TOF): 
calculated for C11H11N2O6 [M+H]+: m/z 267.06, found m/z 267.06. Mp 167-171 °C 
6-maleimido hexanoic acid 
6-aminohexanoic acid (6.5 g, 50 mmol, 1 equiv.) was 
dissolved in glacial acetic acid (200 mL, 0.25M). Maleic 
anhydride (4.9 g, 50 mmol, 1 equiv.) was added and the 
resulting mixture was heated under reflux for 4 h, until 
monitoring by TLC indicated the full consumption of one of 
the starting materials. The acetic acid was removed in vacuo. The residue was taken up in 
chloroform (100 mL) and was washed with 1M HCl (2 x 100 mL) and brine (100 mL). The 
organic phase was dried over Na2SO4 filtered and concentrated in vacuo to yield the crude 
product as a white powder. Flash Chromatography (Silica, 60% EtOAc in Heptane to 80% in 
two steps) afforded the pure products as a white powder (9.1 g, 43.1 mmol, 87%). 1H-NMR 
(400 MHz, CDCl3): δ (ppm) 6.67 (s, 2H), 3.50 (t, J = 7.6 Hz, 2H), 2.30 (t, J = 7.5 Hz, 2H), 1.70-
1.55 (m, 4H), 1.30 (quin, J = 7.5 Hz, 2H); 13C-NMR (100 MHz, CDCl3): δ (ppm) 179.5, 170.9, 
134.1, 37.5, 33.9, 28.2, 26.2, 24.1. Mp 87-92 °C 
 
6-Maleimidohexanoic acid N-hydroxysuccinimide ester 
6-Maleimidohexanoic acid (1055 mg, 5 mmol, 1 
equiv.) was dissolved in freshly dried and distilled 
DMF (35 mL). N-hydroxysuccinimide (590 mg, 5.2 
mmol, 1.05 equiv.) was added and the solution cooled 
to 0°C. Dicyclohexylcarbodiimide (1240 mg, 6 mmol, 
1.2 equiv.) in DMF (15 mL) was added dropwise over 10 minutes after which the reaction 
mixture was stirred for 14 hours while letting it return to room temperature. The mixture 




was then filtered, and concentrated to about 10 mL in vacuo. The residue was taken up in 
EtOAc (150 mL), filtered, washed with 3 M LiCl (2 x 100 mL), dried over Na2SO4, filtered and 
concentrated in vacuo, to yield the crude product as a light brown semi-transparent oil. Flash 
Chromatography (silica, 50% EtOAc in heptane to 70% EtOAc in heptane over 3 steps), 
followed by a recrystallization from chloroform/pentane afforded the product as a fine white 
powder (710 mg, 2.3 mmol, 46%). 1H-NMR (400 MHz, CDCl3): δ (ppm) 6.67 (s, 2H), 3.50 (t, J = 
7.2 Hz, 2H), 2.81 (s, 4H), 2.57 (t, J = 7.6 Hz, 2H), 1.78 (tt. J = 7.6 Hz, 2H), 1.64(tt., J = 8.2 Hz, J = 
7.6 Hz, 2H) Hz 1.41 (tt, J = 8.2 Hz, J = 7.2 Hz, 2H); 13C-NMR (100 MHz, CDCl3): δ (ppm) 170.9, 
169.0, 168.3, 134.0, 37.5, 30.8, 28.0, 25.9, 25.6, 24.1. Low-resolution mass (ESI-POS), 
calculated for C14H17N2O6 [M+H]+: 309.11, found: 309.10. Mp 70-73 °C. 
2-iodoxybenzoic acid (IBX)[33] 
Procedure from literature, ref. 33. In a 2L round bottom flash equipped 
with a mechanical stirrer and internal thermometer, 2-iodobenzoic acid 
(50 g, 0.2 mol, 1 equiv.) was added to a solution of Oxone (200 g, 0.30 mol, 
1.5 equiv.) in dd-H2O (600 mL, 0.5 M). The solution was heated rapidly (<10 
minutes, also using a heat-gun) to 70°C, ensuring the temperature does not 
exceed 73°C, under rapid stirring. After 4h, the solution was cooled to 
approximately 0°C using a bucket with an ice-salt mixture and left to stand for 2 h, stirring 
slowly. The resulting suspension was filtered (20 cm diameter glass filter), and washed 
repeatedly with water (10 x 100 mL) and acetone (2 x 100 mL). The resulting white powder 
was allowed to dry overnight under vacuum (40.7 g, 145 mmol, 73%) 1H-NMR (DMSO-d6): δ 
(ppm) 8.15 (dd, J = 7.8 Hz, J = 1.4 Hz, 1H), 8.01 (dd, J = 7.5 Hz, J = 1.4Hz, 1H), 7.98 (ddd, J = 
7.8Hz, J = 7.5 Hz, J = 1.4 Hz, 1H), 7.84 (ddd, J = 7.7, J = 7.5 Hz, J = 1.4 Hz, 1H). 13C-NMR (DMSO-
d6) δ 167.5, 146.6, 133.4, 133.0, 131.4, 130.1, 125.0 ppm. Mp 233 °C (decomposes). 
General procedure for the synthesis of hydroxylamines 
The starting alcohol (5 mmol, 1 equiv.) and N-hydroxyphtalimide (820 mg, 5 mmol, 1 equiv.) 
were dissolved in CH2Cl2 (40 mL, 0.125 M) and cooled to 0°C after which tributylphosphine 
(1.85 mL, 7.5 mmol, 1.5 equiv.) was added. Diethylazodicarboxylate (40% wt, 3.5 mL, 7.5 
mmol, 1.5 equiv.) in toluene was added dropwise and the resulting solution stirred overnight 
at room temperature. The mixture was concentrated in vacuo and subsequently 
recrystallized from refluxing EtOH (approx. 70 mL) and filtered off. The filtrate was then 
dissolved in EtOH (50 mL) at reflux, after which monomethylhydrazine (0.3 mL, 5.5 mmol, 1.1 
equiv.) was added over 10 minutes by syringe pump. After 1h at reflux, the mixture was 
concentrated in vacuo after which Et2O (50 mL) was added. After 30 minutes, the mixture 
was filtered, after which the liquor was left to stand and filtered again (3 cycles total). The 
resulting solution was concentrated in vacuo to afford the product. 
  




Benzylalcohol (0.52 mL, 5 mmol, 1 equiv.) was treated as described in 
the above procedure. After concentration in vacuo, the product was 
obtained as a clear colourless oil that quickly yellows upon contact with 
air (472 mg, 3.8 mmol, 77%). 1H-NMR (400 MHz, CDCl3): δ (ppm) 7.32-7.29 (m, 5H), 5.25 (br. 
s, 2H), 4.61 (s, 2H); 13C-NMR (100 MHz, CDCl3): δ (ppm) 137.8, 128.4, 127.9, 77.9. 
3,4 dimethoxybenzylhydroxylamine 
3,4-dimehoxybenzylalcohol (840 mg, 5 mmol, 1 equiv.) was reacted 
as described in the above procedure. After the solution was 
concentrated in vacuo, it afforded the product as a colourless oil 
that turns brown over several days at -20°C (use immediately after 
synthesis) - (692 mg, 3.8 mmol, 76%). 1H-NMR (400 MHz, CDCl3): δ 
(ppm) 6.91-6.89 (m, 2H), 6.85-6.81 (m, 1H), 4.63 (s, 2H), 3.88 (s, 3H), 3.85 (s, 3H). 13C-NMR 
(100 MHz, CDCl3): δ (ppm) 149.2, 148.9, 129.8, 121.0, 111.5, 110.0, 77.8, 55.8 (2). 
Attempted Dess-Martin & IBX oxidation of Alamethicin F30 
Dess-Martin Periodinane (15 mg, 35 µmol, 14 equiv.) was added to a solution of Alamethicin 
F30 (5 mg, 2.5 µmol, 1 equiv.) in CH2Cl2 (1 mL) in a HPLC vial equipped with a magnetic stirrer 
and stirred for 2 h. The mixture was filtered, concentrated in vacuo and checked with MALDI-
TOF – only degradation of the peptide was observed. The crude mixture was taken up in 
MeCN (0.5 mL) and analysed using semi-preparative HPLC (40 % A in B to 80% A in B over 40 
minutes), no significant product or starting material was observed. Using IBX (15 mg, 54 µmol, 
21 equiv.) afforded the same result. 
General procedure for the synthesis of Alamethicin-oximes using the Swern oxidation 
DMSO (10 µL, 140 µmol, 56 equiv.) was dissolved in dry CH2Cl2 (1 mL) in a 1.5 mL HPLC-vial 
equipped with a stirring bar and cooled to -78°C using a dry-ice/acetone bath (using metal 
wire to hold up the vial). Oxalyl chloride (9 µL, 104 µmol, 42 equiv.) was added and the 
resulting mixture was stirred for 15 minutes at -78°C. Alamethicin F30 (5 mg, 2.5 µmol, 1 
equiv.) was dissolved in dry CH2Cl2 (1 mL) in a 4 mL capped vial equipped with a magnetic 
stirring bean and cooled to -78°C. The Oxalyl/DMSO mixture was transferred to the 4 mL vial 
using cannula techniques and additional CH2Cl2 (0.5 mL) was added and the mixture was 
stirred for an additional hour at -78°C. Freshly distilled dry triethylamine (28 µL, 200 µmol, 80 
equiv.) was added and the solution stirred for 1 hour, letting the temperature slowly return 
to room temperature. CH2Cl2 (7.5 mL) was added, after which the solution was washed with 
a saturated ammonium chloride solution (10 mL), saturated NaHCO3 (10 mL) and brine (10 
mL). The organic phase was dried over Na2SO4, filtered and concentrated in vacuo. MALDI-
TOF was used to check both the organic and aqueous phase for decomposition. The residue 




was dissolved in MeOH (1 mL), the appropriate hydroxylamine was added (50 µmol, 20 
equiv.) and stirred at rt. MALDI-TOF was used to monitor the reaction (typically 24+ h).  
The mixture was concentrated in vacuo, taken up in acetonitrile and purification was 
performed via semi-preparative HPLC (40% A in B to 100% A over 30 minutes). 
Attempted synthesis of Alamethicin F30 benzyl oxime 
Benzylhydroxylamine (7 mg, 58 µmol, 23 equiv.) in MeOH (1 mL) was added to the 
Alamethicin solution (prepared as described). After 17 and 24 h, no reaction was observed 
by MALDI-TOF, after 40h, significant degradation was observed and the experiment 
terminated, trace amounts of product were observed, but insufficient for purification. 
Attempted synthesis of Alamethicin F30 3,4-dimethoxybenzyl oxime 
3,4-dimethoxybenzylhydroxylamine (10 mg, 55 µmol, 22 equiv.) in MeOH (1 mL) was added 
to the Alamethicin solution (prepared as described above). After 17 and 24 h, no reaction 
was observed by MALDI-TOF. After 40h significant degradation was observed and the 
experiment terminated, no product was observed. 
Attempted synthesis of  Alamethicin F30 n-octyl oxime 
n-octylhydroxylamine HCL-salt (9 mg, 55 µmol, 22 equiv.) in MeOH (1 mL) was added to the 
Alamethicin solution (prepared as described above). After 17 and 24 h, no reaction was 
observed by MALDI-TOF. After 40h, significant degradation was observed and the experiment 
stopped. No (desired) product was identified. 
General procedure for the synthesis of dULC-ALM-F30 – DNA hybrids 
The appropriate amine-modified oligonucleotide was dissolved in Phosphate-buffer (300 µL, 
pH ~7). 6-Maleimidohexanoic acid N-hydroxysuccinimide ester in DMF (100 µL, 20 mg/ml, 
65mM) was added and the mixture gently agitated for 1 hour, after which the progress of the 
reaction was checked using MALDI-TOF. If any starting oligonucleotide remained, an 
additional aliquot of the 6-maleimidohexanoic acid N-hydroxysuccinimide ester in DMF was 
added and agitated for an additional hour (repeat again if needed). The mixture was then 
purified over a Sephadex G10 size exclusion column using dd H2O as per instructions on the 
package. MALDI-TOF was used to determine which fractions contained the modified 
oligonucleotide, which were subsequently freeze-dried (the fractions that contained 
impurities and oligo as well were combined and purified one more round using the same 
purification protocol). 
The modified Oligonucleotide was taken up in dd H2O (200 µL), after which a solution of dULC-
ALM-F30 in DMF (500 µL, 6 mg/mL) was added. The resulting mixture was agitated for 2h at 
room temperature, after which the reaction was checked using MALDI-TOF. If after 6h 
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starting material was still observed, an additional aliquot of the alamethicin solution was 
added (200 µL) and the mixture agitated overnight. Upon completion of the reaction, the 
mixture was passed through a syringe filter (pore size: 10 µm) and subsequently purified 
using semi-preparative HPLC (40% A in B to 80% A in B over 40 minutes, then 100% A in 10 
minutes, staying at 100% for 10 minutes, followed by a 10-minute flush-back). Lyophilisation 
afforded the final product. 
Attempted synthesis of Maleimide-C3-5’-TGATT-3’ 
The 5’-hexylamine modified oligonucleotide 5’-
TGATT-3’ was treated according to the above 
described protocol, with the exception of using 3-
maleimido propanoic acid N-hydroxysuccinimide 
ester in DMF (100 µL, 20 mg/mL, 75 mM). After 
purification, the product was obtained as a clear film on the vessel wall. MALDI-TOF (Pos), 
Calculated [M-H]-: 1805 m/z Found: 1811 m/z Retention time (HPLC, method A): 38 min.  
Attempted synthesis of dULC-ALM-F30 
The maleimide modified oligonucleotide was then treated following the second half of the 
above procedure. No significant product formation was observed after 72h.  
Maleimide-C6-5’-TGATT-3’ 
The 5’-hexylamine modified oligonucleotide 5’-
TGATT-3’ was treated according to the above 
described protocol. After purification, the product 
was obtained as a light white fibrous solid. MALDI-
TOF (Neg), Calculated [M-H]-: 1863 m/z Found: 
1866 m/z Retention time (HPLC, method A): 37 min. No yield was determined. 
dULC-ALM-F30-C6-5’-TGATT-3’ hybrid 
Maleimide-C6-5’-TGATT-3’ was subjected to the second half of the above procedure. After 
purification, the product was recovered as an off-white fine powder. MALDI-TOF (Neg), 
Calculated [M-H]-: 4170 m/z Found: 4181 m/z, HRMS (ESI-Neg): calculated [M-H]-, found: 
Retention time (HPLC, method B): 31 min. Yield over 2 steps: 11%. 
  





5’-hexylamine modified oligonucleotide 5’-GGGTT-
3’ was reacted using a modified version of the 
general procedure: two consecutive size exclusion 
purifications were required in all attempts. The 
product was obtained as a white sticky solid that 
was difficult to dissolve in dd H2O without sonication. MALDI-TOF (Neg), Calculated [M-H]-: 
1904 m/z Found: 1945 m/z [M-2H+K] Retention time (HPLC): 28 min. No yield was 
determined. 
dULC-ALM-F30-C6-5’-GGGTT-3’ hybrid 
Maleimide-C6-5’-GGGTT-3’ was subjected to the second half of the above procedure. After 
purification, the product was recovered as an off-white fine powder. MALDI-TOF (Neg), 
Calculated [M-H]-: 4207 Found: 4248 [M-2H+K]-, HRMS (ESI-Neg): calculated [M-H]-, found: 
Retention time (HPLC): 48 min. Yield over 2 steps: 17%. 
Maleimide-C6-5’-TTAAGCATGGT-3’ 
The 5’-hexylamine modified 
oligonucleotide 5’-
TTAAGCATGG-3’ was treated 
according to the above 
described protocol. After 
purification, the product was 
obtained as a light white fibrous solid. MALDI-TOF (Neg), Calculated [M-H]-: 3742 m/z Found: 
3748 m/z Retention time (HPLC): 35 min.  No yield was determined for this step. 
dULC-ALM-F30-C6-5’-TTAAGCATGGT-3’ hybrid 
Maleimide-C6-5’-TTAAGCATGGT-3’ was subjected to the second half of the above procedure. 
After purification, the product was recovered as an off-white fine powder. MALDI-TOF (Neg), 
Calculated [M-H]-: 6045 m/z Found: 6051 m/z, HRMS (ESI-Neg): calculated [M-H]-, found: 
Retention time (HPLC): 44 min. Yield over 2 steps: 27%. 
5’-ACCATGCTTAA-3’-C6-Maleimide 
The 3’-hexylamine modified 
oligonucleotide 5’-
ACCATGCTTAA-3’ was 
treated according to the 
above described protocol. 
After purification, the 
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product was obtained as a light white fibrous solid. MALDI-TOF (Neg), Calculated [M-H]-: 3671 
m/z Found: 3680 m/z Retention time (HPLC): 39 min. No yield was determined for this step. 
5’-ACCATGCTTAA-3’-C6-dULC-ALM-F30 hybrid 
5’-ACCATGCTTAA-3’-C6-Maleimide was subjected to the second half of the above procedure. 
After purification, the product was recovered as an off-white fine powder. MALDI-TOF (Neg), 
Calculated [M-H]-: 5976 m/z Found: 5981 m/z, HRMS (ESI-Neg): calculated [M-H]-, found: 
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Chapter 4 – Evaluation of dULC-ALM–DNA hybrids in 
Electrophysiology  
4.1. Acknowledgements 
The measurements in this chapter were obtained in collaboration with Gang Huang and with 
the generous assistance of prof. dr. Giovanni Maglia and prof. dr. Armagan Koçer. 
4.2. Black Lipid Membrane Electrophysiology 
In the previous chapter, the synthesis and purification of several DNA-dULC-Alamethicin 
constructs was reported. This chapter will further investigate the pore forming properties of 
these compounds. 
To measure and quantify the activity of a pore-forming compound, such as the pore-forming 
peptide-DNA hybrids created in Chapter 3, electrophysiology is commonly employed as the 
primary analysis tool.[1,2] In these measurements, a lipid bilayer membrane serves as model 
for a cell membrane, on which the pore forming compound (optionally after being activated 
by a selected analyte) is to act. If the membrane is successfully perforated by the peptide 
complex, the pores will allow ions to cross the membrane. When a transmembrane potential 
is applied at the same time, this results in a small, reproducible and quantifiable current. This 
current is both a function of the applied potential and the pore diameter (in the case of pore-
forming compounds). By dividing the observed current by the potential applied (I/U = 
S(Siemens)), the conductance of the pore forming system can be determined, which is, for 
pore forming peptides, believed to be solely dependent on the pore diameter, i.e. the 
number of monomers per pore.  
This model system is highly simplified, generally not taking into account certain factors such 
as the complex physiological environment cells usually grow in, the crowded nature of most 
cell surfaces or intercellular interactions, however, it remains a good primary evaluation tool 
for our molecules [3]  





Scheme 1. Schematic representation of a Planar lipid bilayer (BLM) setup.  
This technique comes in two main varieties: a ‘patch-clamp’ set-up and a ‘black lipid 
membrane’ one (BLM).[4,5] In the former, a part of a cellular (or vesicular) membrane is 
deposited on a special pipette-tip and in the latter, as used in this investigation, a lipid 
mixture dissolved in n-hexadecane is deposited around a pinhole (180 µm) in a Teflon or 
Delrin™ cup and briefly allowed to dry. The cup is inserted into a holder and thereby two 
compartments of equal volume are created which are both filled with electrolyte. One 
compartment is considered henceforth as the cis-membrane compartment, the other one as 
the trans. Both compartments are then equipped with an Ag/AgCl electrode via a salt-bridge. 
Subsequently, the pore forming compound is typically introduced on the cis side in the 
solution, after which its behaviour in the membrane, in terms of conductance across it, can 
be studied by applying a transmembrane potential (V). If an ion-channel (pore) is formed, it 
will allow ions to pass through the membrane. The current generated by the ions’ passage is 
then recorded by the workstation as a function of time.  
In a typical BLM experiment, this current (Ax) is then measured at various potentials (Vx) and 
resolved into conductance (Sx = Ax/Vx) allowing for a quantitative picture of pore formation 
to be established, typically in the form of a bar graph representing the populations per 
conductance range over a period of time or fixed number of events. Other relevant 
information includes pore lifetime (per conductance range), and standard deviation from the 
expected conductance level for that pore-size. 
Measurements are typically performed in two manners. The first is manual stimulation, i.e. 
longer recordings with long dwell times per voltage (typically tens of seconds to minutes), 
following the behaviour of the formed pore over a longer period of time. The second is by 
episodic stimulation: a script in the software cycles the voltage every few seconds. This has 
as a consequence the membrane potential across the membrane gets inverted, which is 
intended to drive all pore-forming compounds from the membrane’s cis side back into 
solution, effectively returning the experiment to the starting conditions. A notable exception 
is the persistence of any stable pores that may have formed, which can resist this effect until 
the potential is raised to the point the bilayer collapses, as demonstrated in the experiments 
performed later in this chapter.  
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Also, any pore forming compound that has managed to fully traverse the membrane will be 
unaffected, as inverting the potential will now allow the pore-forming compound on the 
trans-side to engage in pore forming behaviour. This last event is highly undesirable and is 
reason to stop the ongoing experiment.  
The main observable difference between ‘stable pores’ and membrane traversal caused 
pores is that a stable pore does not suffer any loss of activity, while for membrane traversal 
pores, a small lag is observed between the potential inversion and continuation of pore 
formation. The latter is typically accompanied by different conductance levels being 
preferred due to the different concentration of pore-forming compound on the trans-side of 
the membrane. 
As stated above, once a pore has formed in the membrane, a current is generated and 
recorded by the system. The exact amount of conductance is a function of the pore size. [6] A 
random rift or defect in the membrane will have a randomly defined conductance, and 
therefore pore-size, whereas a pore generated by a pore-forming compound are defined by 
the characteristics of that compound and therefore will display only particular levels of 
conductance. When a trace is analysed, all observed currents across the membrane are 
identified and catalogued as events. Upon processing, random events will disappear to the 
background due to their uniform distribution, whereas events generated by the analyte will 
mainly concentrate in a few bands or levels of conductance and become clearly visible and 
identifiable.  
 
Figure 1. Example trace of a BLM measurement with three conductance levels (by statistical analysis) 
and obscured events/noise (illustration based on own results from an active pore forming peptide). 
When a sufficient length of trace and/or a sufficient number of events have been collected 
in BLM, the data can be processed. First, noise is filtered out if necessary (e.g. noise from the 




membrane, AC interference at 50 Hz). Then conductance levels are defined by visual 
inspection (e.g. levels 0 and 2 in Fig 1), followed by a refinement upon statistical analysis (e.g. 
levels 1 and 3 in Fig 1).  
It is possible to let the software detect and define all levels, however, in the set-up used for 
this chapter it proved to be more time-consuming than manually defining initial levels. After 
defining the relevant levels, relevant events are identified by analysing the stable sections of 
the trace (i.e. sections where no software or human interference may have affected the 
stability of the membrane). Of these events the following characteristics are of particular 
interest: their current amplitude (in pA) and dwell time (in ms). The amplitude can easily be 
transformed into conductance (nS: pA/mV) and is a measure for relative pore size. The dwell 
time can be used without further transformation and is an indication of the life-time of the 
pore and by extension, the stability of the system.  
4.3. Goal 
The goal of this investigation was two-fold. The first objective was to determine whether an 
Oligo-dULC-Alm hybrid still displays pore-forming activity, and if so, to what extent does the 
activity decrease or improve compared to the unmodified peptide. The second objective was 
to determine the effect that DNA-duplex or quadruplex formation of these hybrids have on 
the overall formation behaviour of the pore construct and to establish whether or not these 
techniques can be employed for the development of a (selectively) switchable pore-forming 
peptide. 
4.4. Results & Discussion 
Entry Acronym Hybrid makeup Function 
1 dULC-ALM - Control 
2 HR ALM*-5’-TGA TT-3’ Control 
3 HQ ALM*-5’-GGG TT-3’ G-quadruplex 
4 HSA ALM*-5’ ACC ATG CTT AA-3’ Duplex HSB 
5 HSB 5’-TTA AGC ATG GT-3’-ALM* Duplex HSA 
6 HLA ALM-5’ TAT AGT GCG CTA 
ATC GGA GAC GAA-3’ 
Duplex HLB 
7 HLB 5’-TTC GTC TCC GAT TAG 
CGC ACT ATA-3’-ALM 
Duplex HLA 
Table 1. Assignment of the various DNA-dULC-ALM hybrid compounds with their assigned roles 
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For the evaluation of pore forming behaviour in BLM-analysis, the hybrids synthesized in 
Chapter 3 were studied (table 1). The single stranded compounds (entries 2, 4 and 5) were 
measured separately first. When using the independent strands, no duplex-formation/DNA-
hybridization is expected to take place. This way, the influence of the DNA-strand can be 
compared with the parent dULC-ALM (entry 1). The expectation was to still observe pore-
forming activity, albeit reduced when compared to the unmodified parent peptide. 
Subsequently, the two hybridized duplex pairs (respectively the two 11-oligomers 4,5 and the 
two 24-oligomers 6,7) were evaluated, with the expectation to observe either more prolific 
pore-formation with higher stability, or higher selectivity towards a particular pore size 
compared to the single stranded compounds, or ideally, even the parent peptide.  
Lastly, the G-quadruplex forming conjugate was considered (entry 2) with the expectation 
that it would behave more as a pre-formed pore with tendencies that may match the work 
previously described by Skydstrup and co-workers.[7,8] This would include an increase in life-
time and specific selectivity towards a particular conductance level. All measurements were 
done both in manual and episodic stimulation to obtain optimal information both on the 
onset of pore-formation and the long-term behaviour of the systems.  
  




4.5. Control experiments 
dULC-ALM 
The reference peptide (dULC-ALM) displayed well defined and spaced conductance levels 
(standard deviations in parentheses) at 0.10 nS (σ 0.013 nS), 0.25 nS (σ 0.018 nS), 0.40 (σ 
0.038 nS) and 0.61 nS (σ 0.071 nS),  (Figure 2) with indications that higher conductance states 
can exist, albeit that they are poorly populated and rarely reached in this under these 
conditions. The typical lifetime of an event was 12-15 ms, with pores typically rapidly opening 
and closing in an uncontrolled, unpredictable fashion, as is expected for this particular 
peptide, as previously reported on by DeGrado.[9]  
 
Figure 2. Event histogram displaying the distribution of conductance levels (nS) of native dULC-ALM (3:7 
POPC:DOPE; 7.5 nM dULC Alm, 1M KCl + 10 mM MOPS, pH 7.2) 
 
























































Single strand hybrid HR  
 
Figure 3. Event histogram displaying the distribution of conductance levels (nS) of HR (3:7 POPC : DOPE; 
7.5 nM HR in 1M KCl + 10 mM MOPS, pH 7.2) 
 
Trace 2. Representative trace for HR at 180 mV. 
HR displayed a strong preference for the formation of pores with 0.05-0.06 nS (σ 0.004 nS) 




















































nS (σ 0.007 nS); 0.34 nS (σ 0.008 nS) and 0.54 nS (σ 0.029 nS). Overall, these pores had an 
average event-life time of under 10 ms. The observations that HR was not particularly active 
in terms of events per second and exhibited long lag-times between event-rich periods, 
typically in the order of minutes, combined with the fact that the pores still displayed activity, 
allows for the conclusion that its behaviour is similar to the parent-peptide of des-Aib-
Alamethicin, albeit with lower conductance levels and a smaller difference in conductance 
between each level. This demonstrates that the addition of a DNA-oligonucleotide to the 
peptide does not obstruct the pore-forming capacity of dULC-ALM, in which case only 
normally distributed noise would be observed, but merely hinders pore formation.  
Single strand hybrid HSA 
HSA displayed a more unpredictable behaviour. Rather than slowly building up (or losing) 
activity on the membrane, it mainly gave short, sharply defined bursts, of pore formation. 
During these so-named bursts, the membrane would frequently break, bringing the 
experiment to an unscheduled, early halt: 5 out of the 8 attempts ended early. It displayed 
poorly resolved levels at 0.07 nS (σ 0.012 nS); 0.12 nS (σ 0.013 nS); 0.22 nS (σ 0.017 nS); 0.40 
nS (σ 0.020 nS) and 0.75 nS (σ 0.033 nS), with average pore lifetimes of 20 ms. Its behaviour 
in terms of stability is more like the native peptide dULC-ALM than HR, implying a certain 
stabilization of the pores due to the added DNA-strand. 
The main difference between HSA and either HR or dULC-ALM is its near total lack of 
population in the higher conductance-levels. This may be explained by different interactions 
between the individual units composing the pore, where the one oligomer sequence (in this 
case, HSA) has more affinity for itself than the other and thereby benefits from more self-
stabilizing effects, resulting in slightly more stable pores. The presence of an oligomer on top 
of the pore forming ALM-component may hinder the flow of ions, explaining the lower 
conductance levels of the hybrid compared to HR or dULC-ALM. 
This line of reasoning might explain the visually and statistically observed differences 
between the activity of the observed compounds. Compared to HR, HSA might be more 
prone to form aggregates in solution, which upon contact with the membrane, could explain 
the more pronounced differences in activity: going from completely inactive with a low local 
concentration of HSA to a ‘burst’ when an aggregate makes contact, causing a high local 
concentration of HSA (increasing the risk of a failure of the membrane as well) and back again 
to near inactivity upon aggregate dissipation in the electrolyte or aggregate departure from 
the membrane, interspersed with the occasional period of “normal” activity due to non-
aggregated material. 
  





Figure 4. Event histogram displaying the distribution of the conductance levels (nS) of HAS (3:7 POPC : 
DOPE; 7.5 nM HSA in 1M KCl + 10 mM MOPS, pH 7.2)  
 
















































Single strand hybrid HSB  
 
Figure 5. Event histogram displaying the distribution of the conductance levels of HSB, insert: slightly 
better resolved conductance levels by using the episodic stimulation program (3:7 POPC : DOPE; 7.5 nM 
HSB in 1M KCl + 10 mM MOPS, pH 7.2). 
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Pore formation activity in this hybrid did not commence as straight-forward as with the two 
previously tested materials. Pore formation would only commence on, lacking a better term, 
membranes capable of holding a larger electrical charge, i.e. display higher than normal 
capacitance. The required membrane capacitance for HSB to display activity would lie around 
180 pF. This is a step up from the typical membrane capacitance of 130-140 pF, observed in 
the successful experiments for the other tested hybrids in this chapter. As membrane 
capacitance could not be reliable ‘dialled in,’ the role of membrane capacitance was not 
further investigated as a variable in these experiments. 
The compound was significantly more active in pore formation than the other non-duplex 
forming compounds evaluated (HR and HSA). The lowest levels were the most populated, 
first 0.07 nS (σ 0.006 nS), followed by 0.12 nS (σ 0.013 nS); 0.24 nS (σ 0.022 nS) and 0.40 nS 
(σ 0.038 nS). A last well-defined conductance level was found at 0.58 nS (σ 0.043 nS), with 
broader and less populated conductance levels in the higher regions, for which no 
(meaningful) standard deviation could be calculated. These higher populations lie at 0.81; 
0.95; 1.3; 1.75 and 2.3 nS. The spike at 0.81 could be regarded as an artefact due to its sharp 
definition and absence in the episodic stimulation trace (figure 5, inset), however, it proved 
to be too consistent in the manual stimulation traces to be simply ignored. The average 
lifetime per pore increased significantly compared to HR, increasing from 6 to 24 ms. This still 
indicates mostly short-lived events and noisy pores, but a certain (additional) stabilization 
becomes apparent compared to the previously tested compound. This is especially the case 
when considering the presence of several higher-level conductance states. This behaviour, 
unexpected but not necessarily undesirable, when compared to HR and HSA again underlines 
that the individual oligomer sequence may play a stronger than anticipated role in altering 
the pore-forming abilities of the dULC-ALM peptide. 
  




Single strand hybrid HLA 
 
Trace 5. best activity trace for HLA (observed for 3 seconds) on total 30 minutes. (3:7 POPC : DOPE; 15 
nM HLA in 1M KCl + 10 mM MOPS, pH 7.2) at 210 mV 
This particular hybrid displayed barely any activity when used in either manual or episodic 
stimulation. This behaviour was coherent over several independent attempts, indicating a 
near total loss of pore forming activity. Over 6 hours of measurements, it produced a total of 
5 pore events above the noise threshold, 4 at 0.4 nS, one at 0.74 nS, each lasting about 2 
seconds. Whether these are artefacts or genuine pores generated by the hybrid cannot be 
determined beyond reasonable doubt. The total loss of pore-forming activity is highly 
desirable in its own right, as potentially the duplex formation can restore it, forming a truly 
switchable system. 
Single strand hybrid HLB 
HLB displayed slightly better activity than HLA though these events are better described as 
short-lived noisy attacks/perturbations on the membrane than actual stable pore formation. 
Also, in this instance, insufficient data was obtained for detailed analysis due to a lack of 
general activity of this complex. Indications were found for the existence of 2 conductance 
levels at 0.08 and 0.18 nS respectively, with an average lifetime of 60-80 ms. However, with 
only 3000 observed events, the basis for this analysis is limited. Again, the loss of pore 
formation in its own right is, in principle, a good thing as it puts the goal of achieving a truly 





































Figure 6. Event histogram displaying the distribution of the conductance levels of HLB for illustration 
purposes (episodic stimulation data only). (3:7 POPC : DOPE; 15 nM HLB in 1M KCl + 10 mM MOPS, pH 
7.2). 
 


















































4.6. Summary of control experiments 
The control compounds all display similar trends and conductance levels, with some variance 
in average dwell-times. The main difference compared to des-Aib-ALM is that the 
conductance-levels have shifted closer together, becoming less resolved and that 
populations have shifted to favour the lowest states possible. This indicates that the presence 
of single-strand DNA (non-duplex forming) in general destabilizes pore formation and 
reduces activity. The length and sequence of the oligonucleotide used both do appear to play 
a significant role in the exact extent of these effects, likely due to the oligomers ability to 
form a complex with itself or a second unit, resulting in varying levels of pore stabilization. 
Overall, the behaviour of certain of these hybrids show promise by demonstrating the sought 
after lost tendency to form pores which will allow any positive interactions with their 
complementary strands to be more obvious and would make the creation of a switchable 
system easier. 
4.7. Hybrid duplex and G-quadruplex experiments 
Duplex HS(A+B) 
The duplex HS(A+B) formed by combining HSA and HSB (1:1 proportion) displayed 
extraordinary characteristics compared to its individual constituent compounds, being 
generally more active and less disrupting to the membrane. It also displayed activity in a far 
more extended range in terms of conductance levels (up to 3.2 and 4.1 nS) with a poorly 
resolved section between 1 and 2 nS in manual stimulation. Episodic stimulation here shows 
conductance levels of 1.10, 1.36 and 1.50 nS. The average dwell time was increased to 120 
ms overall, going up to 183 ms in one particular level at 0.88 nS, with individual events lasting 
up to 10s being a relatively common occurrence.  
The observed conductance levels are 0.11 nS (σ 0.033 nS), 0.30 nS (σ 0.028 nS), 0.51 nS (σ 
0.045 nS), 0.60 nS (σ 0.034 nS), 0.85 nS (σ 0.038 nS), 1.66 nS (σ 0.146 nS), 2.59 nS (σ 0.143 
nS), 3.21 nS (σ 0.148 nS), 4.08 nS (σ 0.170 nS) 5.25 nS (σ 0.213 nS) and 6.40 nS (σ 0.232 nS). 
  




Figure 7. Event histogram displaying the conductance levels (nS) of duplex HS in manual stimulation 
(30-minute hold times) Insert: HS in episodic stimulation, showing the earliest stages of pore formation 
(hold time: 2s); bilayer: 3:7 POPC : DOPE; 7.5 nM HSA + 7.5 nM HSB in 1M KCl + 10 mM MOPS, pH 7.2) 
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Combining these findings, it is likely that conductance-level 0,88nS (strongly observed in both 
techniques), which also displayed the 183 ms lifetime average, is now highly preferred, in 
contrast with the control traces, due to the additional stability inferred by the DNA-duplex. 
The lower levels are still filled significantly compared to the control compounds, with some 
of them having a shorter lifetime than others, ranging from 80-183 ms averages with a 
seemingly random distribution (it is not that a larger pore is more stable or vice versa). This 
may be attributed to the stepwise manner in which these pores are formed: the various 
states all benefit from the duplex-stabilization, with the conductance level pore size 0,88 nS 
being the most stabilized over time. The higher conductance states that were observed could 
either stem from the further increase in pore-size or might be attributed to multiple events 
occurring at the same time. Especially for the conductance-levels in the high region (3+ nS), 
it stands to reason that at least a second pore is present, which could also explain the 
broadening of each level to at least a certain degree.  
This experiment appears to deliver the proof of principle that DNA can be used to stabilize a 
pore forming system and is able to introduce newly preferred conductance levels with 
significant occurrence not observed in the parent molecules. This indicates that a DNA-based 
switchable pore forming peptide can in fact be achieved through this method. 
Duplex HL(A+B) 
The longer 24-mer duplex HL(A+B), generated from HLA and HLB, generally displayed 
stabilization as well, although from the experiments it became apparent that the general 
pore-forming activity was reduced when compared to the 11-mer duplex. The complex 
displayed populations at conductance levels 0.06 nS (σ 0.018 nS), 0.14 nS (σ 0.029 nS), 0.20 
nS (σ 0.019 nS), 0.31 nS (σ 0.020 nS), 0.48 nS (σ 0.021 nS) and one more densely populated 
at 0.68 nS (σ 0.030 nS).  Indications of larger pore sizes were also present. Remarkably, the 
average lifetime of a pore improved to 207 ms.  
Overall, it can be surmised that the benefit gained from more stabilization by the oligomer is 
offset by the higher “activation” barrier the construct has to overcome before a pore is 
formed or expanded, resulting in more stable, but generally, smaller pores. The overall 
activity of the system was slightly reduced in terms of events/minute compared to HS, but 
HL, in its own right, is still a highly efficient pore-forming system. As this could indicate that 
preferred pore sizes can (also) be tuned via oligomer length, this could become useful 









Figure 8. Event histogram displaying the distribution of conductance levels (nS) of the duplex HL (Bilayer 
3:7 POPC : DOPE; 7.5 nM HLA + 7.5 nM HLB in 1M KCl + 10 mM MOPS, pH 7.2) 
 


















































Figure 9. Event histogram displaying the distribution of the conductance levels (nS) of quadruplex HQ 
(Bilayer: 3:7 POPC : DOPE; 7.5 nM HQ in 1M KCl + 10 mM MOPS, pH 7.2);  
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The G-quadruplex stabilized HQ was by far the most active compound during the tests in 
addition to generally not breaking the membrane. One highly interesting observation was 
that it was highly resistant to cleaning efforts. After the initial run and rigorous cleaning 
procedures, the Delrin sample cups used (on the Cis-side), generally would still be 
contaminated with HQ, in sufficient quantities that pore-forming activity would persist in 
freshly made membranes for 2-3 more cleaning cycles. It is possible that these quadruplexes 
may be working effectively and reliably at far lower concentrations than the concentration 
used in these experiments.  
After the first conductance state observed at 0.05 nS (σ 0.028 nS), the conductance states at 
0.21 nS (σ 0.022 nS), 0.30 nS (σ 0.021 nS), 0.40 nS (σ 0.026 nS), 0.52 nS (σ 0.032 nS), 0.73 nS 
(σ 0.033 nS) and 0.95 nS (σ 0.056 nS), were occupied evenly, with additional, but only 
marginally active, states up to 6 nS. The average lifetimes per event were around 130 ms, 
going up to 150-200 ms for the higher conductance levels with individual events lasting up to 
2000 ms.  
These findings are a strong indication that, as expected, the G-quadruplex is an excellent 
structure for stabilizing a pore. The construct prefers higher conductance states which 
equates to the existence of stable larger pores. While the gain in pore life-time was not 
particularly better than for the duplex experiments, the simplicity of this system (requiring a 
much shorter sequence and simpler purification) might be the way to explore in order to 
further improve on these characteristics. These observations, who are in accord with earlier 
studies by L. Gjonaj,[10] indicate a more pronounced effect by the G-quadruplex, giving good 
hope that with further optimization, even better results can be obtained. 
4.8. Conclusion 
The goal of this chapter was to determine the effect of introducing a DNA-oligomer that can 
give rise to a DNA-duplex or Quadruplex structure on the pore-forming activity of dULC-ALM. 
It was clearly established by BLM-analysis that overall, these peptide derivates, when unable 
to undergo duplex or quadruplex formation, retain their ability to form transmembrane 
pores, albeit at (severely) reduced activity and lower pore-lifetimes. This indicates that pore 
formation is discouraged by the presence of unhybridized ss-DNA. 
For the duplex hybridized DNA-peptide constructs, HS and HL, a clear improvement was 
observed both in terms of higher conductance levels reached and the lifetime of the pores. 
This stabilization appears to increase with the length of the oligomer involved and therefore 
its increased heterodimer stabilization. It should be noted that the price for more stability is 
that it takes on average longer to form a pore with the longer oligonucleotide (HL) than with 
the shorter (HS). The latter appearing to be generally more active in terms of pore formation 
than both the longer oligonucleotide and the individual compounds measured in the control 
experiments. 




The best results were, as hoped for, obtained with the G-quadruplex forming structure HQ, 
which displayed a significant increase in activity, conductance levels and a good pore-
stability. As quadruplexes are part of many aptameric systems, it is expected that with further 
investigation and proper optimization, the quadruplex hybrids can be employed in a 
switchable pore-forming system without any concern for activity-loss or destabilization.  
It can be concluded that the goals of this chapter were met. It was not only established that 
DNA-dULC-Alm hybrid compounds still display pore forming activity on a membrane but also 
that the attached DNA strand can have different effects on the pore forming process 
depending on its hybridization. A proof of principle has been obtained in that the created 
DNA oligomers can be used to modify and control the behaviour of a pore forming peptide, 
alamethicin in this case.  
However, further investigation and optimization is required before a fully functional 
switchable pore-forming peptide can be developed. The main challenges lie in determining 
concentration dependence of the pore forming activity: i.e. establishing a minimum, 
maximum and optimal concentration for pore forming to take place in the presence of these 
compounds. Also determining the exact influence of the oligonucleotide length and sequence 
would require follow-up. Particularly the study of the influence of the length of the 
oligonucleotide is of the essence, as the introduction of an aptamer invariably will lengthen 
the oligomer-side of the construct, the pore-stabilization has to be sufficient to counteract 
any potential negative effects if and when they occur. 
4.9. Supplementary information 
General experimental 
Planar lipid bilayer experiments were carried out on a Warner Instruments 1440A Bilayer 
Clamp Workstation using a Sun-Stir base in combination with an 8-pole low-pass Bessel Filter 
LPF 8, using Clampex 10.2 acquisition software for digitization. Sampling was done at a 
frequency of 10 kHz. All data was treated using a 99-point boxcar filter prior to further 
processing.  
For the first two rounds of experimentation, 4 mL Delrin cups were used for bilayer support, 
aperture size 250 um. Insulated 1/8 mm Ag-wire (10 cm) with 10 mm gold-plated electrode 
was used for the electrodes, the last 3 cm being exposed and coated in AgCl by treating the 
bare wire with a household grade sodium hypochlorite solution for 10 minutes. Agar salt-
bridges (2% agarose, 3 M KCl, 46x1 mm) were used to complete the circuit.  
The third evaluation was performed on a 1 mL setup with a Teflon membrane clamped 
between two chambers, aperture and remaining setup being identical to the above. No 
significant differences were observed between the datasets obtained with either set of cups. 
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The bilayers were formed by drying 1,5 µL of a 3/7 mixture of palmitoyl oleoyl phosphatidyl 
choline (POPC) and di-oleoyl phosphatidyl ethanolamine (DOPE) (10 mg/ml in n-decane) for 
10 minutes on the flattened face of the Delrin cup, taking care to clear the pinhole by gently 
brushing a Kimtech precision wipe against the inside of the pinhole until a puckering can 
clearly be seen in the deposited droplet of lipid-mixture. 
Subsequently, the cup was placed inside the holder and both holder (Cis side) and cup (trans 
side) were filled with 4 mL of electrolyte solution (1M KCl with 10 mM MOPS buffer at pH 
7.2) and a 2 mm magnetic stir-bar was added to the cis (holder) side after placing the 
assembly inside the measuring chamber. Electrodes were connected to either side, after 
which it was verified whether the pin-hole was open by measuring the total current going 
through the set-up (>10.000 pA). Next, the instrument offset was determined, with any offset 
between +/- 2mV and +/- 1 pA being accepted.  
The headstage was set to “capacitance” to observe the formation of the membrane. The 
membrane itself was formed by gently bubbling air from a lipid-coated pipette tip against the 
pinhole. If the bilayer formed within 15 minutes and reached a stable capacitance of >130 pF 
for over 1 minute, the headstage would be switched back to “current,” magnetic stirring 
engaged and the analyte (10 µl; 3mM stock solution) added by Hamilton syringe to the Cis-
side and the measurement was started. After 3 minutes, stirring was switched off, and 150 
mV of transmembrane potential was applied. If within 5 minutes a signal was detected, 
recording on the measurement would begin. Otherwise, after checking the membrane 
capacitance (>130 pF), the transmembrane potential would be raised to 180 mV for 5 
minutes. If that gave no result, a second dose of analyte was added, followed by 3 minutes 
of stirring while applying 180 mV transmembrane potential followed by another 5 minutes 
without stirring. If after that time no signal was observed, the potential was increased to 210 
mV, before the experiment was discontinued. 
At the start of the measurement, the set-up would remain at its initial voltage for at least 5 
minutes, unless the membrane showed signs of excessive stimulation, in which case voltages 
were lowered in 30 mV increments (down to 90 mV) or the potential would be switched to 
negative (-10 mV) for a short period of time before being returned to a positive value. 
After the initial 5-minute wait, the voltage was set to the desired value for measurements 
(180, 150 and 1000 mV) and left to run, while trying to keep interference to a minimum. The 
runs would either entail manual stimulation of the membrane (long periods of the same 
transmembrane voltage, runs 1 and 2), or episodic stimulation.  
Episodic stimulation had the following format: 2s, +150 mV, 0.1s +0 mV, 2s -150 mV, 0.5s 0 
mV, to be repeated for 200-2000 cycles, depending on the activity of the system – The target 
was to observe at least 20k events, taking into account the relatively high levels of noise 
generated by these particular pore-forming compounds.  




Traces were filtered using a boxcar filter over 99 points, followed by single channel search 
over 8 pre-determined levels (0, 10, 20, 40, 70, 100, 250, and 500 pA). The amplitude 
histogram this search produces (in software) was then used to redefine the lower levels to 
the middle of each of the observed populations (rounded up or down to the nearest integer) 
and the single channel search was subsequently repeated.  
The data from three measurements for each individual sample, each using a fresh membrane, 
were combined and copied to Excel, in particular the following event parameters: Level, 
Event Start, Event Stop, Amplitude, Amp. Sd., and Dwell time. All level 0 and level 8 events 
were discarded as being the baseline and noise/outliers (e.g. electrical switch, disturbing the 
table) respectively. Amplitude (in pA) was then divided by the potential applied (in mV) in the 
specific experiment to yield Conductance (in nS). The conductance data was subsequently 
combined with data from other experiments for comparison and final merger into one 
histogram. Each local maximum in the histogram was subsequently reported, rounded to two 
decimals. As in most, if not all analyses, the peaks could not be deconvoluted and levels were 
assigned manually, a meaningful bias could not be always be obtained and is therefore 
omitted for certain samples. 
Dwell data was taken as is (in ms) and plotted as a logarithmic histogram for each population 
separately and the average value was reported if only one maximum was found in the plot, 
otherwise the local maxima were both given. 
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Chapter 5 – Synthesis and evaluation of a trifunctional scaffold 
for peptide-dye-phospholipid hybrids. 
5.1. Acknowledgements 
In collaboration with dr. Rianne Bartelds, prof. dr. Bert Poolman. 
Part of this chapter has been published in: Syga, L.; de Vries, R.H.; van Oosterhout, H.N.; 
Bartelds, R.; Boersma, A.; Roelfes, G.; Poolman, B. ChemBioChem, 2020, 21, 1320-1328. 
5.2. Introduction 
WALP is a 19-residue α-helical model membrane peptide of sequence: 
GWWLALALALALALALWWA, which is widely studied and modified in localization experiments 
in lipid bilayers. [1,2] Computational studies indicate that WALP localization is affected by the 
ganglioside GM1: a ceramide containing one sialic acid moiety (Figure 1). According to these 
reported simulations, this lipid clusters around the WALP peptide and shuttles it to the liquid 
ordered (Lo) phase, in phase separating membranes: a liquid crystal phase of the membrane, 
related to lipid rafts observed in (cellular) plasma-membranes.  
 
Figure 10. Ganglioside GM1, sialic acid moiety on the left, ceramide on the right. 
In order to observe this shuttling behaviour two separate modification steps are needed on 
the peptide, necessitating a double workup. First, the peptide needs to be palmitoylated in 
vitro, and second, its localization studied in giant unilaminar vesicles (GUVs) by confocal 
microscopy. To be able to localize it, the peptide needs to be visualised by means of a 





covalently attached dye. In order to accomplish both these steps, without disturbing the 
native activity of the WALP peptide, an analogue has to be used which possesses a single 
tethering point at its hydrophilic end to which both dye and palmitoyl moieties can be 
attached. Ideally, this tether point should be a scaffold that allows for the facile attachment 
of various dyes and lipids so that these can be screened without having to perform a long 
multistep synthesis for each combination, potentially losing significant amounts of peptide in 
the process. This scaffold would also allow for the screening of various (WALP) analogues or 
another peptide candidate, should the situation require it.[3] 
The goal of this research was to develop a scaffold that could be employed to quickly attach 
three different large functionalities together, to facilitate studies such as that of WALP. In this 
case, for example, these would be the peptide, the phospholipid and a dye.  
In the ideal case, the construction of the complex containing the developed scaffold and 
three components from the individual building blocks should require minimal synthetic work, 
so that if needed, the work could be carried out in facilities not equipped for specialized 
chemical synthesis. 
 
Figure 11. Examples of basic (non-orthogonal) trifunctional linkers used in biochemistry and labelling 
studies. 
Trifunctional molecules are ubiquitous in chemistry: any molecule that has three functional 
groups can be considered trifunctional. If these groups can be readily employed to undergo 
bond formation with another functional group, it has linking-capabilities and therefore could 
be considered a candidate for being a trifunctional linker or scaffold. Even the simplest of 
examples can already achieve a great variety of potential outcomes, based on stochastics, or 
clever (sub stochiometric) introduction of the groups that need to be incorporated (Figure 
2).[4-6] Tri(-orthogonal)-functional linkers are already more of a challenge but still several 
varieties exist,[7-9] two of which are shown below (Figure 3). 




Figure 12. Two tri-orthogonally functionalized linkers, 4 by Knall and co-workers,[10] 7 by Jiracek et al.[11] 
With the goal in mind, of developing the versatile and easy to use scaffold, we began by 
considering several known trifunctional linker structures that could be used as starting points 
during the design phase. For example, we first considered  the elegant option that is offered 
by a tri-orthogonal “click” scaffold which combines an inverse Electron Demand Diels-Alder 
(iEDDA) with a Copper-catalysed Azide-Alkyne Coupling (Cu-AAC) and a thio-Michael reaction 
(between an α,β-unsaturated ketone and a thiol or similar structure) as promoted Knall et 
al.[10] Second, we considered the approach of Jiracek et al. which was to combine two CuAAC 
click reactions with an aldehyde and/or activated ester couplings.[11] However, both the 
above mentioned strategies were considered to be too elaborate for application in a non-
synthetic chemistry lab where robustness and convenience of the approach are key elements 
for success. 
 
Scheme 2. Idealized functionalization of p-azidophenylalanine with three different functional groups 
(the amine being transformed to a maleimide first) 
Alternatively, amino acids are also considered to be a convenient starting point to create 
linker scaffolds as several of them (the non-apolar amino-acids) offer three potentially 
interesting functional groups, two of which are normally already orthogonal to each other, 
can be easily protected and can already be transformed readily by non-specialists. The R-





group in schematic amino-acid 8 can be readily varied, either by modification of a ‘standard’ 
amino acid, or by synthesizing a new one, and can easily be made to play the role of third, 
orthogonal, functional group.  
Based on this, p-Azidophenylalanine 9 was first selected as target scaffold for this project. In 
this approach, target molecule 10 would be synthesized by introducing the phospholipid 
through amide formation on the free acid (R1), Tamra (R2) could be introduced by a photo-
mediated alkyne-azide coupling reaction, and finally the incorporation of the WALP moiety 
(R3) would be done via a thio-Michael reaction on a maleimide, previously formed from the 
amine .[12-13] However, concerns about the stability of the dye under the proposed conditions 
(UV-light) and the need (from a cost-perspective) to maintain a strict order of introduction: 
lipid first, peptide last, meant this proposal needed to be adapted further. 
Scheme 
3. Use of propargylglycine 11 as a trifunctional scaffold as by J.Oelerich (12) and the proposed construct 
for this chapter (13) 
The solution was inspired by previous work by J. Oelerich, who used propargylglycine 11 in a 
project in collaboration with the group of Cordes et al.[14] He demonstrated the versatility of 
this non-proteinogenic amino acid and showed that this would be the candidate of choice to 
serve as basis for the scaffold.  
5.3. Results and discussion 
With this design, a maleimide is introduced on the amine of propargylglycine via substitution, 
a phospholipid on the acid via coupling (dipalmitoyl-sn-glycero-phosphatidyl-ethanolamine, 
DPPE), a dye (5-Carboxytetramethylrhodamine - TAMRA) via the alkyne and click chemistry. 
The WALP peptide is introduced last by reacting WALP-SH with the maleimide. 
Propargylglycine is commercially available and can alternatively be made in a short amount 
of time, in gram-quantities, using known procedures.[15] 




Scheme 4. Synthesis of L-propargylglycine. a) AcCl, NEt3 CH2Cl2 b), EtONa, Propargylbromide, EtOH c) 
LiOH, H2O. d) Enzymatic resolution by Acylase I, H2O 
Propargylglycine 11 was therefore prepared using the procedure by Granja et al. (scheme 
3).[15] Starting from 2-aminodiethyl malonate 14, acetamido malonate 15 was first formed in 
quantitative yield via acetylation. Introduction of the propargyl moiety via substitution onto 
15 smoothly afforded 16. After quantitative hydrolysis of both ethyl esters, free diacid 17 was 
subjected to mono-decarboxylation to afford racemic N-acetyl propargylglycine 18. 
Enzymatic resolution using Acylase I in water then resulted in the desired L-propargylglycine 
(L-11) and R-N-acetyl propargylglycine (R-18). 
 
Scheme 5. Attempted introduction of a maleimide functionality using direct functionalisation and a 
three-carbon linker, with the putative reaction product. 
Initially, it was attempted to directly functionalize the α-amine with maleic anhydride 
(Scheme 4). These attempts failed, resulting either in a ring-opened product or in a complex 
mixture when harsher conditions were explored. Similarly, when attempting to introduce the 
maleimide via a short three-carbon linker, rearrangement of the desired product was the 
primary outcome of the reaction (21). Results by NMR suggest that 1,5-intramolecular 
addition onto one maleimide ester, followed by ring-opening was the main cause of the 
different outcome.  





Experiments with a longer, in this case six-carbon, linker gave the intended product 22 in 
good yield (50%), using a similar protocol to one used by Jens Oelerich (Scheme 5). In the 
next step, dipalmitoyl-sn-glycero-phosphatidyl-ethanolamine (DPPE) was to be coupled to 
the carboxylic acid to obtain 23. The preferred solvent system to solubilise DPPE (chloroform, 
methanol and water, 6/3.5/0.5 v/v)[16] proved incompatible with coupling reagents, forcing 
us to explore alternatives. The two-step, one-pot coupling system using EDC.HCl gave 
unsatisfactory results in this particular instance.[17] However, a two-step procedure could be 
developed, which was composed of first generating an activated ester, followed by rapid 
removal of the insoluble urea side-products and then addition of the activated ester to the 
solution containing DPPE. This was then stirred for an extended period of time, 10 hours, 
which resulted in us obtaining phospholipid modified scaffold 23 in acceptable yield (41%). 
During optimisation, switching the DPPE solvent system for a combination of chloroform and 
2,6-lutidine greatly improved the yield and scalability of the reaction, allowing for amounts 
of 40-70 mg to be prepared during each attempt. 
 




Scheme 6. Synthesis of DPPE and dye functionalized peptides WALP and dULC-ALM. a) 6-
maleimidohexanoic-O-succinimide, K2CO3 b) i)NHS, DCC; ii) DPPE, 2,6 lutidine; c) Dye-Azide, TBTA, 
CuSO3, Sodium ascorbate; d)WALP or dULC-ALM  in TFE. 





The functionalization of DPPE-modified linker 23 with TAMRA or Cyanine-3 (Cy3) dyes to 
respectively give the penultimate products 24 or 25 was fairly straightforward and needed 
little optimization with approximately 30% isolated yield for both compounds.  
Functionalization with the peptide gave a clear single (brightly coloured and fluorescent) 
product on TLC, however, the desired final products 26 and 28 could not be identified. The 
remaining starting scaffold after completion of the reaction could be removed through 
trituration. However, due to the hybrid properties of the final product, it being poorly soluble 
in any solvent but trifluoroethanol, DMSO and DMF, it proved challenging to purify further 
despite multiple attempts via chromatography (HPLC/UPLC/Flash/(Prep-)TLC), crystallization 
or otherwise, meaning further studies are still needed for this product in order to obtain it in 
high purity and verify the correct structures were obtained. [18]  
An attempt was made with an alternative peptide, a cysteine-containing synthetic analogue 
of Alamethicin, dULC-ALM, another membrane-active short peptide. Reacting dULC-ALM 
with both scaffolds also resulted in the formation of a single new product by TLC. So far, no 
purification was established and the final constructs were ultimately not observed in High 
Resolution Mass Spectrometry (HRMS). However, the complete lack of starting material and 
the observed characteristics strongly imply the successful formation of the conjugates in a 
clean manner, albeit that additional investigations remain necessary. 
 
Scheme 7. Synthesis of a tyrosine derived scaffold until the introduction of DPPE. a) propargyl bromide, 
K2CO3; b) HCl in MeOH (anhydrous) c) 6-maleimidohexanoic acid, Et3N, DIC; d) Me3SnOH, DCE, reflux; 
e) i) NHS, DCC; ii) DPPE, 2,6-lutidine. 
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Simultaneously, a slightly shorter synthetic route, as when compared to the propargylglycine 
one, was attempted based on doubly protected Boc-tyrosine methyl ester following the same 
general strategy (Scheme 6). This amino acid is commercially available at acceptable prices. 
This route would save 3 steps and avoids an enzymatic resolution which is costly in terms of 
time and product losses). 
Starting from protected Boc-tyrosine methyl ester 30, it was first propargylated to 31 in good 
yield followed by a quantitative Boc-deprotection to give the corresponding free amine. 
Subsequently, 6-maleimido hexanoic acid was introduced using DIC as coupling agent, 
resulting in maleimidohexanoic amide 32 in moderate yields. After several attempts to 
hydrolyse the methyl ester, it turned out that most conventional methods were too 
aggressive and caused the decomposition of the material rather than hydrolysis. However, 
when using the Nicolaou ester hydrolysis reaction, which employs trimethyltin hydroxide, the 
free acid was obtained in good yields.[19] DPPE was then introduced using the same protocol 
as in the previous section giving product 33 in moderate yields.  
During the final steps (Scheme 7), Tamra and Cy3 were introduced, without any difficulties 
to give the penultimate products (34 and 35) in similar yields (30%) as those observed with 
the propargylamine strategy. Lastly, the final products were formed by reacting the 
respective scaffolds with either dULC-ALM or WALP-SH. Here again, the formation of a single 
new product with bright colouring and fluorescence was observed, assumed to be the desired 
product (36-39). However, as with the previous section, the product could not be identified 
using HRMS. The unreacted starting scaffolds could be removed by trituration, but a positive 
identification of the product, along with a chromatographic purification were left to be 
achieved later by De Vries and Syga.[24] 






Scheme 8. Synthesis of the final constructs based on Tyrosine as a scaffold. a) dye-azide, CuSO4, TBTA, 
sodium ascorbate; b) WALP or dULC-ALM, TFE. 
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In their work, De Vries and Syga managed to tackle the final challenge by adjusting the final 
part of the synthetic approach, by using a Sulfo-Cy3-containing linker 38, obtained from 
intermediate 33 (Scheme 8). In their approach, the Sulfo-Cy3 azide was coupled to the 
palmitoylated linker 33 again using CuAAC, now with the better water-soluble Tris(3-
hydroxypropyltriazolylmethyl) amine (THPTA). With Sulfo-Cy3-labeled linker 38 in hand, the 
final conjugation with WALP was performed in TFE overnight, using DIPEA as an activating 
base. The resulting mixture could be filtered and subsequently be purified by HPLC, to finally 
obtain the trifunctional hybrid 39, and thereby demonstrating the feasibility of this synthetic 
approach. Later in the article, they describe the favourable properties the hybrid displayed 
for localization in biological membranes, proving a trifunctionalized scaffold  is a viable tool 
for these localization studies. 
 
Scheme 9. Synthesis of final WALP and Sulfo-Cy3 conjugated schaffold 39 from scaffold 33 by De Vries  and Syga.[24] 
a) Sulfo-Cy3 azide, CuSO4, THPTA, TFE, H2O, t-BuOH; b) WALP-SH, DIPEA, TFE. 
5.4. Conclusion  
In order to obtain a scaffold that can readily host three different functionalities with a 
minimum of synthetic work involved, two routes were explored. Using either 





propargylglycine or tyrosine, an, in theory, straight forward and facile tri-orthogonal 
functionalization was attempted. While final purification and a full characterization of these 
four products is still to be achieved, the method shows good promise. These difficulties in 
purification are attributed to the challenging properties of the peptides introduced in the 
construct, rather than to the label itself: both peptides are known to be challenging to handle 
and purify even in their unmodified states. With the success of De Vries and Syga in 
synthesizing, characterizing and biologically testing a very similar construct 39, based on 
palmitoylated intermediate 33, the proof of principle has been provided that this method can 
be employed to assemble constructs varying in, dyes, peptides and lipids, with the key steps 
being straight-forward to perform, likely even outside of a synthetic lab, as was our objective. 
5.5. Supplementary information 
General Information 
Unless noted otherwise, all reactions were carried out under nitrogen atmosphere. Reactions 
were monitored by TLC Silica 60 (Merck Millipore), examined under UV (365 nm and 254 nm), 
and stained by KMnO4, ninhydrin, vanillin or H2SO4 in MeOH (1%). Chromatography was 
performed using the flash-protocols by Still et al. on Silica gel 60 (0.040-0.063 mm) from 
Merck Millipore. [23] 
Unless specified otherwise, all solvents and reagents were obtained commercially (Sigma 
Aldrich, Acros Chemicals and TCI Europe). dULC-ALM-F30 was obtained synthetically, as 
described in chapter 2. WALP-SH was obtained from Bachem. The solvents were used without 
any further purification, reagents were purified if required, following procedures described 
in “Purification of Laboratory Chemicals (sixth edition).”[25] 
The 1H NMR spectra were recorded at 400 MHz and 13C NMR spectra were recorded at 100 
MHz. The chemical shifts are reported in ppm relative to the residual solvent peak.  
Analytical RP-HPLC was performed on a Shimadzu LC-10AD VP machine using XTerra MS C18 
Column, 125Å, 3.5 µm, 4.6 mm X 100 mm 
Semi-preparative RP-HPLC purification was performed on a Sunfire ODB C8 Prep Column, 
100Å, 5 µm, 10 mm X 150 mm, with a flow rate of 2.0 mL/min @ 60°C 
The solvent system was: A = 20% MeOH in iPrOH with 0.1% FA, B = 0.1% FA in H2O (dd) 
Absorbance was monitored at 210 nm, 254 nm and the absorption maximum of the 
respective dye (550 nm range) product percentages are given by peak areas at 210 nm for 
non-fluorescent compounds (e.g. Alamethicin F30), or at the absorption maximum (550 nm 
range) for dye containing compounds. For reasons of convenience, yields were based on the 
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molar absorptivity coefficient of the parent dye, not compensating for the presence of lipid, 
linker or the peptide (assumed to not absorb in that region). 
Low-resolution mass spectra were recorded on a Waters XEvo LC-QTOF (ESI, pos/neg) using 
direct injection of the sample (bypass of the LC system). 
High-resolution mass spectra were recorded on an Orbitrap XL (Thermo Fisher Scientific; ESI 
pos. or neg. mode). 
Experimental Procedures 
Synthesis of 2-acetamido-diethylmalonate (15)[15] 
In a 500 mL three-neck flask equipped with a magnetic stirrer, 2-
aminodiethylmalonate (10.18 g, 50 mmol, 1 equiv.) was dissolved in 
CH2Cl2 (250 mL). Triethylamine (20.8 mL, 150 mmol, 3 equiv.) was 
added and the mixture cooled to 0°C. Acetyl chloride (3.5 mL, 50 mmol, 
1 equiv.) was added using a syringe pump over 30 minutes. The 
resulting solution was stirred for an additional hour, after which it was washed with dilute 
HCl (2 x 200 mL, 1M), water (200 mL), saturated NaHCO3 (200 mL) and brine (200 mL). The 
organic phase was then dried using Na2SO4, filtered and concentrated in vacuo. The product 
was obtained as a white solid and used without further purification (9.65 g 44.5 mmol, 89%). 
1H-NMR (400 MHz, DMSO-d6): δ (ppm) 8.75 (d, J = 7.4 Hz, 1 H), 5.05 (d, J = 7.5 Hz, 1 H), 4.15 
(m, 4H), 1.90 (s, 3H), 1.18 (t, J = 7.0 Hz, 6 H). 13C-NMR (100 MHz, DMSO-d6): δ (ppm) 169.9, 
166.5, 62.8, 56.6, 24.0, 14.0. 
Synthesis of 2-acetamido-2-propargyl-diethylmalonate (16)[15] 
2-acetamido-diethylmalonate 15 (5.4 g, 25 mmol, 1 equiv.) and EtONa 
(2.2 g, 32 mmol, 1.25 equiv.) were dissolved in freshly dried, distilled 
EtOH (200 mL) in a 500 mL three-neck flask under a nitrogen 
atmosphere and stirred for 30 minutes. Freshly distilled propargyl 
bromide (3.2 mL, 32 mmol, 1.25 equiv.) was added in 10 minutes using 
a syringe pump, after which the solution was brought to reflux for 4 
hours, until TLC indicated complete consumption of the starting material. The solution was 
concentrated in vacuo and subsequently dissolved in Et2O (150 mL), washed with saturated 
ammonium chloride (100 mL), NaHCO3 (100 mL), water (100 mL) and brine (100 mL), dried 
over Na2SO4, filtered and concentrated in vacuo, to obtain the crude product as a white 
powder. Recrystallization using Et2O/pentane over three crops afforded the product as fluffy 
white needles (5.01 g, 19.64 mmol, 79%). 1H-NMR (400 MHz, CDCl3): δ (ppm) 6.94 (s, 1H), 
4.25 (m, 4H), 3.26 (d, J = 2.7 Hz, 2H), 2.05 (s, 3H), 1.96 (t, J = 2.7 Hz, 1H), 1.25 (t, J = 7.2 Hz, 
6H); 13C-NMR (100 MHz, CDCl3): δ (ppm) 169.5, 166.4, 78.3, 71.7, 66.0, 63.4, 24.1, 23.2, 14.3. 





Synthesis of 2-acetamido-2-propargylmalonic acid (17)[15] 
2-acetamido-2-propargyl-diethylmalonate 16 (2.5 g, 10 mmol, 1 equiv.) 
was added to a solution of LiOH (1 g, 40 mmol, 4 equiv.) in water (100 
mL, 0.4 M) and heated under reflux for 17 h. The resulting clear solution 
was acidified to pH ≤ 2 using 1M HCl (aq), and subsequently extracted 
with EtOAc (3 x 150 mL). The organic phase was dried over Na2SO4, 
filtered and concentrated in vacuo. The product was obtained as a 
brittle, hard and white solid and was used without further purification (1.9 g, 9.5 mmol, 95%). 
1H-NMR (400 MHz, DMSO-d6): δ (ppm) 8.10 (s, 1H), 3.01 (d, J = 2.7 Hz, 2H), 2.84 (t, J = 2.7 Hz, 
1H), 1.91 (s, 3H). 13C-NMR (100 MHz, DMSO-d6): δ (ppm) 173.2, 173.1, 79.9, 71.9, 53.0, 22.5, 
22.4. 
Synthesis of rac-N-acetyl propargylglycine (18)[15] 
2-acetamido-2-propargylmalonic acid 17 (1 g, 5 mmol, 1 equiv.) was 
dissolved in water (25 mL) and heated under reflux for 3 h. The solution 
was acidified to pH ≤ 1 using 1M HCl (aq) and extracted with EtOAc (5 x 
50 mL). The organic phase was dried over Na2SO4, filtered and 
concentrated in vacuo. Recrystallisation of the crude product from 
CHCl3/pentane afforded the final product as white thin needles (640 mg, 4.1 mmol, 82%). 1H-
NMR (400 MHz, MeOD): δ (ppm) 8.05 (br.s, 1H), 4.53 (t, J = 6.2 Hz, 1H), 2.69 (dd, J = 6.2 Hz, J 
= 2.7 Hz, 2H), 2.35 (t, J = 2.7 Hz, 1H), 1.99 (s, 3H); 13C-NMR (100 MHz, MeOD): δ (ppm)  173.3, 
169.0, 82.9, 71.5, 50.7, 30.2, 22.3. 
Synthesis of L-propargylglycine (L-11) 
Racemic N-acetyl propargylglycine 18 (1 g, 6.45 mmol, 1 equiv.) was 
dissolved in dd H2O (70 mL) and neutralized with aqueous LiOH (1 M) to 
pH 7.5-8.0, by digital pH-meter. Acylase I (5.2 mg; 8.3 U/mmol of acetyl L-
amino acid – follow instructions on the package) was added and the 
resulting mixture stirred at 37°C for 24 h in the oven (water bath works 
too). The mixture was then adjusted to pH = 5.0 by dropwise addition of 1M HCl (aq) and 
filtered over fresh activated charcoal. The filtrate was acidified to pH ≤ 2.0 and extracted with 
EtOAc (6 x 30 mL). The resulting aqueous layer was concentrated in vacuo to 1-2 mL and 
applied to a Dowex-50 (H+) column. The column was rinsed with dd H2O until the outflow was 
of neutral pH, after which the column was eluted with 10% NH4OH (aq). The resulting solution 
was concentrated in vacuo and subsequently crashed with acetone to yield the product as a 
hygroscopic white solid (310 mg, 2.7 mmol, 42%). 1H-NMR (400 MHz, MeOD): δ (ppm) 3.49 
(dd, J = 7.4 Hz, J = 4.3 Hz, 1H), 2.75 (ddd, J = 17.2, J = 4.3, J = 2.7, 1H), 2.62 (ddd, J = 17.2, Hz, 
J = 7.4 Hz, J = 2.7 Hz, 1H), 2.43 (t, J = 2.7 Hz, 1H); 13C-NMR (100 MHz, MeOD): δ (ppm) 169.8, 
77.4, 75.6, 52.1, 22.1; LCMS (ESI-POS): C5H8NO2 [M+H]+: 114.05 m/z, found: 114.05 m/z. 
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Synthesis of L-2-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido)pent-4-ynoic acid 
(22) 
Propargylglycine L-11 (260 mg, 2 mmol, 1 equiv.) 
and K2CO3 (500 mg, 4 mmol, 2 equiv.) were 
dissolved in dd H2O (4 mL, 0.5M) under a nitrogen 
atmosphere in a 15 mL Schlenk flask equipped 
with a magnetic stirrer. 6-maleimido hexanoic acid 
N-hydroxysuccinimide ester (680 mg, 2.4 mmol, 1.2 equiv.) in 1,4 dioxane (2 mL) was added 
and the resulting mixture stirred for 2 hours. The mixture was then acidified to pH = 1 using 
1M HCl (aq) and extracted with EtOAc (5 x 20 mL). The organic phase was dried over Na2SO4, 
filtered and concentrated in vacuo. Flash chromatography of the crude (silica, 5% EtOH in 
CH2Cl2 to 15% in 2 steps) afforded the product as a clear oil that later solidified to form white 
brittle crystals (310 mg, 1 mmol, 50%). 1H-NMR (400 MHz, CDCl3): δ (ppm)  6.67 (s, 2H), 6.43 
(d, J=7.42 Hz, 1H) 4.70 (dt, J=7.62, 4.78 Hz, 1H), 3.49 (t, J=7.22 Hz, 2H), 2.77 - 2.82 (m, 2H), 
2.26 (t, J=7.62 Hz, 2H), 2.04 - 2.08 (m, 1H), 1.53 - 1.72 (m, 4H) 1.31 (quin, J=7.71 Hz, 2H); 13C-
NMR (100 MHz, CDCl3): δ (ppm) 173.5, 173.2, 170.9, 134.1, 113.1, 78.29, 71.9, 37.6, 36.1, 
28.2, 26.1, 24.9, 22.0. HRMS (ESI pos), calculated for C15H19N2O5 [M+H]+: 307,12885, found: 
307.12896.  
Synthesis of (2S)-3-(((2-((S)-2-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido)pent-






2-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido)pent-4-ynoic acid 22 (92 mg, 0.3 
mmol, 3 equiv.) was dissolved in dry THF (3 mL) in a 10 mL Schlenk flask under an argon 
atmosphere. N-hydroxysuccinimide (41 mg, 0.4 mmol, 4 equiv.) and 
dicyclohexylcarbodiimide (75 mg, 0.36 mmol, 3.6 equiv.) were added and the mixture was 
stirred for 4h until the starting material was fully consumed as judged by TLC. The mixture 
was then filtered over celite to remove the white precipitate and concentrated to about 1 mL 
in volume. A mixture of DPPE (70 mg, 0.1 mmol, 1 equiv.) in chloroform (4 mL) was made 
using a few drops of 2,6-lutidine to aid the dissolving process (repeated heating/sonication 
cycles were required, even with the added base – typically the process will take half an hour 
before a clear and stable solution was obtained). After cooling down the DPPE-solution to 





room temperature, it was placed in a sonicating bath before the concentrated solution 
containing the O-succinimide was added drop by drop, making sure the solution did not 
precipitate. If the new solution remained clear after addition, it was left to stir for 12-15 h. 
The mixture was then diluted to 10 mL using additional chloroform and washed with 0.1 M 
HCl (10 mL), water (10 mL) and brine (10 mL). The organic layer was then dried over Na2SO4, 
decanted and dried in vacuo, to obtain the crude as a yellow oil. Flash chromatography (silica, 
MeOH/CH3Cl/NH3 5/95/0.1 to 20/80/0.1 in 3 steps) afforded the product as a clear oil that 
later dried into a glassy film (41 mg, 0.042 mmol, 41%). 1H-NMR (400 MHz, CDCl3): δ (ppm) 
7.62 (br. s., 1H), 6.91 (d, J=7.0 Hz, 1H), 6.68 (s, 2H), 5.22 (br. s., 1H) 4.61 (d, J=5.5 Hz, 1H), 4.34 
(dd, J=11.9, 3.3 Hz, 1H), 4.00 - 4.22 (m, 4H), 3.60 (br. s., 1H), 3.49 (t, J=7.2 Hz, 2H), 2.62 - 2.90 
(m, 2 H), 2.20 - 2.40 (m, 6H), 2.08 - 2.15 (m, 1H), 1.49 - 1.74 (m, 8H), 1.02 - 1.43 (m, 52H), 0.79 
- 0.94 (m, 6H); 13C-NMR (75 MHz, CDCl3): δ (ppm) 173.4,173.0, 134.1, 61.9, 34.2, 34.0, 37.9, 
29.7, 29.5 (mult.), 29.4(mult.), 29.3 (mult.), 29.2, 28.2, 26.1, 24.9, 22.7, 14.1; HRMS (ESI POS) 
Calculated C52H91N3O12P [M+H]+: 980.63349, found: 980.62959. Retention time (HPLC): 43-45 
min. 
NB. the exact number of C in the palmitate groups could not be determined using 13C-NMR 
– the peaks labelled ‘mult.’ indicate higher than normal intensities. 
Synthesis of N-Boc-O-propargyl-L-Tyrosine methyl ester (30) 
Boc-L-tyrosine methyl ester (6 g, 20 mmol, 1 equiv.) was dissolved 
in dry DMF (100 mL, 0.2 M), K2CO3 (11 g, 80 mmol, 4 equiv.) was 
added and the suspension was stirred vigorously. 
Propargylbromide (80% in toluene, 5.2 mL, 40 mmol, 2 equiv.) was 
added and the resulting mixture stirred for 6h. The solution was 
concentrated to approx. 15 mL in vacuo and diluted with EtOAc 
(100 mL). The organic phase was then washed with saturated 
ammonia (100 mL), water (100 mL), 3M LiCl (3 x 100 mL) and brine 
(100 mL), dried over Na2SO4, filtered and concentrated in vacuo. 
Flash chromatography of the crude product (silica, 10% EtOAc in heptane) afforded the 
product as a white solid (5.84 g, 17.5 mmol, 88%). 1H-NMR (300 MHz, CDCl3) δ (ppm) 7.05 (d, 
J=8.7 Hz, 2H), 6.90 (d, J = 8.7 Hz, 2H), 4.94 (br. s., 1H), 4.66 (d, J=2.1 Hz, 2H), 4.54 (br. s., 1H), 
3.71 (s, 3H), 2.89 - 3.12 (m, 2H), 2.51 (t, J=2.3 Hz, 1H), 1.41 (s, 9H); 13C-NMR (75 MHz, CDCl3): 
δ (ppm) 173.0, 157.0, 155.5, 130.7, 129.3, 115.1, 80.0, 78.6, 75.5, 55.8, 54.5, 52.1, 37.4, 28.1. 
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Synthesis of O-propargyl-L-Tyrosine methyl ester HCl salt (30B) 
N-Boc-O-propargyl-L-Tyrosine methyl ester 30 (5 g, 15 mmol, 1 
equiv.) was dissolved in anhydrous MeOH (50 mL) under a nitrogen 
atmosphere. Anhydrous HCl in MeOH was generated by slowly 
adding Acetyl chloride (2.5 mL, 40 mmol, 2.4 equiv.) to dry 
methanol (20 mL) cooled to 0°C. Upon completion of the acetyl 
chloride addition, the HCl solution was added via cannula to the 
Boc-tyrosine solution and left to stir for 30 min. The mixture was 
then concentrated in vacuo, and triturated with CHCl3 (3 x 50 mL), 
to afford the pure product as a white fluffy powder (4 g, 15 mmol, 
quant.). 1H-NMR (300 MHz, DMSO-d6) δ (ppm) 7.10 (d, J=8.7 Hz, 2H), 6.93 (d, J = 8.7 Hz, 2H), 
4.94 (br. s., 1H), 4.66 (d, J=2.1 Hz, 2H), 4.54 (br. s., 1H), 3.75 (s, 3H), 2.95 - 3.18 (m, 2H), 2.49 
(t, J=2.3 Hz, 1H). 
Synthesis of methyl (S)-2-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido)-3-(4-
(prop-2-yn-1-yloxy)phenyl)propanoate (31) 
O-propargyl-L-tyrosine methyl ester HCl salt 
30B (1 g, 4 mmol, 1 equiv.) and 6-
maleimidohexanoic acid (1.3 g, 6 mmol, 1.5 
equiv.) were dissolved in CH2Cl2 (50 mL) at 0 
°C, diisopropylethylamine (1.7 mL, 10 mmol, 
2.5 equiv.) was added, followed by 
diisopropylcarbodiimide (0.95 mL, 6 mmol, 
1.5 equiv.) and a single crystal of DMAP. After 
30 min, the reaction was allowed to warm to 
room temperature, after which the reaction was stirred for an additional 3 h, until full 
consumption of the starting material was observed by TLC. The mixture was filtered over a 
sintered glass filter (P4) and subsequently diluted with CH2Cl2 (50 mL) washed with 1M HCl 
(100 mL), saturated NaHCO3 (100 mL) and brine (100 mL). The organic phase was then dried 
over Na2SO4, filtered and concentrated in vacuo. Flash Chromatography (silica, 50% Et2O in 
heptane) afforded the product as a clear oil (860 mg, 2 mmol, 50%).  1H-NMR (300 MHz, 
CDCl3): δ (ppm) 7.01 (d, J=8.6 Hz, 2H), 6.90 (d, J=8.6 Hz, 2H), 6.68 (s, 2H), 5.85 (d, J=7.4 Hz, 
1H), 4.81 - 4.88 (m, 1H), 4.66 (d, J=2.3 Hz, 2H), 3.72 (s, 3H), 3.49 (t, J=7.2 Hz, 2H), 3.06 (ddd, 
J=25.0, 13.7, 5.9 Hz, 2H), .52 (t, J=2.3 Hz, 1 H) 2.16 (t, J=7.4 Hz, 2 H) 1.60 (mult., 4H), 1.22 - 
1.32 (m, 2H). 13C-NMR (75 MHz, CDCl3): δ (ppm) 172.1, 170.8, 156.7, 134.04, 130.3, 128.8, 
115.0, 78.5, 75.5, 55.8, 53.0, 52.3, 37.6, 37.0, 36.2, 28.2, 26.23, 24.9. HRMS (ESI-POS): 
calculated for C23H26N2O6 [2M+Na]+: 875.5728, found: 875.5788 [2M+Na+]+  
 








yloxy)phenyl)propanoic acid (32) 
Methyl (R)-2-(6-(2,5-dioxo-2,5-dihydro-1H-
pyrrol-1-yl)hexanamido)-3-(4-(prop-2-yn-1-
yloxy)phenyl)propanoate (430 mg, 1 mmol, 1 
equiv.) 31 was dissolved in DCE (5 mL, 0.1 M) 
in a sealed tube. Me3SnOH (360 mg, 2 mmol, 
2 equiv.) was added and the solution was 
heated under reflux (80°C) for 2-3 h, until 
complete consumption of the starting 
material based on TLC. The solution was then 
concentrated in vacuo and flash chromatography (silica, 8% EtOH in CH2Cl2) afforded the 
product as a clear oil that solidifies to a white solid over the course of several days (353 mg, 
0.86 mmol, 86%).  1H-NMR (300 MHz, CDCl3): δ (ppm) 7.09 (d, J=8.7 Hz, 2H), 6.91 (d, J=8.7 Hz, 
2H) 6.68 (s, 2H) 6.12 (d, J=7.2 Hz, 1H) 4.84 (dd, J=11.8, 5.6 Hz, 1H) 4.66 (d, J=2.1 Hz, 2H) 3.48 
(t, J=7.2 Hz, 2H) 3.12 (ddd, J=33.8, 14.4, 5.1 Hz, 2H) 2.53 (s, 1H) 2.19 (t, J=7.4 Hz, 2H) 1.50 - 
1.67 (m, 4H) 1.20 - 1.33 (m, 3H); 13C-NMR (75 MHz, CDCl3): δ (ppm) 174.3, 173.5, 170.9, 156.7, 
134.1, 130.4, 128.7, 115.0, 105.0, 78.6. 75.6, 55.8, 53.2, 37.5, 36.1, 28.1, 26.1, 24.9; 
Synthesis of (2S)-3-(((2-((S)-2-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido)-3-(4-
(prop-2-yn-1-yloxy)phenyl)propanamido)ethoxy)(hydroxy)phosphoryl)oxy)propane-1,2-






acid 32 (100 mg, 0.25 
mmol, 2 equiv.) was 
dissolved in freshly 
distilled THF (3 mL) in a 10 
mL Schlenk flask under an argon atmosphere. N-hydroxysuccinimid (40 mg, 0.35 mmol, 2.6 
equiv.) and dicycolhexylcarbodiimide (65 mg, 0.3 mmol, 2.4 equiv.) were added and the 
mixture was stirred for 2h until the starting material was completely consumed as judged by 
TLC. The mixture was then filtered over celite to remove the white precipitation and 
condensed to about 1 mL in volume. While stirring the first solution, a second mixture of 
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DPPE (50 mg, 0.08 mmol, 1 equiv.) in chloroform (4 mL) was made using a few drops of 2,6-
lutidine to aid the dissolving process (repeated heating/sonication cycles were required). 
After cooling down the DPPE-solution to room temperature, it was placed in a sonicating bath 
before the concentrated solution containing the O-succinimide was added dropwise, making 
sure the solution did not precipitate. If the new solution remained clear after addition, it was 
left to stir for 20 h. The mixture is then diluted to 10 mL using additional chloroform and 
washed with 0.1 M HCl (10 mL), water (10 mL) and brine (10 mL). The organic layer was then 
dried over Na2SO4, decanted and dried in vacuo, to obtain the crude as a yellow oil. Flash 
chromatography (silica, MeOH/CH3Cl/NH3 5/95/0.1 to 20/80/0.1 in 3 steps) afforded the 
product as a clear oil that later dried into a glassy film (43 mg, 0.04 mmol, 53%). 1H-NMR (300 
MHz, CDCl3): δ (ppm) 7.14 (d, J=8.2 Hz, 2H) 6.84 (d, J=8.2 Hz, 2H) 6.69 (s, 2H) 5.17 (br. s., 1H) 
4.83 (br. s., 1H) 4.64 (s, 2H) 4.33 (d, J=10.8 Hz, 1H) 3.66 - 4.12 (m, 5H) 3.47 (s, 2H) 3.39 (t, 
J=6.9 Hz, 2H) 3.01 - 3.12 (m, 1H) 2.82 (br. s., 1H) 2.53 (s, 1H) 1.98 - 2.38 (m, 9H) 1.17 - 1.59 
(m, 59H) 1.06 (br. s., 2H) 0.87 (t, J=6.4 Hz, 6H) 13C-NMR (75 MHz, CDCl3) (indicative peaks): δ 
(ppm) 134.1, 130.25, 58.9, 55.7, 34.0, 31.9, 29.7, 29.4, 29.2, 24.8, 22.7, 14.11. HRMS (ESI-
pos): calculated for C59H97N3O13P [M+H]+: 1086.6754, found: 1086.6739. Retention time 
(HPLC): 42 min. 
General procedure for the incorporation of the photoactive dye label using a copper-
catalysed Alkyne-Azide click-reaction (example: TAMRA) 
The appropriate alkyne (5 µmol, 1 equiv.) and Tamra-azide (5 mg 10 µmol, 2 equiv.) were 
added to a stained (brown) HPLC-vial (1.5 mL) equipped with a screw-cap and solubilized 
using a mixture of THF/tBuOH (0.5 mL, 9:1 v/v). A mixture of CuSO4 (9 mg, 0.06 mmol) and 
TBTA (53 mg, 0.1 mmol) in dd H2O/tBuOH (20 mL 1:19 v/v) was prepared simultaneously and 
a small quantity (approx. 0.2 mL) of the ‘click mix’ was added to the reaction vial. Finally, 
sodium ascorbate (3 mg, 15µmol, 3 equiv.) was added, and the mixture agitated for 24 h. The 
mixture was then passed through a 10 µm filter and purified using semi-preparative HPLC 
(60% A in B to 90% A over 20 minutes, then 100% A in 1 minute, for 10 minutes). The product 
was obtained as a purple film after lyophilisation. 
  





Synthesis of Propargylglycine-based linker with DPPE and Tamra (24) 
 
Maleimidohexyl (dipalmitoyl-glyceryl-phosphatidyl)-ethanolamide modified 
propargylglycine 23 (5 mg, 5 µmol, 1 equiv.) was treated according to the above procedure, 
resulting in a brittle purple film (2.4 mg, 1.6 µmol, 32%). HRMS: HPLC retention time: 38-40 
min (broad). HMRS (ESI-Pos) Calculated for  C80H119N9O16P [M+H]+: 1492.8507, found 
1492.8442. 
Synthesis of Tyrosine-based linker with DPPE and Tamra (34-a) 
 
Maleimidohexyl (dipalmitoyl-glyceryl-phosphatidyl)-ethanolamide modified O-
propargyloxytyrosine 33 (5 mg, 4 µmol, 1 equiv.) was treated according to the above 
procedure, resulting in a brittle purple film (3.1 mg, 1.9 µmol, 38%). HRMS: HPLC retention 
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time: 40-43 min (broad). HMRS (ESI-Pos) Calculated for C87H125N9O17P [M+H]+: 1598.8926 
m/z, found: 1598.9074 m/z. 
Synthesis of Propargyl-based linker with DPPE and Cy3 (25) 
 
Maleimidohexyl (dipalmitoyl-glyceryl-phosphatidyl)-ethanolamide modified 
propargylglycine (1.2 mg, 1 µmol 1 equiv.) 23 was treated according to the above procedure, 
now using Cy3 azide (approx. 1 mg, 2 µmol, 2 equiv.) dissolved in tBuOH/DMSO (0.2 mL, 3:1 
v/v). After purification, the product was recovered as a lilac/purple film in trace quantities 
(100-200 µg, 0.1 µmol, 10%). HPLC retention time: 29-32 min (broad. HMRS: Chemical 
Formula: C86H134N8O13P+ [M+H], Calculated: 1517.9803 m/z, observed 1539.9796 [M+Na]. 
  





Synthesis of Tyrosine-based linker with DPPE and Cy3 (35a) 
 
Maleimidohexyl (dipalmitoyl-glyceryl-phosphatidyl)-ethanolamide modified 
propargylglycine (1.2 mg, 1 µmol 1 equiv.) 33 was treated according with the above 
procedure, now using Cy3 azide (approx. 1 mg, 2 µmol, 2 equiv.) dissolved in tBuOH/DMSO 
(0.2 mL, 3:1 v/v). After purification, the product was recovered as a lilac/purple film in trace 
quantities (400-600 µg, 0.3 µmol, 30%). HPLC retention time: 31-35 min. HMRS: Chemical 
Formula: C92H139N9O14P+ [M+H], calculated: 1625.01736 m/z, observed 1647.03018 [M+Na]. 
 
General procedure for peptide-dye-phospholipid hybrids on a single scaffold. 
The appropriate scaffold was dissolved in degassed trifluoroethanol (so that the 
concentration was approximately 100 µM) under inert conditions, protected from light. The 
peptide (100 nmol, 2 equiv.) was dissolved in trifluoroethanol and degassed as well – the 
scaffold (500 µL, 50 nmol, 1 equiv.)) was then added to the peptide and the mixture was 
gently agitated under inert conditions and shielded from light for the next 48 h. The mixture 
was subsequently precipitated using freshly distilled THF. The residue was then taken up 
again in a minimum of trifluoroethanol and the cycle was repeated up to three times in order 
to remove all unreacted linker from the mixture and obtain the product as a mixture with 
unreacted peptide – HPLC-purification proved to be impossible to date. 
WALP derivatives: 
WALP-Propargyl-TAMRA-DPPE: 26 
A bright purple and fluorescent spot developed at ~rF 0.05 (silica, 100% trifluoroethanol) – 
the unreacted fluorescent scaffold would move to rF 0.80 
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HRMS (ESI-Pos): calculated for C212H316N38O42PS+ [M+H]+: 4129,32122, not observed. 
WALP-Propargyl-Cy3-DPPE: 28 
A lilac (green/yellow fluorescing) spot developed at the baseline in TLC (silica, 100% TFE). The 
unreacted fluorescent scaffold would move to rF 0.65. 
HRMS (ESI-Pos): calculated for C218H331N37O39PS+ [M+H]+: 4154,45078, no resolved target 
peak observed. Some above-baseline activity was observed in the range of 1385-1410 m/z, 
but nothing that could be considered a true peak (with at least s/n = 3). 
WALP-tyrosine-TAMRA-DPPE: 34 
A bright purple and fluorescent spot developed at ~rF 0.05 (silica, 100% trifluoroethanol). 
HRMS (ESI-Pos): calculated for C219H322N38O43PS+ [M+H]+: 4235,36364, not observed. 
WALP-tyrosine-Cy3-DPPE:  36 
A lilac (green/yellow fluorescing) spot developed at the baseline in TLC (silica, 100% TFE). 
HRMS (ESI-Pos): calculated for C224H336N38O40PS+ [M+H]+: 4261,48789, no resolved target 
peak observed. 
dULC-ALM-F30 derivatives: 
dULC-ALM-F30 -Propargyl-TAMRA-DPPE 27 
A bright purple and fluorescent spot developed at ~rF 0.10 (silica, 100% trifluoroethanol). 
HRMS (ESI-Pos): calculated for C191H305N33O42PS+ [M+H]+: 3796,21977, no resolved target 
peak observed; a “bump” in the region of 1275-1290 was observed, which would coincide 
with the M+3Na or M+H+2Na 3+ ion. 
dULC-ALM-F30 -Propargyl-Cy3-DPPE 29 
A lilac (green/yellow fluorescing) spot developed at the baseline in TLC (silica, 100% TFE). 
HRMS (ESI-Pos): calculated for C197H319N32O39PS+ [M+H]+: 3820,33443, no resolved target 
peak observed. 
dULC-ALM-F30 -tyrosine-TAMRA-DPPE 35 
A bright purple and fluorescent spot developed at ~rF 0.10 (silica, 100% trifluoroethanol). 
HRMS (ESI-Pos): calculated for C198H311N33O43PS+ [M+H]+: 3902,26164, no resolved target 
peak observed. A broad peak was found in the 1310-1330 m/z region, indicating potential 
presence of a 3+ ion of the desired mass. 





dULC-ALM-F30 -tyrosine-Cy3-DPPE 37 
A lilac (green/yellow fluorescing) spot developed at the baseline in TLC (silica, 100% TFE). 
HRMS (ESI-Pos): calculated for C203H325N33O40PS+ [M+H]+: 3928,386453, no resolved target 
peak observed. 
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Chapter 6 – An efficient synthesis of electron-rich aminomethyl 
azobenzenes 
6.1. Introduction 
Molecular switches are molecules that can reversibly interconvert between two or more 
stable conformations upon the action of an external stimulus. This switching behaviour has 
been of interest in diverse fields of research for decades, especially when it appears, or is 
introduced into, small organic molecules and (bio-)polymers. The ability to change the 
physico-chemical properties of a molecule in-situ, instead of through the application of 
extensive chemical transformation, by only using ‘simple’ or non-invasive modifiers such as 
light, heat or a messenger molecule, opens up a range of potential applications from 
engineering to medicine. [1-3] 
The azobenzene moiety is an interesting candidate to explore in this respect and has been 
extensively studied as such. The molecule itself, for example, already serves in industry as a 
stabilizer in plastics and as a component of ionic liquids (liquid crystals) and displays excellent 
switching capabilities under mild conditions (i.e. visible light switching).[4-7]  
In her 2011 review on the topic of synthesizing azobenzenes, Merino describes in great detail 
the most common synthetic methods currently in use, none of which appear to have been 
evaluated towards electron-rich azobenzenes. As electron rich azobenzenes allow for 
different synthetic strategies than the corresponding electron poor ones by which they could 
be integrated into larger constructs, it would be interesting to investigate these options 
further. 
Of particular interest are the aminomethyl-functionalized azobenzenes, due to the many 
available methods in which a primary amine can be utilized in functionalization strategies.[8]  
The choice of aminomethyl-functionalization over a simple aniline group is that an aromatic 
amine will be less nucleophilic in comparison and would probably be insufficient to be 
effective in labelling studies. 





Scheme 10. Attempted synthesis of aminomethylazobenzene based on patent literature.[11] 
Of the few known examples in literature, the symmetric 4,4’-aminomethyl-azobenzene that 
was reported by Liu et al.[9] and an azobenzene-derived amino acid was reported by Sewald 
et al.[10] However, they didn’t share a common synthetic route applicable to a wider range of 
variants. 4-aminomethyl-azobenzene itself exists in patent literature which described the 
synthesis of this particular compound.[11]However, reproduction of their results proved to be 
problematic as the reduction of amide 3 to the target amine 4 invariably resulted in the loss 
of the azo-bond and other side-reactions.[11,12] We therefore decided to investigate a novel 
route to these compounds with the goal of applying it in further bioriented studies, for 
example those investigated in the first chapters of this manuscript. 
6.2. Results and discussion 
A route was proposed which would go from commercial 4-nitrobenzylalcohol 5 to the 
corresponding nitroso compound (6, Scheme 2), which would make good branching point for 
generating a library of various azobenzenes.[13] Subsequently 4-nitrosobenzyl alcohol 6 was 
to be converted to azide 9 in three steps. The azide, which on its own could be employed in 
various different reactions,[14,15] is then to be reduced to the methylamino-functionalized 
azobenzene 4.[16,17] Although it can be argued that the intermediate alcohols discussed in this 
chapter could be synthesized more effectively than by using these methods, the synthesis of 
the initial compounds was chosen based on convenience and proof of principle, rather than 
efficiency of the reaction itself and will not be discussed in further detail.[8] 
 
Scheme 11. Synthesis of azidomethyl azobenzene 9 in 5 steps from 4-nitrobenzylalcohol 5. a) i) Zn(0), 
NH4Cl, EtOH/H2O ii) Fe(III)Cl3, H2O; b) aniline, AcOH, EtOH; c) MsCl, Et3N, DMF; d) NaN3, DMF. 




# Phosphine Solvent Additive Time (h) Yield (%) 
1 PPh3 Toluene - 181 SM recovered 
2 PPh3 THF - 181 SM recovered 
3 PPh3 THF/H2O - 181 SM recovered 
4 PBu3 THF - 0.5 Decomp. 
5 PBu3 THF/H2O - 0.5 Decomp. 
6 TCEP THF/ H2O - 2 40% 
7 PBu3 THF/ H2O - 2 70% 
8 PBu3 THF/ H2O HCl 2 85% 
Table 2. screening and optimization of the Staudinger reduction of azidomethyl azobenzene 9 to 
aminomethylazobenzene 4. THF/H2O (95:5 v/v) 1) reaction performed at reflux 
4-nitrosobenzylalcohol 6 was readily synthesized in accordance with literature,[13] although it 
should be noted that its quality varies between batches as the compound appears to be 
sensitive to temperature. Hydroxymethyl azobenzene 7 was subsequently obtained in good 
yield. The sensitivity of azobenzene 7 towards residual acetic acid in the crude mixture was 
remarkable and could result in decomposition before chromatography purification could be 
attempted if the aqueous treatment of the reaction was not rigorous enough to remove all 
traces of acid.  
The transformation of alcohol 7 to the corresponding azide 9 in two steps occurred in (near) 
quantitative yields. However, the subsequent Staudinger reduction using standard conditions 
afforded the product only in trace quantities. It became apparent that triphenylphosphine 
was poorly reactive towards these products (table 1, entry 1-3), whereas tributylphosphine 
gave mainly decomposition at various temperatures (table 1, entry 4-5). When TCEP was used 
as reducing agent, the reaction afforded moderate yields of the desired product (40%). This 
singular behaviour of TCEP was an interesting case which drew our attention, as its behaviour 
in a Staudinger reduction should be similar to tributylphosphine as the terminal carboxyl 
groups in principle only serve to solubilize TCEP in water and are not meant to strongly 
influence the central phosphorous atom. This supposed similarity in behaviour is also 
touched upon by Nepomniaschiy and Arndt in their respective solutions to a similar 
problem.[18,19]   
After further investigations, it was hypothesised that TCEP could form a salt with the newly 
formed amine, causing it to precipitate from the reaction media and thereby avoiding 
degradation during the treatment of the reaction. This hypothesis was confirmed when the 
reductions with tributylphosphine were repeated but this time in the presence of HCl added 




either during workup (entry 7) or during the reaction itself (entry 8), the latter producing the 
best results. After further optimization, aminomethylazobenzene 4 could be obtained reliably 
in good yields as the HCl-salt. 
Encouraged by these promising results, we turned our attention to the scope of the reaction 
as we hoped to be able to obtain a wide variety of derivates, hence obtaining one of the first 
truly general and straightforward methods for the synthesis of aminomethyl azobenzenes 
without the need for extensive protection/deprotection steps. We were also interested in 
the obtained intermediates as we believed they could be of use as well. 
 
# R Isolated yield (%) 
10 -Me 47% 
11 -OMe 38% 
12 NH2 27% 
13 -CH2OH 10% 
14 -OH 58% 
15 -CH2OTBS 27% 
16 -COMe 25% 
17 -SMe 19% 
18 -CH2COOMe 27% 
Table 3. synthesis of a library of azobenzenes from 4-nitrobenzylalcohol. 1) i) Zn(0), NH4Cl; ii) Fe(III)Cl3; 
2) Aniline-derivative, AcOH. 
To this end, various functional groups were added to the 4-nitrosobenzylalcohol core and 
these aniline derivatives were submitted to the reaction conditions (Table 2). We chose to 
limit our investigations to this ring due to time constraints and due to our reasoning that this 
position would be the one where modifications would be the most interesting for further 
use. Overall, the products were obtained in moderate yields, although no attempts were 
made to optimize these reactions. Alkyl and alkyl ether substituents on the aniline gave the 
best yields (38-47%) while free amines, silyl ethers, esters, thioethers and ketones gave 
moderate yields of about 19-27%. Diol 13 was obtained as an inseparable mixture of E/Z 
isomers in the ratio 3:1 (by NMR). 4-aminobenzyl alcohol gave a poor yield. The reaction with 
thioaniline was attempted as well, but did not give the desired product. This behaviour can 
most likely be attributed to its redox potential in relation to the nitrosobenzylalcohol. In 
general, again the sensitivity of the desired azobenzenes towards trace acetic acid after the 
initial workup was remarkable, to the point where we decided to modify our protocol so that 
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the pH of the solution after treatment of the reaction mixture was slightly basic instead of 
neutral (pH = 8-10). This had no significant effect on the initial reaction yield but would allow 
for more time to pass between the end of the reaction and purification, while also making 
for an easier purification due to fewer side-products. 
 
# -R Isolated yield (%) 
19 -Me 98% 
20 -OMe 96% 
21 -NH2 n.d. 
22 -CH2OH/-CH2N3 n.d. 
23 -CH2OTBS 94% 
24 -COMe n.d. 
25 -SMe 96% 
26 -CH2COOMe 81% 
Table 4. Synthesis of azidomethyl azobenzene derivatives in 2 steps with modified protocol. 1) MsCl, 
Et3N; 2) NaN3 
The conversion of the alcohols to their corresponding azides occurred in (near) quantitative 
yields in most cases.[Note 1]  Indeed, for the derivates bearing alkyl, ether or ester substituents, 
the method gave 80-98% yields. Only amino-azidomethyl azobenzene 21, acetyl 
functionalized azidomethyl azobenzene 24 and diazide 22 were not obtained due to 
degradation of the product. For the former a protecting group on the nitrogen may be 
required for the reaction to work as the free amine appeared highly unstable. Sadly, due to 
time constrains this could not be investigated further, however we hypothesise that a Boc 
protecting group would be the preferred initial candidate, as it could be removed during the 
reduction step in the presence of HCl to immediately block the amine from decomposing 
without further synthetic effort, making this a three-step procedure, installing it prior to the 
mesylation.  
 
Scheme 12 Synthesis of two aminomethylazobenzene derivatives - PBu3, HCl, THF;  




The final conversion to the amine was attempted on two compounds: methyl-functionalized 
azidomethyl azobenzene 19 and methoxy-functionalized azidomethyl azobenzene 20 and 
appeared to work accordingly in both instances, with moderate yields for both methyl 
functionalized aminomethylazobenzene 27 and methoxy functionalized 
aminomethylazobenzene 28. However, further investigation into these reactions is in order 
before a definitive conclusion regarding the scope and the application of this approach can 
be reached. 
6.3. Conclusion 
In conclusion, a new promising synthesis towards electron rich aminomethyl azobenzenes 
was developed for the future use in polymers and bio-constructs such as pore forming 
peptides. The synthetic route offers much versatility and allowed us to obtain several 
previously undocumented azobenzenes from azobenzylalcohol, in good overall yields. From 
these could be obtained versatile azide bearing intermediates which can potentially undergo 
several transformations of interest for both biological and synthetic applications. This 
included obtaining, in a straightforward manner, the corresponding amines as was 
demonstrated by the synthesis of compounds 27 and 28. Also, this route may potentially be 
employed in an Aza-Wittig reaction, although this line was not investigated so far. Both these 
functional groups could in principle be used to attach these switches to the constructs 
described in the previous chapters, to be able to study the effect of structural changes on 
their activity for example, which might bring interesting insight on their mode of action. 
Although this method has not yet been tested fully and more research would be in order, the 
results so far are promising as to both the scope and overall yield of the process. 
Notes 
1) Experiments from table 3 and beyond are single experiment only, as time had run 
out. This affects azide functionalization and reduction in the scope section of this 
chapter (compound 19 and onward). 
6.4. Supplementary information  
General information 
Unless noted otherwise, all reactions were carried out under nitrogen atmosphere. Reactions 
were monitored by TLC Silica 60 (Merck Millipore), examined under UV (365 nm and 254 nm), 
and stained by KMnO5, ninhydrin, vanillin or H2SO4 in MeOH (1%). Chromatography was 
performed using the flash-protocols by Still et al. on Silica gel 60 (0.040-0.063 mm) from 
Merck Millipore. [16] 
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Unless specified otherwise, all solvents and reagents were obtained commercially (Sigma 
Aldrich, Acros Chemicals and TCI Europe). The solvents were used without any further 
purification, reagents were purified if required, following procedures described in 
“Purification of Laboratory Chemicals (sixth edition).”[17] 
The 1H NMR spectra were recorded at 400 MHz and 13C NMR spectra were recorded at 100 
MHz. The chemical shifts are reported in ppm relative to the residual solvent peak.  
High-resolution mass spectra were recorded on an Orbitrap XL (Thermo Fisher Scientific; ESI 
pos. or neg. mode).  
Experimental procedures 
4- Nitrosobenzylalcohol (6) 
p-nitrobenzylalcohol (3.2 g, 21 mmol, 1 equiv.) and ammonium 
chloride (1.6 g, 29 mmol, 1.4 equiv.) were dissolved in 160 mL of an 
ethanol-water mixing solvent (5:1) under argon, and then zinc 
powder (4.1 g, 63 mmol, 3 equiv.) was added at room temperature. After 2 h stirring, the 
suspension was filtered, followed by pouring into 500 mL aqueous solution of FeCl3·6H2O (6.8 
g, 25 mmol, 1.2 equiv.) in an ice bath, after which the solution was stirred for an additional 2 
h. The resultant aqueous solution was extracted by CH2Cl2 (100 mL x3). After evaporation of 
the organic phase in vacuo, (4-nitrosophenyl)methanol was obtained as a mixture with p-
nitrobenzylalcohol (2.78 g total, calculated 1.37 g, 10 mmol, 48% (4-nitrosophenyl)methanol 
estimated from NMR analysis), which was used without further purification. 1H-NMR of the 
mixture (400 MHz, CDCl3): δ (ppm) 8.23 (d, J=8.6 Hz, 2H), 7.91 (d, J=8.4, 2H), 7.61 (d, J=8.6 Hz, 
2H), 7.54 (d, J=9.0 Hz, 2H), 4.84 (d, 2H), 1.89 (s, br, 1H).  
4-hydroxymethylaniline 
Palladium on charcoal (10% w/w, 350 mg, 14mg/mmol) was charged 
in a three-neck flask (250 mL) and placed under nitrogen (3 cycles) 
and wetted with freshly distilled toluene (10 mL). 4-
nitrobenzylalcohol (3.83 g, 25 mmol, 1 equiv.) was dissolved in 
methanol (50 mL) and added to the flask using a syringe, after which additional methanol 
was added (50 mL). The flask was cooled to 0 °C after which hydrazine-hydrate (6.25 mL, 125 
mmol, 5 equiv.) in methanol (14 mL), was added to the mixture dropwise over 30 minutes. 
The mixture was stirred at room temperature until all the starting 4-nitrobenzylalcohol was 
consumed on TLC. The reaction mixture was filtered over celite and activated charcoal and 
concentrated in vacuo to about 8-10 mL. The crude was purified directly with flash-
chromatography (silica, heptane:EtOAc +1% Et3N:  1:1 to 1:4), resulting in 4-
hydroxymethylaniline as white (quickly yellowing to air/light) crystals (24.5 mmol, 97%). 1H-




NMR (400 MHz, CDCl3): δ (ppm) 7.10 (d, J=8.2 Hz, 2H), 6.60 (d, J=8.2 Hz, 2H), 4.48 (s, 2H), 3.40 
(br.s, 2H). 13C-NMR (100 MHz, DMSO-d6): δ (ppm) 145.9, 131.2, 128.9, 115.1, 64.9. 
tert-butyldimethyl((4-nitrobenzyl)oxy)silane 
To a solution of 4-nitrobenzylalcohol (3.2 g, 21 mmol, 1 equiv.) in 
THF (50 mL, 0.2 M) was added tert-butyldimethylsilyl chloride 
(4.8 g, 32 mmol, 1.5 equiv.), triethylamine (8.5 mL, 63 mmol, 3 
equiv.) and a few crystals of imidazole. The reaction mixture was 
then stirred for 3h at room temperature, until TLC indicated complete consumption of the 
starting material. The solution was then concentrated in vacuo. The residue was taken up in 
EtOAc (50 mL), washed with saturated ammonium chloride (50 mL), NaHCO3 (50 mL) and 
brine (50 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude product was 
obtained as a clear oil that solidified upon standing. Flash chromatography (silica, 5% EtOAc 
in heptane) afforded the pure product as a clear, viscous oil that solidified upon contact with 
a pipette. Yield was determined for the clear and colourless oil (5.6 g, 21 mmol, 100%). 1H 
NMR (400 MHz, CDCl3): δ (ppm) 8.20 (d, J = 8.2 Hz, 2H), 7.49 (d, J = 8.2 Hz, 2H), 4.82 (s, 2H), 
0.96 (s, 9H), 0.13 (s, 6H). 13C NMR (100 MHz, CDCl3): δ (ppm) 149.0; 146.9; 126.4; 123.3; 63.8; 




 Palladium on charcoal (10% w/w, 350 mg, 14mg/mmol) was 
charged in a three-neck flask (250 mL) and placed under nitrogen 
(3 cycles), after which freshly distilled toluene (10 mL) was added 
to form a slurry. Tert-butyldimethyl((4-nitrobenzyl)oxy)silane  (5.6 g, 21 mmol, 1 equiv.) was  
dissolved in methanol (50 mL) and added to the flask using a syringe, after which additional 
methanol was added (50 mL). The flask was cooled to 0 °C after which hydrazine-hydrate 
(6.25 mL, 125 mmol, 6 equiv.) in methanol (14 mL), was added to the mixture dropwise over 
30 minutes. The mixture was subsequently stirred at room temperature until all the starting 
4-nitrobenzylalcohol was consumed, indicated by TLC. The reaction mixture was filtered over 
celite and activated charcoal and concentrated in vacuo to about 8-10 mL. The crude product 
was directly purified with flash-chromatography (silica, 30% EtOAc in Heptanes to 60% in 2 
steps), resulting in the product as a colourless oil (4.5 g, 19.8 mmol, 92%). %). 1H NMR (400 
MHz, CDCl3): δ (ppm) 7.11 (d, J = 8.2 Hz, 2H); 6.68 (d, J = 8.2 Hz, 2H); 4.62 (s, 2H); 3.59 (v.br. 
s, 2H); 0.92 (s, 9H); 0.07 (s, 6H); 13C NMR (100 MHz, CDCl3): δ 145.4; 131.7; 127.5; 114.9; 65.0; 
25.9; 18.3; -5.2. 
  




To a solution of (4-nitrosophenyl)methanol (275 mg, 2 
mmol, 1 equiv.) and aniline (200 µL, 2.2 mmol, 1.1 equiv.) 
in ethanol (20 mL, 0.1M) was added glacial acetic acid (2 
mL). The reaction was stirred at rt until full conversion of 
the nitroso-compound (typically 5-8 h). To the mixture was 
added dd H2O (40-100 mL) which resulted in the precipitation of a bright orange crystalline 
solid. The solid was dissolved in EtOAc (50 mL), washed with saturated NaHCO3 (50 mL), dd 
H2O (50 mL) and brine (50 mL), after which the organic phase was dried over Na2SO4 and 
concentrated in vacuo. Chromatography (silica, heptanes:EtOAc 2:1) yield the product as a 
bright orange powder (needles) in 40-80% yield. 1H NMR (CDCl3, 400 MHz): δ (ppm) 7.95−8.89 
(m, 4H), 7.62−7.51 (m, 5H), 4.76 (d, J = 5.8 Hz, 2H), 4.39 (br s, 1H, OH); 13C NMR (CDCl3, 100 
MHz): δ (ppm) 153.5, 152.5, 147.1, 132.0, 130.1, 128.0, 127.7, 123.5, 64.2; 
 
(E/Z)-1-(4-(azidomethyl)phenyl)-2-phenyldiazene (9) 
To (4-(phenyldiazenyl)phenyl)methanol (1.9 g, 15 mmol, 1.0 
equiv.) in dry DMF (75 mL, 0.2 M) was added freshly distilled 
triethylamine (4.2 mL, 30 mmol, 2 equiv.) and mesyl chloride 
(1.8 mL, 22.5 mmol, 1.5 equiv.), which resulted mildly 
exothermic reaction upon which the mixture turned bright 
red and opaque. After consumption of all starting material (typically within 5 min), NaN3 (2.05 
g, 31.5 mmol, 2.1 equiv.) was added and the mixture was stirred overnight at rt, during which 
the colour of the mixture returned to orange. The reaction mixture was concentrated in 
vacuo to approx. 5 mL, after which EtOAc (100 mL) was added and the solution washed with 
1M HCl (100 mL), saturated NaHCO3 (100 mL), and brine (100 mL). The organic phase was 
dried over Na2SO4 and dried in vacuo. Flash chromatography (silica, heptanes:EtOAc 8:1 for 
Rf = 0.25) afforded the product as a very light, brittle, pale orange compound in 95% yield. 
1H-NMR (CDCl3, 300 MHz): δ (ppm) 8.00-7.90 (m, 4H); 7.58-7.46 (m, 5H); 4.45 (s, 2H). 13C-
NMR (CDCl3, 75 MHz): δ (ppm) 152.4, 152,1, 137.5, 131.2, 129.3, 127.8, 123.3, 122.2, 53.9. 
HRMS: calculated for C13H12N5 (M+H+): m/z 238.10872, found: m/z 238.10905. 
(E/Z)-(4-(phenyldiazenyl)phenyl)methanamine (4) 
To a solution of (E/Z)-1-(4-(azidomethyl)phenyl)-2-
phenyldiazene (475 mg, 2 mmol, 1 equiv.) in THF:1M HCl 
(95:5, 10 mL, 0.2 M) at -20°C was added PBu3 (760 µL, 3 
mmol, 1.5 equiv.) dropwise over 30 minutes, after which 
the mixture was allowed to stir at rt for 2h, during whichN2 
gas slowly evolved, to form a slurry of golden flakes in a red solution. To this solution were 




added drops concentrated HCl until the gas-evolution subsided. After cooling to -20°C, the 
mixture was filtered. The residue was washed with additional ice-cold THF, resulting in the 
target product as HCL salt, orange crystals (190 mg, 0.9 mmol, 45%). The remaining liquid 
was concentrated in vacuo, resulting in a black oil, which, upon contact with chromatographic 
silica immediately turns orange. Flash Chromatography (1:1 heptanes:EtOAc → MeOH + 1% 
NH3) afforded an additional 40% yield (as orange powder), resulting in a total yield of 85% 
(360 mg, 1.7 mmol). 1H-NMR (MeOD, 300 MHz): δ (ppm) 7.98 (d, J = 8.5 Hz, 2H); 7.93 (dd, J = 
7.7, 2.1 Hz, 2H); 7.66 (d, J = 8.5 Hz, 2H); 7.60-7.50 (m, 3H); 13C-NMR (DMSO-D6, 75 Hz): δ 
(ppm)  152.4, 152.1, 137.4, 130.8, 129.3, 123.2, 122.4, 105.7, 42,6. HRMS (ES+): calculated 
for C13H14N3 (M+H+): m/z 212.11822, found: m/z 212.11849. 
 
General procedure for the synthesis of hydroxymethylazobenzenes 
To a solution of freshly prepared (4-nitrosophenyl)methanol (48% w/v, 1.39 g, 5 mmol, 1 
equiv.) in dry ethanol (20 mL, 0.25 M) under nitrogen was added the appropriate p-
aminophenyl compound (6 mmol, 1.2 equiv.), followed by glacial acetic acid (2 mL). The 
resulting mixture was allowed to stir at room temperature for at least 12 h, or until one of 
the reagents was fully consumed by TLC. To the mixture was added dd H2O (40-100 mL) until 
the crude product precipitated. The precipitate was filtered off and taken up in EtOAc (50 
mL), and washed with saturated NaHCO3 (50 mL), H2O (50 mL) and brine (50 mL). The organic 
phase was then dried over Na2SO4, filtered and concentrated in vacuo.  
Alternatively, after the initial addition of H2O, the solution was extracted with EtOAc (3 x 100 
mL). the organic phase was then concentrated to about 100 mL in volume and processed as 
described before. 
The pure compound was obtained by flash chromatography or by recrystallization from hot 
EtOAc. 
(E/Z)-(4-(p-tolyldiazenyl)phenyl)methanol (10) 
As described, starting from p-toluidine (650 mg, 6 mmol, 
1.2 equiv.). Recrystallization from refluxing EtOAc with 
pentane afforded the product as dark orange crystals 
(530 mg, 2.3 mmol, 47%). 1H-NMR (300 MHz, DMSO-d6): 
δ (ppm) 7.80 (dd, J=16.4, 8.2 Hz, 4H) 7.50 (d, J=8.7 Hz, 
2H) 7.36 (d, J=8.2 Hz, 2H) 5.35 (br. s., 1H) 4.58 (s, 2H) 2.37 (s, 3H); 13C-NMR (DMSO-D6, 75 Hz): 
δ (ppm)  152.5, 150.7, 141.8, 137.9, 129.8, 128.8, 123.3 (2), 65.1, 21.5 
 
 




As described, starting from p-anisidine (760 mg, 6 mmol, 
1.2 equiv.). Flash chromatography (silica, 50% EtOAc in 
heptanes) afforded the product as brittle dark orange 
crystals (460 mg, 1.9 mmol, 38%). 1H-NMR (300 MHz, 
DMSO-d6): δ (ppm) 7.80 - 7.92 (m, 4H) 7.50 (d, J=8.7 Hz, 
2H) 7.06 (d, J=9.2 Hz, 2H) 4.68 (s, 2H) 3.88 (s, 3H) 13C-
NMR (DMSO-D6, 75 Hz): δ (ppm)  162.1, 152.2, 147.0, 
143.1, 127.4, 124.8, 122.8, 114.22, 64.9, 55.6. 
(E/Z)-(4-((4-aminophenyl)diazenyl)phenyl)methanol  (12) 
As described, starting from p-phenylenediamine 
(650 mg, 6 mmol, 1.2 equiv.). Flash chromatography 
(silica, 70% EtOAc in heptanes) afforded the product 
as brittle bright orange crystals (300 mg, 1.3 mmol, 
27%). 1H-NMR (300 MHz, DMSO-d6): δ (ppm)  7.66 
(dd, J=18.2, 8.5 Hz, 4H) 7.42 (d, J=8.2 Hz, 2H) 6.64 (d, 
J=8.7 Hz, 2H) 6.04 (s, 2H) 5.26 (t, J=5.9 Hz, 1H) 4.54 (d, J=5.6 Hz, 2H); 13C-NMR (DMSO-D6, 75 
Hz): δ (ppm)  153.1, 151.8, 144.5, 143.2, 127.5, 125.5, 122.0, 113.8, 63.0. 
(E/Z)-(diazene-1,2-diylbis(4,1-phenylene))dimethanol (13) 
As described, starting from p-aminobenzylalcohol 
(740 mg, 6 mmol, 1.2 equiv.). Flash 
chromatography (silica, 70% EtOAc in heptanes) 
afforded the product as bright orange powder 
containing an inseparable mixture of E/Z-isomers 
(ratio 1:3) (120 mg, 0.5 mmol, 10%).  1H-NMR (300 MHz, DMSO-d6): δ (ppm) 7.85 (d, J=8.2 Hz, 
4H); 7.44 - 7.57 (d, J = 8.2 Hz, 4H); 5.43 (s, 2H) 4.62 (s, 4H); 13C-NMR (DMSO-D6, 75 Hz): δ 
(ppm)  145.9, 131.2, 127.7, 115.2, 65.0.  
(E)-4-((4-(hydroxymethyl)phenyl)diazenyl)phenol (14) 
As described, starting from p-aminophenol (650 mg, 
6 mmol, 1.2 equiv.). Flash chromatography (silica, 
70% EtOAc in heptanes) afforded the product as 
bright orange powder (800 mg, 3.5 mmol, 58%). 1H-
NMR (300 MHz, DMSO-d6): δ (ppm) 10.24 (s, 1 H) 7.73 
- 7.80 (m, 4H) 7.47 (d, J=8.7 Hz, 2H) 6.92 (d, J=8.7 Hz, 2H) 5.30 (t, J=5.9 Hz, 1H) 4.56 (d, J=5.6 
Hz, 2H); 13C-NMR (DMSO-D6, 75 Hz): δ (ppm)  151.9 149.7, 144.1, 143.0, 127.4, 125.9, 123.2, 
129.9, 64.9. 





 As described, starting from 4-(((tert-
butyldimethylsilyl)oxy)methyl)aniline (1.4 g, 6 
mmol, 1.2 equiv.). Flash chromatography 
(silica, 40% EtOAc in heptanes) afforded the 
product as a brilliant red solid (420 mg, 1.3 
mmol, 27%).  1H-NMR (300 MHz, DMSO-d6): δ (ppm) 7.84 (dd, J=8.2, 3.6 Hz, 4H) 7.50 (dd, 
J=8.2, 5.1 Hz, 4H) 5.35 (t, J=5.6 Hz, 1H) 4.79 (s, 2H) 4.58 (d, J=5.6 Hz, 2H) 0.90 (s, 9H) 0.08 (s, 
6H); 13C-NMR (DMSO-D6, 75 Hz): δ (ppm)  151.5, 151.3, 146.8, 145.2, 127.5, 127.2, 122.9, 
122.8, 64.3, 62.9, 26.3, 18.5, -4.8. 
(E/Z)-1-(4-((4-(hydroxymethyl)phenyl)diazenyl)phenyl)ethan-1-one (16) 
As described, starting from 4-aminoacetophenon 
(810 mg, 6 mmol, 1.2 equiv.). Flash chromatography 
(silica, 40% EtOAc in heptanes) afforded the product 
as a pale-orange solid (500 mg, 1.3 mmol, 25%). 1H-
NMR (300 MHz, DMSO-d6): δ (ppm) 8.04 - 8.23 (m, 
2H) 7.84 - 8.01 (m, 4H) 7.54 (d, J=7.2 Hz, 2H) 5.38 (t, 
J=5.4 Hz, 1H) 4.60 (d, J=5.1 Hz, 2H) 2.62 (s., 3H); 13C-NMR (DMSO-D6, 75 Hz): δ (ppm)  197.1, 
154.4, 151.3, 147.8, 146.8, 130.1, 127.6, 123.3, 123.0, 65.6, 20.9 
(E/Z)-(4-((4-(methylthio)phenyl)diazenyl)phenyl)methanol (17) 
 As described, starting from 4-(methylthio)aniline (835 
mg, 6 mmol, 1.2 equiv.). Flash chromatography (silica, 
50% EtOAc in heptanes) afforded the product as a red 
sticky powder (250 mg, 1 mmol, 19%). 1H-NMR (300 
MHz, DMSO-d6): δ (ppm) 7.88 (t, J=8.2 Hz, 4H) 7.49 (d, 
J=8.2 Hz, 2H) 7.34 (d, J=8.7 Hz, 2H), 5.32 (s, 1H), 4.77 (s, 
2H) 2.55 (s, 3H); 13C-NMR (DMSO-D6, 75 Hz): δ (ppm)  
152.1, 149.9, 143.6, 142.9, 127.4, 125.9, 123.4, 123.0, 64.9, 15.3. 
methyl (E/Z)-2-(4-((4-(hydroxymethyl)phenyl)diazenyl)phenyl)acetate (18) 
 As described, starting from methyl 4-
(aminophenyl)acetate (990 mg, 6 mmol, 1.2 
equiv.). Flash chromatography (silica, 33% EtOAc 
in heptanes) afforded the product as brown brittle 
powder (580 mg, 1.3 mmol, 27%). 1H-NMR (300 
MHz, CDCl3): δ (ppm) 7.90 (dd, J=8.2, 7.2 Hz, 4H) 
7.38 - 7.57 (m, 4H) 4.79 (s, 2H) 4.73 - 4.77 (m, 2H) 
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3.70 - 3.75 (br. s, 3H); 13C-NMR (DMSO-D6, 75 Hz): δ (ppm) 171.8 152.0 (2), 139.5, 137.1, 
130.0, 129.3, 123.8, 123.5, 70.9, 65.2, 42.0. 
General procedure for the synthesis of azidomethyl azobenzenes 
The appropriate 4-hydroxymethylazobenzene (1 mmol, 1 equiv.) was dissolved in dry DMF 
(10 mL, 0.1 M) under a nitrogen atmosphere. Triethylamine (420 µL, 3 mmol, 3 equiv.) was 
added, followed by MsCl (120 µL, 1.5 mmol, 1.5 equiv.), resulting in an opaque solution. After 
30 minutes, sodium azide (200 mg, 3 mmol, 3 equiv.) was added and the suspension was 
stirred vigorously for 14h. EtOAc (50 mL) was added and the mixture was then washed with 
1M HCl (50 mL), saturated NaHCO3 (50 mL), 3M LiCl (2 x 50 mL) and brine (100 mL). The 
organic phase was dried over Na2SO4 and dried in vacuo. Flash Chromatography (silica, 10-
15% EtOAc in Heptanes) afforded the products as orange to red powders. 
(E/Z)-1-(4-(azidomethyl)phenyl)-2-(p-tolyl)diazene (19) 
(E/Z)-(4-(p-tolyldiazenyl)phenyl)methanol 10 (220 mg, 1 
mmol, 1 equiv.) was treated following the above 
protocol. Flash chromatography (silica, 10% EtOAc in 
heptanes) afforded the pure compound as a fine orange 
powder (246 mg, 1 mmol, 98%). 1H-NMR (300 MHz, 
DMSO-d6): δ (ppm) 7.92 (d, J=8.2 Hz, 2H) 7.84 (d, J=8.2 Hz, 2H) 7.46 (d, J=8.2 Hz, 2H) 7.32 (d, 
J=7.8 Hz, 2H) 4.43 (s, 2H) 2.45 (s, 3H); 13C-NMR (DMSO-D6, 75 Hz): δ (ppm)  154.7, 141.8, 
138.0, 129.8, 128.8, 125.9, 123.2, 122.9, 54.4, 21.5. 
(E/Z)-1-(4-(azidomethyl)phenyl)-2-(4-methoxyphenyl)diazene (20) 
(E/Z)-(4-((4-
methoxyphenyl)diazenyl)phenyl)methanol 11 (230 
mg, 1 mmol, 1 equiv.) was processed using the 
described method. Flash chromatography (silica, 15% 
EtOAc in heptanes) afforded the pure compound as a 
red solid. (261 mg, 1 mmol, 96%). 1H-NMR (300 MHz, 
DMSO-d6): δ (ppm) 7.87 - 7.96 (m, 4H) 7.45 (d, J=8.6 
Hz, 2H) 6.99 - 7.06 (m, 2H) 4.42 (s, 2H) 3.90 (s, 3H); 13C-NMR (DMSO-D6, 75 Hz): δ (ppm) 162.2, 
152.4, 147.0, 143.1, 128.8, 124.9, 123.0, 114.3, 63.9, 55.6. 
  




Attempted synthesis of (E/Z)-4-((4-(azidomethyl)phenyl)diazenyl)aniline (21) 
(E/Z)-(4-((4-aminophenyl)diazenyl)phenyl)methanol 
12 (220 mg, 1 mmol, 1 equiv.) was treated as 
described above. No product was observed, also the 
in hindsight expected mesylamide was not recovered 
in significant quantities. The starting material was not 
recovered and was assumed to have degraded.  
Putative synthesis of (E/Z)-4-((4-(azidomethyl)phenyl)diazenyl)aniline (22) 
(E/Z)-(4-((4-aminophenyl)diazenyl)phenyl)methanol 
14 (220 mg, 1 mmol, 1 equiv.) was treated as 
described above. A single product was isolated in 
minimal quantities. 1H-NMR (300 MHz, DMSO-d6): δ 
(ppm) 7.83 - 7.90 (m, 2H) 7.52 (d, J=8.2 Hz, 2H) 7.45 (d, 
J=8.2 Hz, 2H) 6.89 - 6.96 (m, 2H) 5.65 (br. s., 1H) 4.65 (s, 2H); 13C-NMR (DMSO-D6, 75 Hz): δ 
(ppm) 158.5, 152.4, 147.1, 139.6, 129.4, 125.1, 122.9, 115.9, 45.8. 
Attempted synthesis of (E/Z)-1,2-bis(4-(azidomethyl)phenyl)diazene (23) 
(E/Z)-(diazene-1,2-diylbis(4,1-
phenylene))dimethanol 13 (240 mg, 1 mmol, 1 
equiv.) was treated per the above method, with the 
exception that 3 mmol of MsCl, 6 mmol of 
triethylamine and 6 mmol sodium azide were used 
in the same volume of solvent. No diazide was recovered, nor a significant amount of 





(350 mg, 1 mmol, 1 equiv.) was treated per the 
above method. Flash Chromatography (silica, 
5% EtOAc in heptanes) afforded the pure 
product as a scarlet powder (362 mg, 0.95 mmol, 94%). 1H-NMR (300 MHz, DMSO-d6): δ 
(ppm) 7.92 (dd, J=10.7, 8.4 Hz, 4H) 7.47 (dd, J=8.4, 2.9 Hz, 4H) 4.83 (s, 2H) 4.43 (s, 2H) 0.97 
(s, 9H) 0.13 (s, 6H); 13C-NMR (DMSO-D6, 75 Hz): δ (ppm) 151.9, 151.8, 147.3, 145.2, 128.8, 
126.5, 123.2, 122.9, 64.6, 54.4, 26.3, 18.5, -4.8. 
  






16 (250 mg, 1 mmol, 1 equiv.) was treated as 
described. Product: 120 mg, 1H-NMR (300 MHz, 
DMSO-d6): δ (ppm) 8.09 - 8.13 (m, 2H) 7.97 (dd, J=8.2, 
5.9 Hz, 4H) 7.54 (d, J=8.2 Hz, 2H) 4.81 (s, 2H) 2.67 (s, 
3H); 13C-NMR was not recorded. 
 (E/Z)-1-(4-(azidomethyl)phenyl)-2-(4-(methylthio)phenyl)diazene (26) 
(E/Z)-(4-((4-
(methylthio)phenyl)diazenyl)phenyl)methanol 17 (260 
mg, 1 mmol, 1 equiv.) was treated as per described 
procedure. Flash chromatography (silica, 10% EtOAc in 
heptanes) afforded the product as a red solid (273 mg, 
0.96 mmol, 96%). 1H-NMR (300 MHz, DMSO-d6): δ (ppm) 
7.90 (dd, J=16.2, 8.4 Hz, 4H) 7.46 (d, J=8.2 Hz, 2H) 7.31 - 
7.39 (m, 2H) 4.43 (s, 2H) 2.56 (s, 3H); 13C-NMR (DMSO-D6, 75 Hz): δ (ppm) 151.8, 149.3, 144.5, 
138.6, 128.9, 125.9, 123.4, 123.2, 55.1, 15.0. 
methyl (E/Z)-2-(4-((4-(azidomethyl)phenyl)diazenyl)phenyl)acetate (27) 
Methyl (E/Z)-2-(4-((4-(hydroxymethyl) phenyl) 
diazenyl)-phenyl)acetate 18 (280 mg, 1 mmol, 1 
equiv.) was treated as described above. The azide 
was recovered after flash chromatography (silica, 
10% EtOAc in heptanes) (251 mg, 0.81 mmol, 81%). 
1H-NMR (300 MHz, DMSO-d6): δ (ppm) 7.91 (dd, 
J=14.3, 8.4 Hz, 4H) 7.46 (dd, J=11.9, 8.4 Hz, 4H) 4.43 
(s, 2H) 3.72 (m, 5H); 13C-NMR (DMSO-D6, 75 Hz): δ (ppm) 172.5 151.67, 138.2, 137.2, 130.1, 
128.8, 123.3, 123.1, 72.1, 54.4, 41.4. 
General procedure for the synthesis of aminomethyl azobenzenes 
To the appropriate 4-azidomethylazobenzene (0.5 mmol, 1 equiv.) in THF (5 mL) at -20 °C was 
added tributylphosphine (250 µL, 1 mmol, 1 equiv.) dropwise over 30 minutes, followed by 
5M HCl (0.5-1 mL). If a precipitate was formed, the mixture was filtered and the resulting 
solid washed with ice-cold THF and Et2O and subsequently recovered. The remaining organic 
phase was treated as if no precipitation had taken place. 




If no precipitate was observed, the mixture was concentrated in vacuo, and directly purified 
using Flash-Chromatography – using the acidity of the silica to break-up the intermediates 
(silica, double length column, 5% MeOH in CH2Cl2 + 0.5% NH3). After collecting the product 
fractions, they were concentrated in vacuo, redissolved in Et2O, filtered and finally 
precipitated with a drop of 5M HCl (aq), concentrated again at own discretion (the extremely 
fine powder gets stuck in P4 glass filters, clogging them). 
(E/Z)-(4-(p-tolyldiazenyl)phenyl)methanamine HCl salt (single experiment) (28) 
(E/Z)-1-(4-(azidomethyl)phenyl)-2-(p-tolyl)diazene 19 
(130 mg, 0.5 mmol, 1 equiv.) was treated to the above 
procedure. The product was obtained after Flash 
Chromatography and trituration using pentane/THF 
(1:1 v/v) to remove the last traces of 
tributylphosphinoxide. The product was recovered as a dull orange powder (240 mg, 0.4 
mmol, 78%). 1H-NMR (300 MHz, DMSO-d6): δ (ppm) 7.95 (d, J = 8.5 Hz, 2H), 7.82 (d, J = 8.8 
Hz, 2H), 7.64 (d, J = 8.5 Hz, 2H), 7.38 (d, J = 8.5 Hz, 2H), 4.21 (s, 2H), 2.44, (s, 3H). 13C-NMR 
was not recorded. 
(E/Z)-(4-((4-methoxyphenyl)diazenyl)phenyl)methanamine (single experiment) (29) 
(E/Z)-1-(4-(azidomethyl)phenyl)-2-(4-
methoxyphenyl)diazene 20 (130 mg, 0.5 mmol, 1 
equiv.) was processed according to the above 
procedure. The product was purified using both Flash 
Chromatography, followed by additional trituration 
(THF) after the formation of the HCl-salt. The product 
was recovered as a reddish-orange finely divided solid 
(101 mg, 0.36 mmol, 73%). 1H-NMR (300 MHz, DMSO-d6): δ (ppm) 7.92 (m, 4H), 7.62, (d, J = 
8.3 Hz, 2H), 7.10 (d, J = 9.0 Hz, 2H), 4.20 (s, 2H), 3.90 (s, 3H). 13C-NMR was not recorded. 
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Chapter 7 – Overview and perspective 
7.1. Introduction 
The previous chapters of this manuscript were dedicated to describing the experimental work 
performed and discussing the emanating results in detail. This chapter will focus on 
evaluating these results and accomplishments in a broader sense. In the past five chapters, a 
few key central concepts were put forward which will be discussed further:  
• DNA as a means to influence behaviour of a pore forming peptide; 
• hybrid molecules embody the best and worst of both worlds; 
• the use of scaffolds for labelling peptides; 
• The need for simple and robust (organic) chemistry. 
7.2. Research Overview and Achievements  
Chapters 2-4 are all focussed on employing DNA to modify the pore-forming behaviour of 
pore-forming peptide Alamethicin. Chapter 2 described the successful development of a 
manual SPPS technique for the synthesis of alamethicin and derivatives. The method gave 
the desired peptide in sufficient quantities required for the later experiments, benefitting 
from powerful Fluorine-mediated couplings with a scavenger, resulting in near-quantitative 
yields per step. However, this method to obtain the peptide was still time-consuming owing 
to its lack of automation, while each synthesis would yield enough peptide for only a few 
experiments. This pushed us to develop the alternative, more straightforward and time-
efficient solution, of employing dUL(C)-ALM: an Alamethicin analogue lacking the Aib 
residues in favour of Leu, which can be made in larger batch sizes in overnight automated 
SPPS. 
In the original design, it was envisioned to directly attach amine-modified oligomers onto the 
C-terminus of Alamethicin, and later dULC-ALM, using an elegant two-step oxidation-
conjugation technique developed by the group of Whitesides. In chapter 3, it was 
demonstrated that elegance does unfortunately not always indicate simplicity or robustness: 
a string of poor outcomes prompted us to reconsider the synthetic plan, and, ultimately, 
revert to an earlier peptide-oligonucleotide conjugation strategy based on the thiol-
maleimide coupling, as was originally performed by L. Gjonaj. 
As a result, six different DNA-Alamethicin hybrids were created, by which the influence of 
DNA on the activity of the peptide could be established (single stranded and hybridized vs 
duplex or quadruplex). Synthesizing the diverse molecules was relatively easily accomplished. 
However, by combining an extremely hydrophobic peptide to a very polar and hydrophilic 




DNA-oligomer, we created compounds whose original characteristics, in terms of 
hydrophilicity and hydrophobicity, did not blend into one average, but instead stacked, 
creating hybrids very peculiar and unique in their behaviour. This resulted in significant 
challenges when attempting to purify and characterise these, not previously described, 
constructs. However, sufficient amounts of the pure hybrids were obtained for further use. 
The true lesson of chapter 3 should therefore read: ‘in making hybrid molecules of two 
distinctly different species, you do not (only) combine the best characteristics, but definitely 
the challenges of both worlds,’ – a quote kindly offered by prof. dr. J.G. Roelfes. 
In chapter 4 was demonstrated how a DNA-oligomer affects the pore forming ability of dULC-
ALM. A single strand oligomer managed to destabilize and slightly inhibit pore-formation. 
When hybridized to double-stranded DNA with a peptide-DNA construct with a 
complementary sequence, it greatly improved pore stability, both in size and lifetime. The 
same improvements were seen when using a G-quadruplex to bring multiple peptides 
together. The shorter oligomer strands also displayed an increase in overall activity compared 
to the unmodified peptide, whereas the longer sequence appeared to still decrease the 
overall activity. These findings clearly provide a proof of principle that DNA-hybridization can 
be used as a means to develop a DNA-aptamer based switchable pore-forming system that 
can act as a molecular sensor. 
Chapter 5 revolved around the development of connecting 3 large biologically relevant 
moieties on the same core element. Two readily accessible amino acids were selected and 
modified to host a hydrophobic peptide (WALP or dULC-ALM), one of two dyes (Cy3 or 
TAMRA) and a phospholipid (DPPE) with a minimum of synthetic operations required. Also, 
in this case, hybrid molecules embody the best and worst of both worlds, particularly during 
purification.  
Again, the simplicity and robustness of the synthetic method behind these templates was 
taken as a central value, to ensure ease of use of these new tool compounds, even outside 
of a regular chemistry lab (e.g. the biochemical laboratory where the constructs were 
evaluated for their effectiveness). The method was tested in a bid to synthesize a small library 
of hybrids. However, the final products could not be identified in time. Despite the 
dissatisfying outcome, the scaffolds themselves proved to be a versatile and reliable method 
to combine distinctly different molecules together in close proximity, as was later shown in 
follow-up work by Syga and De Vries in their 2020 ChemBioChem publication.  
The final synthetic chapter took place not on the interface of synthesis with 
biomolecular/chemical biology as the others had, but rather on that of polymer science and 
organic synthesis. In this chapter, the development an electron rich aminomethyl 
azobenzene was discussed, which intended to be incorporated in a larger construct to make 
it potentially a photosensitive/-switchable construct. After the target molecule was obtained 
in excellent yield, the route taken toward the target proved versatile: a library of previously 
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unexplored/inaccessible electron-rich methylazide/amine modified azobenzenes was 
envisioned. Unfortunately, a lack of time left part of this project unfinished and open to 
further experimentation. 
7.3. Perspective and recommendations 
The overall goal of this thesis was to develop a molecular sensor, based on an artificial, 
switchable pore forming peptide, using a DNA-aptamer as a recognition/switching moiety. In 
this thesis, a proof of principle has been clearly demonstrated that DNA can be used to 
control pore-formation, increase pore stability and tailor pore sizes. 
However, it fell short of its ambitious ultimate goal: a functional sensor is still out of reach. 
Such a goal, it has become apparent, requires far more time and concerted effort than a 
single thesis can encompass. Future studies are needed to shed more light on critical aspects 
such as the role of the length of the DNA-oligomer and the impact of the sequences used. In 
parallel, studies can commence on using a Thrombin-aptamer in combination with either G-
quadruplex stabilisation (best pore forming results), or duplex stabilisation (more easily 
achieved with a complementary strand) to develop a rudimentary switch.  
For convenience, both in terms of handling and pore-analysis, a different peptide should be 
employed. dULC-ALM fulfilled a particular need when the project started, but in hindsight 
may have caused more issues in purification and pore-analysis than it solved in terms of 
availability and ease of synthesis. One can think of regular Alamethicin, which should be more 
readily accessible since the last publication by Brimble and co-workers. In their work, they 
describe a safe, reliable and surprisingly expeditious manual synthesis of Alamethicin and 
analogues (Chapter 2). Alternately, GALA peptides or even simpler LLS-type peptides could 
be considered – ultimately, any barrel-stave type of peptide will suffice, provided it has better 
handling/purification characteristics.  
Chapter 5 had as a goal to develop a trifunctional scaffold to help visually monitor the 
behaviour of WALP and Alamethicin (dULC) while anchored to a lipid membrane via an 
attached phospholipid. This synthetic approach was met with mixed success. Up until the 
final incorporation of the peptide, the method proved to be robust and give the target 
compounds in moderate to good yield. However, presumably, upon introduction of the 
peptides, the: “hybrid compounds have hybrid properties,” again came into play, and with 
the conditions chosen for the experiments, the final products could not be identified or 
recovered. Syga en De Vries later managed to complete the challenge of optimizing and 
identifying the final products. In doing so they also managed to demonstrate the viability of 
the method as we had envisioned it, providing another tool in the toolbox for making 
(complex) hybrid compounds. 




In Chapter 6, a versatile and reliable route was developed to produce a methylamino 
azobenzene monomer. As this route potentially gave access to electron rich azobenzenes in 
the azide (and later amine) form, a library was synthesized for evaluation. Preliminary results 
appear to indicate that this library can be finished with medium to good yields, arriving at 
several not previously described compounds. Furthermore, as the method employs a 
synthetically interesting azide intermediate, in hindsight, the azide may be as interesting to 
explore for conjugation purposes as the amine based azobenzenes explored in this chapter. 
In all, this method has not yet been tested for its full potential and should receive further 
attention, both in terms of the library, its potential applications and further optimisation of 
the reaction conditions. 





In this thesis, the use of DNA to modify the behaviour of a transmembrane pore-forming 
peptide is described. The work presented here serves as a proof of principle towards 
developing a DNA-peptide hybrid molecular sensor. 
Pore-forming peptides (PFP’s) operate by (reversibly) opening pores in lipid bilayers (e.g. 
cellular membranes), these pores consist out of multiple peptides, although the exact 
number of peptides, per pore, may vary. When these pores are formed, ions that were 
previously blocked by the membrane may now freely move from either side of the membrane 
to the other through the pore. In a controlled environment, such as with Black-Lipid 
Membrane electrophysiology, the current the passes through the membrane in this manner 
may be quantified. The current associated with a particular pore size is quantifiable and 
reproducible. Furthermore, pores have discrete sizes due to number of peptides required for 
a certain pore size. Therefore, these peptides may serve as a basis for a sensor, for which a 
reproducible, quantifiable and preferably discrete output is required. 
When a PFP is modified on a terminus, it typically will retain its ability to form a 
transmembrane pore, provided the pore-forming section of the peptide is left intact and 
available to the membrane. However, the terminal modification of the PFP will affect the 
performance of the peptide: it may reduce or even completely destroy its pore-forming 
activity by favouring dissociation from the membrane, or by preventing the recruitment of 
the additional peptides required to form a pore. Alternatively, these modifications my 
promote pore formation/stabilize existing pores. Also, with modifications, it is possible to 
selectively promote particular pore sizes. With the development of a sensor in mind, it would 
be favourable to find a modification that, under the appropriate environmental conditions 
promotes a particular pore to form (with its associated current as signal output), while 
blocking pore formation when the conditions are not met.  In the work described in thesis, 
Alamethicin F30 and its dULC-analogue, both well-known pore-forming peptides that allow 
for extensive C-terminal modifications without completely losing activity were used. 
Single-strand DNA oligomers, as explored in this thesis, are interesting as terminal 
modifications, as they typically would hinder pore formation due to their great hydrophilicity. 
However, when hybridized to form duplexes, quadruplexes or other configurations, DNA may 
be employed to bring together several PFP’s in the same location, which should greatly 
promote pore formation with an even number of peptides in the pore (4, 6, etc…). 
Furthermore, certain sequences of (single strand) DNA, aptamers, are known to selectively 
respond to the presence of a target molecule, changing their conformation in the process. 
This combination of DNA and PFP is therefore highly interesting to pursue as a potential 
molecular sensor. 




Several challenges arise when trying to make a hybrid our of a highly amphipathic peptide 
and hydrophilic oligonucleotides. The first challenge was to obtain a viable amount of the 
peptide in a relatively short amount of time, (over)expression being not an option. 
Chapter 2 described the successful development of a manual SPPS technique for the 
synthesis of alamethicin and derivatives. The method gave the desired peptide in sufficient 
quantities required for the later experiments, benefitting from powerful Fluorine-mediated 
couplings with a scavenger, resulting in near-quantitative yields per step. Due to the length 
of the synthesis, the yields remained in the single-digit range. In conclusion, despite the 
promise of the method, dULC-ALM was preferred over actual ALM as it was available via 
automated SPPS in shorter time and higher yield. 
Chapter 3 describes how the challenge of forming a hybrid peptide-DNA molecule, with 
hybrid properties was overcome. Initially the hybrid synthesis was attempted by using an 
elegant two-step oxidation-conjugation technique developed by the group of Whitesides. 
After initial failure, a peptide-oligonucleotide conjugation strategy based on the thiol-
maleimide coupling, originally performed by L. Gjonaj in her work, yielded the desired 
outcome. Six different, new DNA-dULC-ALM F30 hybrids were synthesised and subsequently 
successfully isolated and characterized for the first time. 
Chapter 4 describes the BLM-electrophysiological experiments on the six hybrids obtained in 
chapter 3. Here it was demonstrated how the presence of various C-terminal DNA-oligomers 
affect the pore forming ability of dULC-ALM. Single strand oligomers destabilize pores, 
resulting in shorter lifetimes, and slightly inhibit pore-formation. When hybridized to double-
stranded DNA with a peptide-DNA construct with a complementary sequence, it greatly 
improved pore stability, both in size and lifetime. The same improvements were seen when 
using a G-quadruplex to bring multiple peptides together. The sequence lengths also 
appeared to affect pore forming behaviour: shorter oligomer duplex strands displayed a 
higher activity compared to the longer duplex and the unmodified reference peptide. The 
longer oligomer duplex was less active than the reference peptide. These findings clearly 
provide a proof of principle that DNA-hybridization can be used as a means to develop a DNA-
aptamer based switchable pore-forming system that can act as a molecular sensor. 
Chapter 5 was a different approach to influencing a membrane active peptide. The goal here 
was to introduce two larger moieties to a hydrophobic peptide (WALP) while not affecting 
the its interaction with the membrane. To meet the challenge, both moieties were to be 
introduced on the same scaffold, after which the scaffold was attached to the peptide. Two 
viable cores were identified and successfully conjugated to one of two dyes (Cy3 or TAMRA) 
and a phospholipid (DPPE) with a minimum of synthetic operations required. The final 
constructs with WALP unfortunately could not be isolated. This promising lead was later 
followed up on and completed in work by Syga en De Vries in their 2020 ChemBioChem 
publication.  




In chapter 6 there is a change of pace, as this work took place not on the interface of synthesis 
with biomolecular/chemical biology as the others had, but rather on that of polymer science 
and organic synthesis. A new, electron rich aminomethyl azobenzene was synthesized and 
characterized, which intended to be incorporated in a larger polymer, to make the latter into 
a photosensitive/-switchable material. After the target molecule was obtained in excellent 
yield, the route taken toward the target proved versatile: a library of previously 
unexplored/inaccessible electron-rich methylazide/amine modified azobenzenes was 
envisioned. Time constraints left several questions unanswered. 
The final chapter puts each of the previous chapters in the perspective of the bigger picture: 
which questions have been answered, which ones are left open. And more importantly, 
which new questions have appeared, and what might be done to continue the project to a 
success. 
 





In dit proefschrift wordt het gebruik beschreven van DNA om het gedrag van 
transmembraan porievormende peptiden te beïnvloeden. Het hier beschreven werk dient 
als bewijs voor het principe dan een DNA-peptide hybride verbinding kan dienen als 
moleculaire sensor. 
Porievormende peptiden (PVP’s) werken door (reversibel) poriën in een lipide membraan te 
vormen (zoals bijvoorbeeld een celmembraan). Deze poriën worden uit meerdere PVP’s 
gevormd, het exacte aantal in een porie kan variëren. Als een porie is gevormd in een 
membraan, kunnen o.a. ionen die eerder door het membraan werden geblokkeerd nu vrij 
van de ene kant van het membraan naar het andere bewegen via de porie. Als er een 
spannings-gradiënt over het membraan staat, zal de stroom van ionen specifiek een kant op 
bewegen.  In een gecontroleerd experiment, zoals bij “Black-Lipid Membrane”- 
elektrofysiologie, kan een dergelijke stroom reproduceerbaar worden gemeten en 
gekwantificeerd. Hieruit is gebleken dat PVP’s discrete niveaus aan stroomsterkte door een 
membraan kunnen opwekken. Deze discrete niveaus ontstaan doordat de poriegrootte 
afhangt van het aantal peptiden (altijd een heel getal) dat deelneemt aan de porie. De 
stroomsterkte door een porie kan daarmee gebruikt worden als output voor een sensor en 
de PVP als systeem om een dergelijk signaal mee te genereren.  
Als een PVP wordt gemodificeerd aan een van zijn uiteindes, behoudt deze doorgaans zijn 
porievormende eigenschappen, mits het porievormend domein beschikbaar blijft voor het 
membraan en niet anderszins is aangetast. Een modificatie aan het uiteinde kan het gedrag 
van het peptide zelf wel beïnvloeden: het porievormend gedrag kan geremd worden, of 
zelfs volledig stilgelegd door de affiniteit voor het membraan te verlagen, of door te 
verhinderen dat een tweede peptide bij het aangepaste peptide in de buurt komt, wat wel 
vereist is voor het vormen van een porie. Anderzijds kan het porievormend gedrag, of de 
levensduur van een individuele porie ook verbeterd worden. Daarnaast is het ook mogelijk 
om de formatie van poriën met een specifiek aantal peptiden te selectief stimuleren. Met 
de ontwikkeling van een sensor in het achterhoofd zou het gunstig zijn om een modificatie 
te ontwikkelen die bij de gewenste omstandigheden het PVP aanzet tot het vormen van een 
specifieke porie (met bijbehorende stroomsterkte) en bij afwezigheid van die 
omstandigheden alle porievorming verhindert. In dit proefschrift zijn als PVP Alamethicine 
F30 en het dULC analoog ervan gebruikt. Beiden zijn uitvoerig gebruikt in onderzoek naar 
PVP’s en de modificaties ervan en zijn daarbij uitermate geschikt bevonden als platformen 
die zelfs bij relatief grote modificaties niet noodzakelijkerwijs hun activiteit verliezen. 
Enkelstrengs-DNA, zoals ook bestudeerd in dit proefschrift, is een interessante modificatie 
voor aan het C-terminale uiteinde van een PVP. Ongehybridiseerd zou het hydrofiele 




karakter van het oligomeer de interacties van het PVP met een membraan moeten 
verminderen en daarmee porievorming afremmen. Gehybridiseerd tot een duplex, 
quadruplex of andere vorm, brengt het DNA meerdere PVP’s bij elkaar en verhoogt 
daarmee de lokale concentratie. Op het membraan zou dit tot meer porievormende 
activiteit en/of stabielere poriën kunnen leiden. Daarnaast zou hiermee een specifiek aantal 
PVP’s in een porie gestimuleerd kunnen worden. Tot slot kunnen sommige, specifieke DNA-
sequenties (aptameren), binden aan een bepaalde doelverbinding en daarmee hun 
conformatie aanpassen. Deze combinatie van eigenschappen maakt dat een hybride van 
DNA en een PVP een interessante kandidaat is voor de ontwikkeling van een moleculaire 
sensor.  
Bij het maken van een DNA-PVP hybride, waarbij het DNA zeer hydrofiel is en het PVP 
amphipatisch, komen een aantal uitdagingen bovendrijven. 
Hoofdstuk 2 beschrijft de succesvolle ontwikkeling van een handmatige SPPS-methode voor 
het synthetiseren van alamethicine en afgeleiden daarvan. De methode leverde het 
gewenste peptide op, met voldoende opbrengst voor vervolg-experimenten. De kracht van 
de methode zat in de Fluoride-activering van de inkomende aminozuren tijdens de 
koppeling, gecombineerd met een silyl ether ‘scavenger,’ waardoor de opbrengst per 
individuele stap bijna volledig was. Door de lengte van de synthese bleef de opbrengst van 
de gehele route beperkt tot enkele procenten na opzuivering. Als gevolg daarvan, ondanks 
het succes met de methode, is gekozen om toch het dULC-ALM analoog in te zetten in plaat 
van het originele peptide. 
Hoofdstuk 3 beschrijft de hoe de uitdaging van de conjugatie van het PVP met DNA 
oligomeren is aangegaan en hoe deze materialen zijn gezuiverd en gekarakteriseerd. In 
eerste instantie werd geprobeerd om met een elegante oxidatie-conjugatie in twee 
stappen, origineel door de groep van Whitesides ontwikkeld, de gewenste hybriden te 
verkrijgen. Na tegenslag in de vertaling van de methode, is met succes teruggevallen op een 
thiol-maleïmide koppeling, eerder verkend door L. Gjonaj in haar proefschrift. Zes nieuwe, 
verschillende DNA-dULC-ALM F30 hybriden zijn op deze manier verkregen en vervolgens 
voor het eerst succesvol gezuiverd en gekarakteriseerd.  
Hoofdstuk 4 behandelt de BLM-elektrofysiologische experimenten die vervolgens met de 
zes DNA-ALM hybriden uit hoofdstuk 3 zijn uitgevoerd. Hierin werd aangetoond hoe de 
aanwezigheid van verschillende DNA-oligomeren op de C-terminus van dULC-ALM het 
porievormende karakter van het PVP beïnvloedt. Enkelstrengs oligomeren remmen, zoals 
verwacht, de mate waarin poriën worden gevormd in het membraan en verkorten de 
levensduur van de poriën wanneer ze gevormd zijn, tegenover een ongemodificeerd 
peptide als referentie. Wanneer de enkelstrengs verbindingen worden gehybridiseerd tot 
dubbelstrengs DNA door het toevoegen van een verbinding met een complementaire 
streng, verbetert de levensduur en grootte van de poriën sterk. Eenzelfde verbetering 




wordt waargenomen als een G-quadruplex wordt gebruikt om meerdere peptiden bijeen te 
brengen. De lengte van de oligomeer lijkt ook effect te hebben op de activiteit. De hybrides 
met een kortere streng vertoonden als duplex een hogere activiteit t.o.v. de 
ongemodificeerde referentie, terwijl de langere oligomeren een lagere activiteit 
vertoonden. Op basis van deze verbindingen wordt duidelijk dat DNA geschikt is om het 
gedrag van een PVP te beïnvloeden en het in principe mogelijk moet zijn om een DNA-PVP 
gebaseerde sensor te ontwikkelen. 
Hoofdstuk 5 omschrijft een andere aanvliegroute naar het beïnvloeden van een 
membraanactief peptide. Het doel was hier om twee grote functionele groepen te 
introduceren op het uiteinde van een peptide (WALP), zonder hierbij de werking van het 
peptide op een lipide membraan significant te verstoren. Hier werd de uitdaging aangegaan 
door beide functionele groepen eerst te koppelen aan een centraal platform, om 
vervolgens het platform aan het peptide te verbinden. Twee kandidaat-platformen werden 
geselecteerd en succesvol geconjugeerd met een kleurstof (Cy3 of TAMRA) en een 
fosfolipide (DPPE), met slechts een minimum aan synthetische handelingen. De 
verbindingen werden daarna met WALP geconjugeerd, maar het gewenste eindproduct kon 
op dat moment niet worden geïsoleerd. De belofte van dit platform werd in een 
vervolgonderzoek door Syga en De Vries wel waargemaakt, zoals ook staat beschreven in 
hun ChemBioChem publicatie. 
Hoofdstuk 6 heeft een andere focus, aangezien het werk zich niet afspeelt op het grensvlak 
tussen synthese en biomoleculaire chemie/chemische biologie, maar meer op het vlak van 
polymeren en synthese. In dit hoofdstuk wordt de synthese en karakterisatie van een 
nieuw, elektronrijk aminomethyl azobenzeen beschreven, met het doel om deze in een 
polymeer in te bouwen en zo doende het polymeer fotosensitief/schakelbaar te maken. 
Nadat het gewenste molecuul was verkregen met een hoge opbrengst, bleek de methode 
geschikt om verschillende, niet eerder zo eenvoudig verkregen elektronrijke 
methylazide/amine azobenzenen te maken. Helaas was er te weinig tijd meer beschikbaar 
om alle openstaande vragen voor dit hoofdstuk te beantwoorden. 
Het laatste hoofdstuk, tot slot, probeert om elk van de voorgaande hoofdstukken weer in 
het perspectief van het grote doel te plaatsen: welke vragen zijn beantwoord, welke vragen 
staan nog open, en vooral: welke nieuwe vragen zijn op het toneel verschenen. Tot slot 
bevat dit hoofdstuk wat overdenkingen hoe een vervolgstudie het project zo goed mogelijk 
naar een succesvol einde zou kunnen brengen. 





Met de verdediging van dit proefschrift is een eind gekomen aan een lange, 
hobbelige weg. Deze promotie heeft wellicht iets anders gebracht dan we gehoopt 
hadden, maar was desalniettemin een bijzondere ervaring en een goede 
leerschool. Dat alles uiteindelijk goed is afgelopen, is aan een paar bijzondere 
mensen te danken. 
Om te beginnen: Gerard. Toen we in 2012 aan dit avontuur begonnen, hadden we 
geen van beiden kunnen weten dat het zo lang zou duren. Ik wil je graag bedanken 
voor het vertrouwen dat je gedurende de gehele periode in me hebt gesteld en je 
professionele opstelling ook wanneer we lijnrecht tegenover elkaar stonden.  
Je hebt anders dan ik verwachtte, maar substantieel bijgedragen aan mijn groei en 
ontwikkeling. Ook heb je mijn ogen geopend voor een carrière buiten de 
academische wereld en ik denk dat we het erover eens kunnen zijn dat dat een 
gouden zet is geweest. 
Door jouw inzet en vertrouwen heb je mij gestimuleerd om me op alle fronten 
verder te ontwikkelen. Hiervoor mijn oprechte dank. 
Prof. Bert Poolman wil ik graag bedanken voor de prettige discussies en het bijna 
eindeloze vertrouwen in de lopende samenwerkingsprojecten, vooral op die 
momenten dat een goede afloop ver buiten bereik leek. 
Theodora en Monique, zonder jullie was dit proefschrift er nooit geweest. Dankzij 
jullie hulp, expertise en vooral ook de vele gezellige praatjes in het kantoor, zowel 
op wetenschappelijk gebied als daarbuiten, lukte het altijd weer om de volgende 
uitdaging op te pakken. 
Rianne, hartelijk dank voor de fijne samenwerking op het lab: je goede ideeën, 
vertrouwen, en je warme vriendschap daarbuiten, tijdens dit traject. 
Misha & Kevin: thank you for your invaluable insights into episodic stimulation 
experiments and helping me out with the final measurements on the hybrid 
complexes. 
Ook dank aan prof. Giovanni Maglia, prof. Armagan Koçer en dr. Arnold Boersma 
voor de aangename samenwerking. 




Many thanks to the Village Idiot “subgroup” (JB, Kaja, Suresh, Anne, Erik, Iwan en 
Brian), where on an average day more world-changing and revolutionary chemistry 
was discussed in a single coffee break than in many a meeting.  
JB, since we met back at the EPFL in the group of prof. Zhu, we’ve had quite the run 
together – and definitely our share of adventure. Thanks first of all for being a great 
friend for all these years (and going strong). I, all the way to the present day, enjoy 
the great discussions about science and the world at large alike, evenings well-
spent and the tradition of tearing up a few slopes once in a while.  
Olivier, for us it has also been quite some time since we were fume hood 
neighbours, I have highly appreciated your interest and occasional insight 
throughout the process and long after. 
Kaja, as the artistically most inclined of the bunch, you made sure to add colour to 
many a conversation. Also, many thanks for providing me with the cover of this 
thesis! 
Carmen, voor een classica en echte alfa kan het niet makkelijk zijn: je kind een 
organisch chemicus. Je was erg kritisch toen ik aan dit proces begon en eerlijk is 
eerlijk: je had gelijk – dat ik iets anders waar wil(de) hebben en actief mijn best 
deed om het zo te blijven zien, doet daar niks aan af. Toch heb je me altijd 
onvoorwaardelijk gesteund: mijn verhalen en overdenkingen aangehoord (al had ik 
ze, wat jou betreft, soms waarschijnlijk in het Russisch kunnen vertellen), waar dat 
kon met me meegedacht en gekeken naar en vanuit het bredere perspectief. Ook 
al woon ik al ruim 14 jaar op eigen kracht, thuis is nog altijd thuis: een vertrouwde 
en warme plek. Ik ben bijzonder blij dat ik deze periode met jou en Marc heb 
kunnen delen. 
Marc, waarschijnlijk ben je al die tijd wel mijn ‘trouwste fan’ geweest. Door een 
wrede speling van het lot kun je er straks niet bij zijn om al het werk verzilverd te 
zien, maar ik weet dat je in gedachten elke meter samen met me hebt afgelegd. 
Vergeleken met Carmen of mij ben je een man van weinig woorden, maar des te 
scherpere analyses. Vaak lukte het je om in één rake opmerking de kern van een 
zaak, waar we al een uur omheen draaiden, samen te vatten: een besmuikt, licht 
plagend lachje en dan, geheel terloops, die voltreffer. Ik ben ervan overtuigd dat dit 
bijzondere talent in de verzamelde werken van Elsschot van een passende 
omschrijving is voorzien. Die heb ik nu niet paraat, dus dat citaat hou je van me 
tegoed.  




Paul en Miet Beckers: opa, oma, als het op mij aankwam waren jullie altijd trots: of 
het onderzoek nou liep, of totaal niet – als je je maar blijft inzetten, niet 100%, 
maar ongeveer 70-80% van wat je echt kan, dan kom je er wel. Of het ook voor een 
proefschrift geldt: terugkijkend denk ik van wel. Met 100% geef je echt te veel en 
die les is me bijgebleven. Het is erg jammer dat ik de dag zelf niet meer met jullie 
beiden kan doorbrengen.  
Jovana, when we first met, you met me as a freshly minted PhD-student, by the 
time we started our relationship I was just beginning my final year. We never 
disagreed on anything, except that core-business of mine: chemistry (which you 
always claim you are done with, but somehow chemistry still isn’t done with you). 
Still, you supported me through thick and thin, even at times you were convinced I 
was the biggest budala, in the whole world. I’m honoured and grateful to have you 
at my side quite permanently these days. Also, I’m very thankful for the way your 
parents, Jasmina and Dragan welcomed me into the family, always showing 
interest and insight, Baka too of course. 
Monique, dank voor de gezellige en leuke bridge-avonturen op APIH en daarbuiten.  
Anke, als een van mijn oudste vrienden ontsnap ook jij niet aan een eervolle 
vermelding op deze pagina. 
Loes en Bert Beugelsdijk: zo langs de zijlijn hebben jullie het hele proces trouw 
gevolgd, met regelmatig goed advies ‘by proxy.’ Hartelijk dank daarvoor! 
Tot slot ook een woord van dank voor mijn collega’s binnen Zeolyst, locatie Delfzijl, 
voor het geduld, vertrouwen en vooral ook de prettige samenwerking: Henk Jan, 
Sjoerd, Jurrien, Jan Visscher, Jan Willem, Joke, Jan Scholte, Jan van de Velde, 
Wiepke, Patrick, Cristina, Willem, Bert, Jan Brouwer, Ben, DerkJan, het lab en de 
productieploegen (mocht ik nog iemand missen, dan bij dezen). 
Zeolyst International, Conshohocken location: Dave “Coops,” Jim, Daniel, Jeff, Phil, 
Josh, Paul, Meg, Anthony, Hong-Xin and Bill, and the many talented operators and 
technicians.  
Ook hartelijk dank aan degenen die mijn voorliefde voor de wetenschap en 
scheikunde in het bijzonder hebben gewekt en verder hebben laten doorgroeien: 
Prof. Dr. Romano Orru (VU), dr. Eelco Ruijter (VU), dr. Jan van Maarseveen (UvA), 
prof. Dr. Henk Hiemstra (UvA), prof. Dr. Jieping Zhu (EPFL), en aan de bron: Niek 
van Noort en Gymnasium Beekvliet.





Het laatste woord is voor Josefien “Tante Fien” Gijskens: zonder jouw onwrikbare 
geloof, steun en vertrouwen in mij, was dit avontuur al opgehouden voordat ik 
zelfs maar mijn eerste plan had kunnen bedenken. Weet dat je niet vergeten 
bent en dat het is gegaan zoals je lang geleden hebt voorzien: “’t is een mirk, maar 
hij komt er wel.” 
